<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d307694ddef14a.htm
<DESCRIPTION>DEFINITIVE PROXY STATEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Definitive Proxy Statement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&nbsp;&nbsp;&#9746; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Filed by a Party other than the
Registrant&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Preliminary Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Additional Materials</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Soliciting Material Pursuant to &#167; 240.14a-12</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Cytokinetics, Incorporated </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement if Other Than the Registrant) </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box) </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">No fee required.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>1.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of each class of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>2.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate number of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>3.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing
fee is calculated and state how it was determined):</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>4.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proposed maximum aggregate value of transaction:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>5.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total fee paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amount Previously Paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form, Schedule or Registration Statement No.:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing Party:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date Filed:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g307694g97t32.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Cytokinetics, Incorporated </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>May&nbsp;18, 2017 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">To the Stockholders: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders of Cytokinetics, Incorporated (the &#147;Company&#148;), a Delaware
corporation, will be held on Thursday, May&nbsp;18, 2017, at 10:30 a.m. local time, at the Embassy Suites Hotel, 250 Gateway Boulevard, South San Francisco, CA 94080, for the following purposes: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:3%; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">1. To elect L. Patrick Gage, Edward M. Kaye and Wendell Wierenga as Class&nbsp;I Directors, each to serve for a three-year
term and until their successors are duly elected and qualified (Proposal One); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:3%; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">2. To ratify the selection by the
Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm to the Company for the fiscal year ending December&nbsp;31, 2017 (Proposal Two); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:3%; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">3. To approve an amendment to the Company&#146;s Amended and Restated 2004 Equity Incentive Plan (the &#147;A&amp;R 2004
EIP&#148;) to increase the number of authorized shares reserved for issuance under the A&amp;R 2004 EIP by 3,900,000&nbsp;shares. (Proposal Three); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:3%; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">4. To approve, on an advisory basis, the compensation of the named executive officers, as disclosed in the Company&#146;s
Proxy Statement for the 2017 Annual Meeting of Stockholders (Proposal Four); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:3%; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">5. To determine, on an advisory basis,
the frequency with which the stockholders of the Company wish to have an advisory vote on the compensation of the named executive officers (Proposal Five); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:3%; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">6. To transact such other business as may properly be brought before the meeting and any adjournment(s) thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The foregoing items of business are more fully described in the Proxy Statement accompanying this Notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Only stockholders of record at the close of business on March&nbsp;27, 2017 are entitled to notice of and to vote at the meeting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:9pt; font-family:ARIAL">Sincerely, </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:54%; text-indent:-2%">


<IMG SRC="g307694g93t45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:9pt; font-family:ARIAL">Sharon A. Barbari </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:9pt; font-family:ARIAL">Corporate Secretary </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">South San
Francisco, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">March&nbsp;31, 2017 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>YOUR VOTE IS IMPORTANT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>THIS PROXY STATEMENT IS FURNISHED IN CONNECTION WITH THE SOLICITATION OF PROXIES BY THE COMPANY, ON BEHALF OF THE BOARD OF DIRECTORS,
FOR THE 2017 ANNUAL MEETING OF STOCKHOLDERS. THE NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIALS IS BEING DISTRIBUTED ON OR ABOUT APRIL&nbsp;6, 2017. IF YOU ARE A STOCKHOLDER OF RECORD YOU CAN VOTE YOUR SHARES USING ONE OF THE FOLLOWING METHODS:
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt"><B>COMPLETE AND RETURN A WRITTEN PROXY CARD</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt"><B>BY INTERNET OR TELEPHONE</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt"><B>ATTEND THE COMPANY&#146;S 2017 ANNUAL MEETING OF STOCKHOLDERS AND VOTE</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>ALL STOCKHOLDERS ARE CORDIALLY INVITED TO ATTEND THE MEETING. HOWEVER, TO ENSURE YOUR REPRESENTATION AT THE MEETING, YOU ARE URGED TO
MARK, SIGN, DATE AND RETURN THE PROXY CARD THAT MAY BE MAILED TO YOU AS PROMPTLY AS POSSIBLE IN THE POSTAGE-PREPAID ENVELOPE PROVIDED FOR THAT PURPOSE OR VOTE YOUR SHARES BY INTERNET OR TELEPHONE. ANY STOCKHOLDER ATTENDING THE MEETING MAY VOTE IN
PERSON EVEN IF HE OR SHE HAS RETURNED A PROXY CARD OR VOTED BY INTERNET OR TELEPHONE. PLEASE NOTE, HOWEVER, THAT IF YOUR SHARES ARE HELD OF RECORD BY A BROKER, BANK OR OTHER NOMINEE AND YOU WISH TO VOTE AT THE MEETING, YOU MUST OBTAIN A PROXY ISSUED
IN YOUR NAME FROM THAT RECORD HOLDER. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><I>Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><I>Stockholders to be Held on May&nbsp;18, 2017 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>This Proxy Statement, Notice of Annual Meeting and Form of Proxy Card and the 2016 Annual Report to Stockholders are available at
</B><B><I>cytokinetics.com/proxy</I></B><B>. You may obtain directions to the Annual Meeting of Stockholders by directing a request to: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>Investor Relations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>Cytokinetics, Incorporated </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>280 East Grand Avenue </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>South San Francisco, California 94080 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>email: </B><B><I>investor@cytokinetics.com</I></B><B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>Telephone: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">650-624-3283</FONT></FONT> </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><A NAME="toc"></A>TABLE OF CONTENTS </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" COLSPAN="5" STYLE="BORDER-BOTTOM:1.00pt solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt"><B><A HREF="#toc307694_1">Information Concerning Solicitation and
Voting</A></B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT STYLE="font-size:9pt"><B><A HREF="#toc307694_2">Proposal&nbsp;One:</A></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT STYLE="font-size:9pt"><B><A HREF="#toc307694_2a">Election of Three Class&nbsp;I Directors</A></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right"><FONT STYLE="font-size:9pt"><B>4</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT STYLE="font-size:9pt"><B><A HREF="#toc307694_3">Proposal&nbsp;Two:</A></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT STYLE="font-size:9pt"><B><A HREF="#toc307694_3a">Ratification of Selection of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm to the Company for the
 Fiscal Year Ending December&nbsp;31, 2017</A></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right"><FONT STYLE="font-size:9pt"><B>5</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT STYLE="font-size:9pt"><B><A HREF="#toc307694_4">Proposal&nbsp;Three:</A></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT STYLE="font-size:9pt"><B><A HREF="#toc307694_4a">Approval of an Amendment to the Amended and Restated 2004 Equity Incentive Plan (the &#147;A&amp;R 2004 EIP&#148;) Increasing
 the Number of Authorized Shares reserved for issuance under the A&amp;R 2004 EIP by 3,900,000&nbsp;shares</A></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right"><FONT STYLE="font-size:9pt"><B>7</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT STYLE="font-size:9pt"><B><A HREF="#toc307694_5">Proposal&nbsp;Four:</A></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT STYLE="font-size:9pt"><B><A HREF="#toc307694_5a">Approval, on an Advisory Basis, of Executive Compensation</A></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right"><FONT STYLE="font-size:9pt"><B>14</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT STYLE="font-size:9pt"><B><A HREF="#toc307694_6">Proposal&nbsp;Five:</A></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT STYLE="font-size:9pt"><B><A HREF="#toc307694_6a">Advisory Vote on Frequency of Executive Compensation</A></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right"><FONT STYLE="font-size:9pt"><B>15</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" COLSPAN="5" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B><A HREF="#toc307694_7">Forward Looking Statements</A></B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right"><B>16</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" COLSPAN="5" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B><A HREF="#toc307694_8">Security Ownership of Certain Beneficial Owners and Management</A></B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right"><B>17</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" COLSPAN="5" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B><A HREF="#toc307694_9">Board of Directors</A></B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right"><B>19</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><A HREF="#toc307694_10">Director Skills, Experience and Background</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><A HREF="#toc307694_11">Board Leadership Structure</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><A HREF="#toc307694_12">Board Role in Risk Oversight</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><A HREF="#toc307694_13">Independence of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><A HREF="#toc307694_14">Board of Directors Meetings and Committees</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" COLSPAN="5" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B><A HREF="#toc307694_15">Executive Officers</A></B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right"><B>25</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><A HREF="#toc307694_16">Executive Skills, Experience and Background</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" COLSPAN="5" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B><A HREF="#toc307694_17">Executive Compensation</A></B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right"><B>27</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><A HREF="#toc307694_18">Compensation Discussion and Analysis</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><A HREF="#toc307694_19">Compensation and Talent Committee Report</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><A HREF="#toc307694_20">Summary Compensation Table</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><A HREF="#toc307694_21">Grants of Plan-Based Awards in 2016</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><A HREF="#toc307694_22">Outstanding Equity Awards at December&nbsp;31, 2016</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><A HREF="#toc307694_23">Option Exercises and Vesting of Stock in 2016</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><A HREF="#toc307694_24">Potential Payments Upon Termination or Change of Control</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" COLSPAN="5" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B><A HREF="#toc307694_25">Director Compensation</A></B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right"><B>43</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><A HREF="#toc307694_26">Director Summary Compensation Table for 2016</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc307694_27"></A>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><A HREF="#toc307694_27">43</A></TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#toc307694_27"></A>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" COLSPAN="5" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B><A HREF="#toc307694_28">Report of the Audit Committee of the Board of Directors</A></B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right"><B>45</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" COLSPAN="5" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B><A HREF="#toc307694_31">Section&nbsp;16(A) Beneficial Ownership Reporting Compliance</A></B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right"><B>46</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" COLSPAN="5" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B><A HREF="#toc307694_33">Certain Business Relationships and Related Party Transactions</A></B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right"><B>46</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" COLSPAN="5" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B><A HREF="#toc307694_35">Indemnification of Directors and Officers</A></B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right"><B>53</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" COLSPAN="5" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B><A HREF="#toc307694_37">Householding of Proxy Materials</A></B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right"><B>54</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" COLSPAN="5" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B><A HREF="#toc307694_39">Other Matters</A></B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right"><B>54</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B><A HREF="#toc307694_40">Appendix&nbsp;A:</A></B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B><A HREF="#toc307694_41">Amended and Restated 2004 Equity Incentive Plan</A></B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right"><B><FONT STYLE="white-space:nowrap">A-1</FONT></B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>&nbsp;</B></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>CYTOKINETICS, INCORPORATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>280 East Grand Avenue </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>South San Francisco,
California 94080 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>PROXY STATEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>FOR THE ANNUAL MEETING OF
STOCKHOLDERS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>May&nbsp;18, 2017 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_1"></A>INFORMATION CONCERNING SOLICITATION AND VOTING </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Board of Directors of Cytokinetics,
Incorporated (the &#147;Company&#148;, &#147;we&#148;, &#147;us&#148;, &#147;our&#148;) is soliciting proxies for use at the Annual Meeting of Stockholders (the &#147;Annual Meeting&#148;) to be held at the Embassy Suites Hotel, 250 Gateway
Boulevard, South San Francisco, CA 94080, on Thursday, May&nbsp;18, 2017, at 10:30 a.m. local time, and at any adjournment(s) thereof, for the purposes set forth herein and in the accompanying Notice of Annual Meeting of Stockholders. Our principal
executive offices are located at the address listed at the top of the page and the telephone number is <FONT STYLE="white-space:nowrap">(650)&nbsp;624-3000.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Pursuant to rules adopted by the Securities and Exchange Commission (the &#147;SEC&#148;), we have elected to provide access to our proxy
materials over the internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the &#147;Notice&#148;) because our Board of Directors is soliciting your proxy to vote at the Annual Meeting, including at any
adjournments or postponements of the meeting. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice or request to receive a printed set of the proxy materials. Instructions on how to access the
proxy materials over the internet or to request a printed copy may be found in the Notice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">We intend to mail the Notice on or about
April&nbsp;6, 2017 to all stockholders of record entitled to vote at the Annual Meeting. We may send you a proxy card, along with a second Notice, on or after April&nbsp;16, 2017. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">WE WILL PROVIDE WITHOUT CHARGE TO ANY STOCKHOLDER SOLICITED BY THESE PROXY SOLICITATION MATERIALS A COPY OF OUR ANNUAL REPORT ON FORM <FONT
STYLE="white-space:nowrap">10-K,</FONT> TOGETHER WITH THE FINANCIAL STATEMENTS REQUIRED TO BE FILED WITH THE ANNUAL REPORT ON FORM <FONT STYLE="white-space:nowrap">10-K,</FONT> UPON REQUEST OF THE STOCKHOLDER MADE IN WRITING TO CYTOKINETICS,
INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CALIFORNIA, 94080, ATTN: INVESTOR RELATIONS, ANNUAL STOCKHOLDER MEETING. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Record Date and Share
Ownership </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Common stockholders of record at the close of business on March&nbsp;27, 2017 (the &#147;Record Date&#148;) are
entitled to notice of and to vote at the Annual Meeting and at any adjournment(s) thereof. We have one class of common shares issued and outstanding, designated as Common Stock, $0.001 par value per share (the &#147;Common Stock&#148;). As of the
Record Date, 163,000,000 shares of Common Stock were authorized and 43,241,281&nbsp;shares were issued and outstanding. As of the Record Date, 10,000,000 shares of Preferred Stock were authorized and none were outstanding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Revocability of Proxies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Any proxy given
pursuant to this solicitation may be revoked by the person giving it at any time before its use by: (i)&nbsp;issuing a later proxy, (ii)&nbsp;delivering to us at our principal offices (Attention: Corporate Secretary) a written notice of revocation,
or (iii)&nbsp;attending the Annual Meeting and voting in person. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Voting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">On all matters, each common share has one vote. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Cost of Proxy Solicitation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">We will pay for the
entire cost of soliciting proxies. In addition to these proxy materials, our directors and employees and D.F. King&nbsp;&amp; Co., Inc. (&#147;D.F. King&#148;), our proxy solicitor, may also solicit proxies in person, by telephone or by other means
of communication. Directors and employees will not be paid any additional compensation for soliciting proxies, but D.F. King will be paid its customary fee of approximately $7,500, plus
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses if it solicits proxies. We may also reimburse brokerage firms, banks and other agents for the cost of forwarding proxy materials to beneficial
owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>INFORMATION CONCERNING SOLICITATION AND VOTING </B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Voting in Person or by Proxy Card </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">If you are a stockholder of record, you may vote in person at the Annual Meeting or vote by proxy using the proxy card. Whether or not you
plan to attend the Annual Meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the Annual Meeting and vote in person if you have already voted by proxy. To vote in person, come to the Annual Meeting and we will
give you a ballot when you arrive. To vote using the proxy card, simply complete, sign and date the proxy card (that you may request or that we may elect to deliver at a later time), and return it promptly in the envelope provided. If you return
your signed proxy card to us before the Annual Meeting, we will vote your shares as you direct. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Voting via the Internet or by Telephone </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Stockholders may also vote their shares by proxy by means of the telephone or on the Internet. The laws of the State of Delaware, under
which we are incorporated, specifically permit electronically transmitted proxies, provided that each such proxy contains or is submitted with information from which the Inspector of Elections can determine that such proxy was authorized by the
stockholder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The telephone and Internet voting procedures below are designed to authenticate stockholders&#146; identities, to allow
stockholders to grant a proxy to vote their shares and to confirm that stockholders&#146; instructions have been recorded properly. Stockholders granting a proxy to vote via the Internet should understand that there may be costs associated with
electronic access, such as usage charges from Internet access providers and telephone companies, which must be borne by the stockholder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>For Shares Registered
in Your Name </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Stockholders of record as of the close of business on the Record Date may go to <I>investorvote.com/cytk </I>to
vote by proxy their shares by means of the Internet. They will be required to provide our number and control number contained on your Notice. The voter will then be asked to complete an electronic proxy card. The votes represented by such proxy will
be generated on the computer screen and the voter will be prompted to submit or revise them as desired. Any stockholder using a touch-tone telephone may also grant a proxy to vote shares by calling <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-652-8683</FONT></FONT></FONT> and following the recorded instructions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>For Shares Registered
in the Name of a Broker or Bank </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Most beneficial owners whose stock is held in street name receive instructions for granting
proxies from their banks, brokers or other agents, rather than our proxy card. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">A number of brokers and banks are participating in a
program provided through Broadridge Financial Solutions that offers the means to grant proxies to vote shares via telephone and the Internet. If your shares are held in an account with a broker or bank participating in the Broadridge Financial
Solutions program, you may grant a proxy to vote those shares telephonically by calling the telephone number shown on the instruction form received from your broker or bank, or via the Internet at Broadridge Financial Solutions&#146; web site at
<I>proxyvote.com. </I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>General Information for All Shares Voted via the Internet or by Telephone </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Votes submitted via the Internet or by telephone must be received by 11:59 p.m., Eastern Time on May&nbsp;17, 2017. Submitting your proxy
via the Internet or by telephone will not affect your right to vote in person should you decide to attend the Annual Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Quorum; Abstentions; Broker <FONT
STYLE="white-space:nowrap">Non-Votes</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Votes cast by proxy or in person at the Annual Meeting (&#147;Votes Cast&#148;)
will be tabulated by the Inspector of Elections (the &#147;Inspector&#148;) who is expected to be a representative from Computershare Shareowner Services, our transfer agent and registrar. The Inspector will also determine whether or not a quorum is
present. Except in certain specific circumstances, the affirmative vote of a majority of shares present in person or represented by proxy at a duly held meeting at which a quorum is present is required under Delaware law for approval of proposals
presented to stockholders. In general, Delaware law provides that a quorum will be present if stockholders holding at least a majority of shares entitled to vote are present in person or represented by proxy at the meeting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Inspector will treat shares that are voted WITHHELD or ABSTAIN as being present and entitled to vote for purposes of determining the
presence of a quorum. However, such shares will not be treated as votes in favor of approving any matter submitted to the stockholders for a vote. When proxies are properly dated, executed and returned, or if instructions are
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>INFORMATION CONCERNING SOLICITATION AND VOTING </B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">properly carried out for Internet or telephone voting, the shares represented by
such proxies will be voted at the Annual Meeting in accordance with the stockholder&#146;s instructions. If no specific instructions are given, the shares will be voted (i)&nbsp;for the election of the nominees for directors set forth herein;
(ii)&nbsp;for the ratification of PricewaterhouseCoopers LLP; (iii)&nbsp;for approval of [an amendment to] the A&amp;R 2004 EIP to increase the number of authorized shares reserved for issuance under the A&amp;R 2004 EIP by 3,900,000&nbsp;shares;
(iv)&nbsp;for approval, on an advisory basis, of the compensation of the named executive officers; (v)&nbsp;for approval, on an advisory basis, that the frequency with which the stockholders of the Company wish to have an advisory vote on the
compensation of the Company&#146;s named executive officers is three years, and (vi)&nbsp;upon such other business as may properly come before the Annual Meeting or any adjournment thereof at the discretion of the proxy holder, but will not be voted
in the election of directors other than as provided in (i)&nbsp;above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">If a broker indicates on the proxy or its substitute that such
broker does not have discretionary authority as to certain shares to vote on a particular matter (&#147;broker <FONT STYLE="white-space:nowrap">non-votes&#148;),</FONT> then those shares will be considered as present with respect to establishing a
quorum for the transaction of business. Discretionary items are proposals considered routine under the rules of the New York Stock Exchange (&#147;NYSE&#148;) on which your broker may vote shares held in street name in the absence of your voting
instructions. <FONT STYLE="white-space:nowrap">Non-discretionary</FONT> items are matters that may substantially affect the rights or privileges of stockholders, such as mergers, stockholder proposals, elections of directors (even if not contested)
and executive compensation, including the advisory stockholder votes on executive compensation and on the frequency of stockholder votes on executive compensation. On <FONT STYLE="white-space:nowrap">non-discretionary</FONT> items for which you do
not give your broker instructions, the shares will be treated as broker <FONT STYLE="white-space:nowrap">non-votes.</FONT> Accordingly, your broker or nominee may not vote your shares on Proposal One without your instructions, but may vote your
shares on Proposals Two and Three. We believe that the tabulation procedures to be followed by the Inspector are consistent with the general statutory requirements in Delaware concerning voting of shares and determination of a quorum. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> with respect to proposals set forth in this proxy statement will not be
considered &#147;Votes Cast&#148; and, accordingly, will not affect the determination as to whether the requisite number of Votes Cast has been obtained with respect to a particular matter. Abstentions and broker
<FONT STYLE="white-space:nowrap">non-votes</FONT> will be counted towards the quorum requirement. If there is no quorum, a majority of the votes present at the meeting may adjourn the meeting to another date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Deadline for Receipt of Stockholder Proposals </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Stockholders are entitled to present proposals for action at a forthcoming meeting if they comply with the requirements of our bylaws and
the rules established by the Securities and Exchange Commission (the &#147;SEC&#148;) under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). Under these requirements, proposals of our stockholders that are intended to
be presented by such stockholders at our 2018 Annual Meeting of Stockholders must be received by us no later than December&nbsp;1, 2017. Proposals submitted by this date will also be considered for inclusion in next year&#146;s proxy materials. If
you wish to bring a matter before the shareholders at next year&#146;s annual meeting and you do not notify us before February&nbsp;14, 2018, for all proxies we receive, the proxyholders will have discretionary authority to vote on the matter,
including discretionary authority to vote in opposition to the matter. A copy of the relevant bylaws provisions relating to stockholder proposals is available upon written request to Cytokinetics, Incorporated, 280 East Grand Avenue, South San
Francisco, California 94080, Attention: Corporate Secretary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Results of the Voting at the Annual Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Preliminary voting results will be announced at the Annual Meeting. Final voting results will be published in a current report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> that we expect to file within four business days after the Annual Meeting. If final voting results are not available to us in time to file a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT>
within four business days after the Annual Meeting, we intend to file a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> to publish preliminary results and, within four business days after the final results are known to us, file an
additional current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> to publish the final results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_2"></A>PROPOSAL ONE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_2a"></A>ELECTION OF THREE CLASS I DIRECTORS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Nominees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Our Board of Directors currently has
eight members. We have a classified Board of Directors, which is divided into three classes of directors whose terms expire at different times. The three classes are currently comprised of the following directors: </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Class&nbsp;I consists of L. Patrick Gage, Edward M. Kaye and Wendell Wierenga, who will serve until the 2017 Annual
Meeting of Stockholders and until their successors have been duly elected and qualified. Dr.&nbsp;Gage, Dr.&nbsp;Kaye and Dr.&nbsp;Wierenga&nbsp;will stand for election as Class&nbsp;I directors at this Annual Meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Class&nbsp;II consists of Robert I. Blum and Sandford D. Smith, who will serve until the 2018 Annual Meeting of
Stockholders; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Class&nbsp;III consists of Santo J. Costa, John T. Henderson and B. Lynne Parshall, who will serve until the 2019 Annual
Meeting of Stockholders and until their successors have been duly elected and qualified. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">At each Annual Meeting of
Stockholders, the successors to directors whose terms will then expire will be elected to serve from the time of election and qualification until the third Annual Meeting of Stockholders following such election and until their successors have been
duly elected and qualified. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of an equal number of directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Unless otherwise instructed, the proxy holders will vote the proxies received by them for our three nominees named below, who are
currently directors of the Company who were previously elected by the stockholders, except for Dr.&nbsp;Kaye, who was appointed as a member of the Board of Directors in May 2016 and was recommended for nomination to the Board of Directors by our
Nominating and Corporate Governance Committee. The nominees have consented to be named as nominees in the proxy statement and to continue to serve as directors if elected. If any nominee becomes unable or declines to serve as a director or if
additional persons are nominated at the meeting, the proxy holders intend to vote all proxies received by them in such a manner as will assure the election of the nominees listed below if possible (or, if new nominees have been designated by the
Board of Directors, in such a manner as to elect such nominees), and the specific nominees to be voted for will be determined by the proxy holders. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The nominees for the Class&nbsp;I directors are as follows: </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt"><I>L. Patrick Gage </I> </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt"><I>Edward M. Kaye</I> </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt"><I>Wendell Wierenga</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Biographical information for each Class&nbsp;I director can be found below in the Board of Directors section. We are not aware of any
reason that any nominee will be unable or will decline to serve as a director. The term of office of each person elected as a Class&nbsp;I director will continue until our 2020 Annual Meeting of Stockholders and until a successor has been elected
and qualified. There are no arrangements or understandings between any director or executive officer and any other person pursuant to which he or she is or was to be selected as a director or officer of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Vote Required </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Directors will be elected by a
plurality vote of the shares of Common Stock present or represented and entitled to vote on this matter at the Annual Meeting. Accordingly, the candidates receiving the highest number of affirmative votes of shares represented and voting on this
proposal at the Annual Meeting will be elected directors of the Company. Votes withheld from a nominee and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will be counted for purposes of determining the presence or absence of a quorum but,
because directors are elected by a plurality vote, will have no impact once a quorum is present. See &#147;Quorum; Abstentions; Broker <FONT STYLE="white-space:nowrap">Non-Votes.&#148;</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>THE CLASS II AND III DIRECTORS RECOMMEND THAT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>STOCKHOLDERS VOTE </B><B><I>FOR </I></B><B>THE CLASS I NOMINEES LISTED ABOVE. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_3"></A>PROPOSAL TWO </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_3a"></A>RATIFICATION OF SELECTION OF PRICEWATERHOUSECOOPERS LLP </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM TO THE COMPANY FOR </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>THE FISCAL YEAR ENDING DECEMBER&nbsp;31, 2017 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Audit Committee of the Board of Directors has selected PricewaterhouseCoopers LLP, an independent registered public accounting firm,
to audit our financial statements for the fiscal year ending December&nbsp;31, 2017, and recommends that the stockholders vote for ratification of such selection. Although action by stockholders is not required by law, the Board of Directors has
determined that it is desirable to request ratification of this selection by the stockholders. Notwithstanding the selection or ratification, the Audit Committee, in its discretion, may direct the selection of a new independent registered public
accounting firm at any time during the year, if the Audit Committee determines that such a change would be in our best interest. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Representatives of PricewaterhouseCoopers LLP are expected to be present at the meeting and will be afforded the opportunity to make a
statement if they desire to do so, and are expected to be available to respond to appropriate questions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Principal Accountant Fees and Services </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Fees incurred for professional services provided by our independent registered public accounting firm for each of the last two fiscal
years were: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #fcfcfc"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Years Ended<BR>December&nbsp;31,</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">2016</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">2015</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Audit Fees</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$1,069,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$842,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Audit-Related Fees</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">189,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Tax Fees</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Other Fees</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$1,260,175</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$844,740</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">PricewaterhouseCoopers LLP served as our independent registered public accounting firm for the years ended
December&nbsp;31, 2016, 2015 and 2014. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">For the fiscal years ended December&nbsp;31, 2016 and 2015, Audit Fees were $1,069,375 and
$842,940, respectively. The Audit Fees included fees of $1,003,375 for 2016 and $842,940 for 2015 associated with the annual audit of our financial statements, Sarbanes-Oxley Act compliance and the interim review of our financial statements included
in quarterly reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q.</FONT> Audit Fees also include services provided in connection with the issuance of comfort letters, and consents relating to registration statement filings with the SEC and
tax provision review. Additionally in 2016, Audit-Related Fees of $189,000 were billed for services provided in connection with accounting consultation for our partnership and co-investment activities. Other Fees consist of the cost of our
subscription to an accounting research tool provided by PricewaterhouseCoopers LLP. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">All audit services and <FONT
STYLE="white-space:nowrap">non-audit</FONT> services provided to us by our independent registered public accounting firm are required to be <FONT STYLE="white-space:nowrap">pre-approved</FONT> by the Audit Committee. The <FONT
STYLE="white-space:nowrap">pre-approval</FONT> of <FONT STYLE="white-space:nowrap">non-audit</FONT> services to be provided by PricewaterhouseCoopers LLP includes making a determination that the provision of the services is compatible with
maintaining the independence of PricewaterhouseCoopers LLP as our independent registered public accounting firm. All services for audit and other fees set forth in the table above were <FONT STYLE="white-space:nowrap">pre-approved</FONT> by the
Audit Committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>PROPOSAL TWO </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Vote Required </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The affirmative vote of the
holders of a majority of the shares present in person or represented by proxy and entitled to vote at the Annual Meeting will be required to ratify the selection of PricewaterhouseCoopers LLP. Abstentions will have the same effect as negative votes.
Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are counted towards a quorum, but are not counted for any purpose in determining whether this matter has been approved. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>THE BOARD OF DIRECTORS RECOMMENDS THAT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>STOCKHOLDERS VOTE </B><B><I>FOR </I></B><B>RATIFICATION OF THE SELECTION BY THE AUDIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>COMMITTEE OF THE BOARD OF DIRECTORS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>PRICEWATERHOUSECOOPERS LLP AS INDEPENDENT REGISTERED PUBLIC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>ACCOUNTING FIRM TO THE COMPANY </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>FOR THE FISCAL
YEAR ENDING DECEMBER&nbsp;31, 2017. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_4"></A>PROPOSAL THREE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_4a"></A>APPROVAL OF AN AMENDMENT TO THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>AMENDED AND RESTATED 2004 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">We are asking our stockholders to approve the Company&#146;s Amended and Restated 2004 Equity Incentive Plan (the &#147;A&amp;R 2004
EIP&#148;), to increase the number of authorized shares of Common Stock reserved for issuance under the A&amp;R 2004 EIP by 3,900,000&nbsp;shares. The Board of Directors has approved the increase of the authorized share reserve under the A&amp;R
2004 EIP, subject to approval from our stockholders at the Annual Meeting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Company&#146;s 2004 Equity Incentive Plan (the
&#147;2004 EIP&#148;) was originally adopted by our Board of Directors in January 2004 and approved by our stockholders in February 2004. Our stockholders approved amendments to the 2004 EIP in May 2008,&nbsp;May 2009,&nbsp;May 2010,&nbsp;May 2011,
May 2012 and May 2015. A total of 266,667 shares of our Common Stock were initially authorized for issuance under the 2004 EIP. The authorized amount was thereafter increased: (i)&nbsp;by application of the evergreen provisions of the 2004 EIP,
through May 2008; (ii)&nbsp;by shares returned to our 1997 Stock Option/Stock Issuance Plan (the &#147;1997 Plan&#148;) that were rolled into the 2004 EIP pursuant to the terms of the 2004 EIP; and (iii)&nbsp;by stockholder approval at each of the
Company&#146;s annual meetings from May 2008 through May 2015. As of February&nbsp;28, 2017, a total of 7,737,190&nbsp;shares of our Common Stock were authorized for issuance under the 2004 EIP. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Board of Directors believes that this is an appropriate time to update the terms of the A&amp;R 2004 EIP with respect to a number of
substantive provisions, and it therefore approved an amendment and restatement of the A&amp;R 2004 EIP. In addition, our Board of Directors believes that the number of shares of our Common Stock that remain available for issuance under the A&amp;R
2004 EIP is insufficient to achieve the purposes of the plan over the term of the plan. Accordingly, the Board of Directors is now requesting that the stockholders approve the A&amp;R 2004 EIP, as well as an increase to the number of authorized
shares of Common Stock reserved for issuance under the A&amp;R 2004 EIP of 3,900,000&nbsp;shares. The Board of Directors has approved this increase to the authorized share reserve, subject to approval from our stockholders at the Annual Meeting. If
this Proposal Three is not approved by our stockholders, the A&amp;R 2004 EIP will continue in accordance with its existing terms, and there will be no such increase to the number of shares of Common Stock reserved for issuance under the A&amp;R
2004 EIP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Amendment to the Amended and Restated 2004 Equity Incentive Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The following is a summary of the proposed amendment to the A&amp;R 2004 EIP. This summary is qualified in its entirety by reference to
the actual text of the A&amp;R 2004 EIP and the proposed amendment thereto, which is appended to this Proxy Statement as Appendix&nbsp;A. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">We propose to increase the number of authorized shares of our Common Stock reserved for issuance under the A&amp;R 2004
EIP by an additional 3,900,000&nbsp;shares, from 7,737,190&nbsp;shares as of February&nbsp;28, 2017 to 11,637,190&nbsp;shares, subject to stockholder approval of this amendment. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Board of Directors believes that the approval of the A&amp;R 2004 EIP is essential to our continued success. We believe that our
employees are one of our most valuable assets and that the issuance of awards under the A&amp;R 2004 EIP is a critical factor in our ability to attract and retain outstanding and highly skilled individuals in the extremely competitive labor markets
in which we operate. Such awards also are crucial to our ability to motivate our employees to achieve our goals. This Proposal Three is intended to provide sufficient shares to fund anticipated equity awards under the A&amp;R 2004 EIP until our 2018
Annual Meeting of Stockholders. If approved, the number of authorized shares of Common Stock available for issuance under the A&amp;R 2004 EIP, as a percentage of the number of shares of our Common Stock issued and outstanding, would be consistent
with those of our Peer Companies (as defined in the Compensation Discussion and Analysis section of this proxy statement). For our Peer Companies, this percentage ranges between 2.4% and 4.5% annually. For the past three years (2014 through 2016)
the Company has granted an average of 4.2% annually, based on the number of shares of our Common Stock issued and outstanding. As discussed above, the Board of Directors believes that our ability to issue awards to our employees under the A&amp;R
2004 EIP at a level that is competitive with our Peer Companies is critical to our ability to succeed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>A&amp;R 2004 EIP Outstanding Awards and Available Shares
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">As of February&nbsp;28, 2017, a total of 6,048,149 shares of our Common Stock were subject to outstanding stock options awarded
under the A&amp;R 2004 EIP. As of such date, these stock option awards had a weighted average exercise price of $9.47 per share and a weighted average remaining term of 7.14 years. No stock option awards were granted under the A&amp;R 2004 EIP in
which the exercise price for the underlying shares was less than the fair market value of such shares on the date of grant. As of February&nbsp;28, 2017, there were 461,252 unvested restricted stock units outstanding and 800,507 shares available for
grant, respectively, under the A&amp;R 2004 EIP </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>PROPOSAL THREE </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Summary of the Amended and Restated 2004 Equity Incentive Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The following is a summary of the principal features of the A&amp;R 2004 EIP, as approved by the Board of Directors and subject to
stockholder approval as described in this Proposal&nbsp;Three. The summary is qualified in its entirety by reference to the A&amp;R 2004 EIP, appended to this Proxy Statement as Appendix&nbsp;A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The A&amp;R 2004 EIP provides for the grant of the following types of incentive awards: (i)&nbsp;stock options, including incentive stock
options and nonstatutory stock options, (ii)&nbsp;stock appreciation rights (&#147;SARs&#148;), (iii)&nbsp;restricted stock, (iv)&nbsp;restricted stock units, (v)&nbsp;performance shares, and (vi)&nbsp;performance units. Each of these is referred to
as an &#147;Award.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Eligibility. </I>Under the A&amp;R 2004 EIP, eligible individuals include employees and consultants who
provide services to us as well as members of our Board of Directors. As of February&nbsp;28, 2017, each of our approximately 136 employees, 34 consultants and each of our 7 <FONT STYLE="white-space:nowrap">non-employee</FONT> directors will be
eligible for Awards under the A&amp;R 2004 EIP. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Number of Shares of Stock Available Under the A&amp;R 2004 EIP.</I>&nbsp;The
maximum aggregate number of shares that may be issued under the A&amp;R 2004 EIP, after giving effect to the addition of shares proposed to be added under this Proposal Three, is 11,637,190&nbsp;shares. During the term of the A&amp;R 2004 EIP, we
will at all times reserve and keep available such number of shares of our Common Stock as will be sufficient to satisfy the requirements of the A&amp;R 2004 EIP. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Fungible Ratio</I>. Under the 2004 EIP, shares of stock subject to Awards that are not options or SARs (called &#147;Full Value&#148;
Awards) count against the share reserve as two shares for every one share subject to such an Award, and if shares subject to such Full Value Awards are forfeited or repurchased by us and would otherwise return to the 2004 EIP, then two times the
number of shares so forfeited or repurchased will become available for future issuance under the 2004 EIP. With respect to Awards granted on and after May&nbsp;20, 2015 under the A&amp;R 2004 Plan, shares of our Common Stock subject to Full Value
Awards will count against the share reserve as 1.17 shares for every one share of stock subject to such an Award, and if shares subject to such Full Value Awards are forfeited or repurchased by us and would otherwise return to the A&amp;R 2004 EIP,
as described below, 1.17 times the number of shares of stock so forfeited or repurchased will become available for future issuance under the A&amp;R 2004 EIP. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Return of Shares Subject to an Option or SAR</I>. Shares that have actually been issued under the A&amp;R 2004 EIP under any Award,
including an option, will not be returned to the A&amp;R 2004 EIP and will not become available for future issuance under the A&amp;R 2004 EIP. Upon exercise of a SAR settled in shares, the gross number of shares covered by the portion of the SAR so
exercised will cease to be available under the A&amp;R 2004 EIP. If the exercise price of an option is paid by a tender to us of shares owned by the participant, the number of shares available for issuance under the A&amp;R 2004 EIP will be reduced
by the gross number of shares for which the option is exercised. Shares used to pay the exercise price of an Award and/or used to satisfy tax withholding obligations will not become available for future grant or sale under the A&amp;R 2004 EIP. If
an Award that is an option or SAR expires or becomes unexercisable without having been exercised in full, the unpurchased shares which were subject to the Award will become available for future grant or sale under the A&amp;R 2004 EIP. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Return of Shares or Units Subject to Full Value Awards</I>. With respect to Full Value Awards, if shares are repurchased or reacquired
by us or units are forfeited by the participant due to failure to vest, the repurchased shares or forfeited units which were subject to the Award will become available for future grant or sale under the A&amp;R 2004 EIP. To the extent an Award is
paid out in cash rather than stock, such cash payment will not reduce the number of shares available for issuance under the A&amp;R 2004 EIP. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Maximum Shares Issuable under Incentive Stock Options</I>. The maximum number of shares that may be issued upon the exercise of
incentive stock options under the A&amp;R 2004 EIP will be 11,637,190. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">If we declare a stock dividend or engage in a reorganization
or other change in our capital structure, including in connection with a merger, the Administrator (as defined below) will make appropriate adjustments under the A&amp;R 2004 EIP with respect to (i)&nbsp;the number and class of shares available for
issuance, (ii)&nbsp;the number, class and price of shares subject to outstanding Awards, (iii)&nbsp;the maximum number of shares issuable, and (iv)&nbsp;the specified <FONT STYLE="white-space:nowrap">per-person</FONT> limits on Awards to reflect the
change. As of February&nbsp;28, 2017, the closing price of a share of our Common Stock as reported on the NASDAQ Capital Market was $10.60. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Administration of the A&amp;R 2004 EIP.</I>&nbsp;The Board of Directors, or a committee of directors or of other individuals satisfying
applicable laws and appointed by the Board of Directors (referred to as the &#147;Administrator&#148;), will administer the A&amp;R 2004 EIP. The Board of Directors has delegated administration of the A&amp;R 2004 EIP to the Compensation and Talent
Committee of the Board of Directors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Subject to the terms of the A&amp;R 2004 EIP, the Administrator has broad authority to
administer, interpret and construe the A&amp;R 2004 EIP and Awards granted under the A&amp;R 2004 EIP. The Administrator, may, among other things, determine the employees, consultants, and directors who will receive Awards, the numbers and types of
Awards to be granted and the terms and conditions of Awards, including the relevant vesting conditions, and in the case of stock options and SARs, the periods of their exercisability. The Administrator may also amend outstanding awards. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Administrator may, with stockholder approval, implement an exchange program under which (i)&nbsp;outstanding Awards may be surrendered
or cancelled in exchange for Awards of the same type, Awards of a different type, or cash; (ii)&nbsp;participants </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>PROPOSAL THREE </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">would have the opportunity to transfer any outstanding Awards to a financial institution or other person or entity selected by the Administrator; and/or
(iii)&nbsp;the exercise price of an outstanding Award could be reduced. However, subject to certain mandatory adjustment provisions set forth in the A&amp;R 2004 EIP (and described above), the Administrator cannot amend the terms of any Award to
reduce the exercise price of such outstanding Award or cancel an outstanding Award in exchange for cash or other Awards with an exercise price that is less than the exercise price of the original Award, without stockholder approval. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">All decisions, determinations and interpretations made by the Administrator will be final and binding on all participants and any other
holders of Awards. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Options and Stock Appreciation Rights.</I><I></I>&nbsp;The Administrator may grant nonstatutory stock options,
incentive stock options and SARs under the A&amp;R 2004 EIP. The Administrator determines the number of shares subject to each option or SAR. The aggregate fair market value, determined at the time of grant, of shares of stock with respect to
incentive stock options that are exercisable for the first time by a participant during any calendar year under all of our stock plans may not exceed $100,000. The stock options or portions of stock options that exceed this limit are treated as
nonstatutory stock options. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The exercise price of options and SARs granted under the A&amp;R 2004 EIP will be no less than the fair
market value of our Common Stock on the date of grant, except that the exercise price of an incentive stock option granted to any participant who owns more than 10% of the total voting power of all classes of our outstanding stock will be at least
110% of the fair market value of the stock on the grant date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The term of each option or SAR will be set forth in the Award agreement
and may not exceed ten years, except that the term of an incentive stock option granted to a participant who owns more than 10% of the total voting power of all classes of our outstanding stock may not exceed five years. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">After a participant terminates service with us, the participant may exercise the vested portion of his or her option or SAR for the period
of time stated in the Award agreement (not to exceed the original term of the Award). If no such period of time is stated in the participant&#146;s Award agreement, the participant (or, if applicable, the participant&#146;s estate) generally may
exercise the option or SAR for (i)&nbsp;three months following the participant&#146;s termination for reasons other than death or disability, and (ii)&nbsp;twelve months following the participant&#146;s termination due to death or disability. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Administrator determines the form of payment it will accept when a participant exercises an option or SAR, which may include
(i)&nbsp;cash, (ii)&nbsp;check, (iii)&nbsp;other shares of stock (provided that such shares have a fair market value on the date of surrender equal to the aggregate exercise price of the shares as to which the option or SAR will be exercised and
that the acceptance of such shares, as determined by the Administrator, will not result in adverse accounting consequences to the Company), (iv)&nbsp;consideration received by us under a cashless exercise program implemented by us, (v)&nbsp;other
consideration and methods of payment permitted by applicable laws, or (vi)&nbsp;any combination of the foregoing methods of payment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Unless otherwise stated in the applicable Award Agreement, an individual holding or exercising an Option or SAR shall have none of the
rights of a stockholder (for example, the right to receive cash or dividend payments or distributions attributable to the subject Shares or to direct the voting of the subject Shares) until the shares covered thereby are fully paid and issued to
him. In no case shall an individual holding an Option receive cash or dividend payments or distributions or dividend equivalents attributable to unvested Shares underlying an Option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Restricted Stock.</I>&nbsp;An Award of restricted stock is an issuance of shares of our Common Stock, subject to restrictions that
lapse (or vest) based upon the satisfaction of the applicable terms and conditions (including vesting) established by the Administrator in its sole discretion. The Administrator will determine the number of shares granted pursuant to an Award of
restricted stock. The Administrator, in its discretion, may accelerate the time at which any restrictions will lapse or be removed. The Award agreement generally will grant us a right to repurchase or reacquire the shares upon the termination of the
participant&#146;s service with us for any reason, including death or disability. On the date set forth in the Award agreement, all unvested restricted stock will be forfeited to us. Any dividends declared with respect to shares of our Common Stock
subject to an Award of restricted stock shall be paid to participants only after the underlying restricted stock has vested or has been earned and not during the performance or service vesting period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Restricted Stock Units. </I>An Award of restricted stock unit represents the right, subject to certain terms and conditions, to be
issued one share of stock for each unit that vests or otherwise satisfies applicable performance conditions. Each Award of restricted stock units will be evidenced by an Award agreement that will set forth the terms and conditions of the Award. The
Administrator may establish service-based or other vesting criteria (including performance-based vesting criteria) in its discretion, which, depending on the extent to which such criteria are met, will determine the number of restricted stock units
to be paid to participants. The restricted stock units will vest at a rate determined by the Administrator; provided, however, that after the grant of the restricted stock units, the Administrator, in its sole discretion, may reduce or waive any
vesting provisions for such restricted stock units. Vested restricted stock units will be settled in shares of our Common Stock as soon as administratively practicable following the date on which such restricted stock units vest. On the date set
forth in the Award agreement, all unvested restricted stock units will be forfeited to us. No dividends or dividend equivalent rights will be paid to participants unless and until the underlying Award of restricted stock unit has vested. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>PROPOSAL THREE </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Performance Shares and Performance Units.</I>&nbsp;Performance shares and performance units are Awards under which the release of
shares or vesting of units requires the achievement of performance goals or objectives or other conditions established by the Administrator. The Administrator will determine the number of performance shares or performance units to be granted to a
participant. Each Award of performance units or performance shares will be evidenced by an Award agreement and will specify the performance period and such other terms and conditions as determined by the Administrator, including the rate at which
the shares or units will vest. After the applicable performance period has ended, any performance shares or performance units earned or vested will be paid, in the Administrator&#146;s sole discretion, in the form of cash, shares of our Common
Stock, or in a combination thereof. The extent to which the performance objectives are met will determine the number and/or the value of performance units and performance shares to be paid out to participants, however, the Administrator may reduce
or waive any performance objectives or other vesting provisions for such performance unit or performance share, in its sole discretion. On the date set forth in the Award agreement, all unearned or unvested performance units and performance shares
will be forfeited to us. No cash dividends or distributions declared with respect to shares of our Common Stock subject to the performance shares or performance units shall be paid to any participant unless and until the participant vests in such
underlying performance shares or performance units.&nbsp;Any stock dividends declared on shares of our Common Stock that are subject to a performance share or performance unit will be subject to the same restrictions and will vest at the same time
as the performance shares and performance units from which said dividends were derived. All unvested dividends will be forfeited by the participants to the extent their underlying performance shares or performance units are forfeited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:1%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Performance-Based Awards under Section&nbsp;162(m) of the Code </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The A&amp;R 2004 EIP allows us to grant Awards that may qualify as &#147;performance-based compensation,&#148; so that the value of such
Awards is not subject to the $1&nbsp;million limitation on deductibility of compensation paid to a &#147;covered employee&#148; under Section&nbsp;162(m) of the Code. &#147;Covered employees&#148; are generally the chief executive officer and the
top three most highly compensated officers other than the chief financial officer. While we believe it is in the best interests of the Company and our stockholders to preserve the ability to grant &#147;performance-based compensation&#148; under
Section&nbsp;162(m) of the Code, in certain circumstances, we may determine to grant compensation to covered employees that will not qualify as &#147;performance-based compensation&#148; for purposes of Section&nbsp;162(m) of the Code. Moreover,
even if we intend to grant compensation that qualifies as &#147;performance-based compensation,&#148; we cannot guarantee that such compensation ultimately will be deductible by us. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">For the grant of awards under a plan to qualify as &#147;performance-based compensation&#148; under Section&nbsp;162(m) of the Code, among
other things, the plan must (1)&nbsp;describe the employees eligible to receive such awards, (2)&nbsp;provide a <FONT STYLE="white-space:nowrap">per-person</FONT> limit on the number of shares subject to stock options and performance stock awards,
granted to any employee under the plan in any year, and (3)&nbsp;include one or more <FONT STYLE="white-space:nowrap">pre-established</FONT> business criteria upon which the performance goals for performance awards may be granted (or become vested
and/or exercisable). These terms must be approved by our stockholders and, accordingly, we are requesting our stockholders to approve the A&amp;R 2004 EIP, which includes terms regarding eligibility for awards,
<FONT STYLE="white-space:nowrap">per-person</FONT> limits on awards and the business criteria for performance awards granted under the A&amp;R 2004 EIP (as described in the summary below). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Under the A&amp;R 2004 EIP, Awards may be subject to one or more of the following performance goals, either alone or in combination
(collectively, the &#147;Performance Goals&#148;): (a)&nbsp;cash position, (b)&nbsp;clinical progression, (c)&nbsp;collaboration arrangements, (d)&nbsp;collaboration progression, (e)&nbsp;earnings per share, (f)&nbsp;a financing event, (g)&nbsp;net
income, (h)&nbsp;operating cash flow, (i)&nbsp;market share, (j)&nbsp;operating expenses, (k)&nbsp;operating income, (l)&nbsp;product approval, (m)&nbsp;product revenues, (n)&nbsp;profit after tax, (o)&nbsp;projects in development,
(p)&nbsp;regulatory filings, (q)&nbsp;return on assets, (r)&nbsp;return on equity, (s)&nbsp;revenue growth, and (t)&nbsp;total stockholder return, (u)&nbsp;implementation of, progression in or completion of projects or processes (including, without
limitation, progress in research or development programs, progress in regulatory or compliance initiatives, clinical trial initiation, clinical trial enrollment, clinical trial results, new or supplemental indications for existing products,
regulatory filing submissions, regulatory filing acceptances, regulatory or advisory committee interactions, regulatory approvals, product supply and systems development and implementation), (v)&nbsp;completion of a joint venture or other corporate
transaction, (w)&nbsp;employee retention, (x)&nbsp;budget management and (y)&nbsp;to the extent that an Award is not intended to comply with Section&nbsp;162(m) of the Code, other measures of performance selected by the Board of Directors. Any
Performance Goals may be used to measure the performance of the Company as a whole, a business or divisional unit of the Company, or with respect to an individual participant&#146;s performance. In addition, Performance Goals may be measured
relative to a peer group or index or to another Performance Goal, and the Performance Goals may differ from one participant to the next and from one Award to the next. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Prior to the date that will not jeopardize qualification of an Award intended to qualify as &#147;performance-based compensation&#148;
under Section&nbsp;162(m) of the Code, the Administrator will determine whether any significant element(s) will be included in or excluded from the calculation of any Performance Goal with respect to any participant. In all other respects,
Performance Goals will be calculated in accordance with the Company&#146;s financial statements, generally accepted accounting principles, or under a methodology established by the Administrator prior to the issuance of an Award, which is
consistently applied and identified in the financial statements, including footnotes, or the management discussion and analysis of the Company&#146;s annual report. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>PROPOSAL THREE </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Under the A&amp;R 2004 EIP, for Awards that are intended to qualify as &#147;performance-based compensation&#148; under
Section&nbsp;162(m) of the Code, no participant will receive an Award of options or SARs covering more than 500,000 shares of stock. With respect to Awards of performance shares or performance units that are intended to qualify as
&#147;performance-based compensation&#148; under Section&nbsp;162(m) of the Code, no participant will receive an Award of more than 500,000 performance shares (or the equivalent in performance units). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Transferability of Awards.</I>&nbsp;Awards are generally not transferable, and all rights with respect to an Award granted to a
participant generally will be available during a participant&#146;s lifetime only to the participant. The Administrator, however, may make an Award transferable to certain family members, trusts or related business entities of the participant, or to
organizations as charitable donations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Change in Control.</I>&nbsp;In the event of a change in control of the Company (as defined
in the A&amp;R 2004 EIP and described below), each outstanding Award will be assumed or an equivalent option or right substituted by the successor corporation or a parent or subsidiary of the successor corporation. If the successor corporation
refuses to assume or substitute for the Award, then: (i)&nbsp;the participant will fully vest in, and have the right to exercise, all of his or her outstanding options and SARs, including shares as to which such Awards would not otherwise be vested
or exercisable; (ii)&nbsp;all restrictions on restricted stock will lapse; and, (iii)&nbsp;with respect to performance shares, performance units and restricted stock units, all performance goals or other vesting criteria will be deemed achieved at
target levels and all other terms and conditions met. In addition, if an option or SAR is not assumed or substituted for in the event of a change in control, the Administrator will notify the participant that the option or SAR will be fully vested
and exercisable for a period of time prior to the change in control determined by the Administrator in its sole discretion, and the option or SAR will terminate upon the expiration of such period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">With respect to Awards granted to a <FONT STYLE="white-space:nowrap">non-employee</FONT> director of the Company that are assumed or
substituted for, if on the date of or following such assumption or substitution the participant&#146;s status as a director or a director of the successor corporation, as applicable, is terminated other than upon a voluntary resignation by the
participant not at the request of the successor, then: (i)&nbsp;the participant will fully vest in, and have the right to exercise, his or her options and SARs as to all of the shares subject to the Award; (ii)&nbsp;all restrictions on restricted
stock shall lapse; and, (iii)&nbsp;with respect to performance shares, performance units and restricted stock units, all performance goals or other vesting criteria will be deemed achieved at target levels and all other terms and conditions met.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">For purposes of the A&amp;R 2004 EIP, a change in control generally means the occurrence of any of the following events: (i)&nbsp;any
&#147;person&#148; (as defined in Sections&nbsp;13(d) and 14(d) of the Exchange Act) becomes the &#147;beneficial owner&#148; (as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;13d-3</FONT> of the Exchange Act), directly or indirectly, of
securities of the Company representing 50% or more of the total voting power of our then outstanding voting securities; (ii)&nbsp;consummation of the sale or disposition by us of all or substantially all of our assets; (iii)&nbsp;a change in the
composition of the Board of Directors occurring within a <FONT STYLE="white-space:nowrap">two-year</FONT> period, as a result of which fewer than a majority of the directors are &#147;incumbent directors&#148; (as defined in the A&amp;R 2004
EIP);&nbsp;or (iv)&nbsp;consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto
continuing to represent at least 50% of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Amendment and Termination of the A&amp;R 2004 EIP.</I>&nbsp;The Administrator has the authority to amend, alter, suspend or terminate
the A&amp;R 2004 EIP at any time, except that stockholder approval will be required for any amendment to the A&amp;R 2004 EIP to the extent required by applicable laws. No amendment, alteration, suspension or termination of the A&amp;R 2004 EIP will
impair the rights of any participant without his or her consent. The A&amp;R 2004 EIP will terminate on May&nbsp;20, 2025 unless the Administrator terminates it earlier. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>New Plan Benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Awards that an employee,
director or consultant may receive under the A&amp;R 2004 EIP are granted in the Administrator&#146;s discretion and are not subject to set benefits or amounts, and we have not approved any Awards that are conditioned on stockholder approval of the
A&amp;R 2004 EIP. Therefore, we cannot currently determine the benefits, amounts or number of shares subject to Awards that may be granted in the future to our executive officers and other employees, directors or consultants under the A&amp;R 2004
EIP. For information on the number of shares subject to awards granted under the 2004 EIP during 2016 for our named executive officers, see the &#147;Grants of Plan Based Awards Table in 2016&#148; later in this proxy statement. The total number of
shares subject to awards granted in fiscal 2016 under the 2004 EIP was 1,493,675. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Federal Income Tax Consequences </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The following is a summary of the principal United States federal income taxation consequences to participants and us with respect to
participation in the A&amp;R 2004 EIP. This summary is not intended to be exhaustive and does not discuss the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>PROPOSAL THREE </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">income tax laws of any local, state or foreign jurisdiction in which a participant may reside. The information is based upon current federal income tax
rules and therefore is subject to change when those rules change. Because the tax consequences to any participant may depend on his or her particular situation, each participant should consult his or her tax adviser regarding the federal, state,
local, and other tax consequences of the grant or exercise of an Award or the disposition of shares of stock acquired under the A&amp;R 2004 EIP. The A&amp;R 2004 EIP is not qualified under the provisions of Section&nbsp;401(a) of the Code and is
not subject to any of the provisions of the Employee Retirement Income Security Act of 1974, as amended. Our ability to realize the benefit of any tax deductions described below depends on our generation of taxable income as well as the requirement
of reasonableness, the provisions of Section&nbsp;162(m) of the Code and the satisfaction of our tax reporting obligations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Nonstatutory Stock Options. </I>No taxable income is reportable when a nonstatutory stock option is granted to a participant. Upon
exercise, the participant will recognize ordinary income in an amount equal to the excess of the fair market value (on the exercise date) of the shares purchased over the exercise price of the option. Any taxable income recognized in connection with
an option exercise by an employee of the Company is subject to tax withholding by us. Any gain or loss recognized upon any later disposition of the shares would be capital gain or loss. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Incentive Stock Options.</I>&nbsp;No taxable income is reportable when an incentive stock option is granted or exercised (except for
purposes of the participant&#146;s alternative minimum tax at exercise, if any, in which case the amount of tax is the same as for nonstatutory stock options). If the participant exercises the option and then later sells or otherwise disposes of the
shares more than two years after the grant date and more than one year after the exercise date, the difference between the sale price and the exercise price will be taxed as capital gain or loss. If the participant exercises the option and then
later sells or otherwise disposes of the shares before the end of the <FONT STYLE="white-space:nowrap">two-</FONT> or <FONT STYLE="white-space:nowrap">one-year</FONT> holding periods described above, he or she generally will have ordinary income at
the time of the sale equal to the fair market value of the shares on the exercise date (or the sale price, if less) minus the exercise price of the option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Stock Appreciation Rights.</I>&nbsp;No taxable income is reportable when a SAR is granted to a participant. Upon exercise, the
participant will recognize ordinary income in an amount equal to the amount of cash received and/or the fair market value of any shares received. Any gain or loss recognized upon any later disposition of the shares would be capital gain or loss.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Restricted Stock and Performance Shares.</I>&nbsp;A participant generally will not have taxable income at the time an Award of
restricted stock or performance shares are granted. Instead, he or she will recognize ordinary income in the first taxable year in which his or her interest in the shares underlying the Award becomes either (i)&nbsp;freely transferable, or
(ii)&nbsp;no longer subject to substantial risk of forfeiture. However, the recipient of a restricted stock Award may elect, under Section&nbsp;83(b) of the Code, to recognize income at the time he or she receives the Award in an amount equal to the
fair market value of the shares underlying the Award (less any cash paid for the shares) on the date the Award is granted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Restricted Stock Units and Performance Units.</I>&nbsp;A participant generally will not have taxable income at the time restricted
stock units or performance units are granted. Instead, he or she will recognize ordinary income upon distribution of shares with respect to a restricted stock unit in an amount equal to the fair market value of those shares. Any gain or loss
recognized upon any other disposition of the shares would be capital gain or loss. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Section</I><I></I><I>&nbsp;409A. </I>If an
Award is subject to and fails to satisfy the requirements of Section&nbsp;409A of the Code the participant may recognize ordinary income on the amounts deferred under the Award, to the extent vested, which may be prior to when the compensation is
actually or constructively received. Also, if an Award that is subject to Section&nbsp;409A of the Code fails to comply with the provisions of Section&nbsp;409A of the Code, Section&nbsp;409A of the Code imposes an additional 20% federal income tax
on compensation recognized as ordinary income, as well as interest on such deferred compensation. Some states may also apply a penalty tax (for instance, California imposes a 20% penalty tax in addition to the 20% federal penalty tax). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Tax Effect for the Company; Section</I><I></I><I>&nbsp;162(m).</I>&nbsp;We generally will be entitled to a tax deduction in connection
with an Award under the A&amp;R 2004 EIP in an amount equal to the ordinary income realized by a participant and at the time the participant recognizes such income (for example, upon exercise of a nonstatutory stock option), provided that we satisfy
certain tax withholding requirements applicable to such income. Section&nbsp;162(m) of the Code limits the deductibility of compensation paid to our Chief Executive Officer (i.e., our principal executive officer) and to each of our three most highly
compensated executive officers for the taxable year (other than the principal financial officer). As discussed above, the A&amp;R 2004 EIP has been designed to permit the Administrator to grant Awards that are intended to qualify as
performance-based compensation within the meaning of Section&nbsp;162(m) of the Code for purposes of satisfying the exemption from these deduction limits, but not all Awards may so qualify, and the Administrator retains full discretion to grant
Awards that are not intended to so qualify. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">THE FOREGOING IS ONLY A SUMMARY OF THE EFFECT OF FEDERAL INCOME TAXATION UPON
PARTICIPANTS AND THE COMPANY WITH RESPECT TO THE GRANT AND EXERCISE OF AWARDS UNDER THE A&amp;R 2004 EIP. IT DOES NOT PURPORT TO BE COMPLETE, AND DOES NOT DISCUSS THE TAX CONSEQUENCES OF A PARTICIPANT&#146;S DEATH OR THE PROVISIONS OF THE INCOME TAX
LAWS OF ANY MUNICIPALITY, STATE OR FOREIGN COUNTRY IN WHICH THE PARTICIPANT MAY RESIDE. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>PROPOSAL THREE </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Vote Required and Board of Directors Recommendation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The approval of the amendment to the A&amp;R 2004 EIP requires the affirmative vote of a majority of the shares present in person or
represented by proxy at the Annual Meeting. Abstentions will have the same effect as negative votes. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are counted towards a quorum, but are not counted for any purpose in determining whether
this matter has been approved. The A&amp;R 2004 EIP will not become effective if our stockholders do not vote FOR its approval. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>THE BOARD OF
DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE </B><B><I>FOR </I></B><B>APPROVAL </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>OF THE AMENDMENT TO THE AMENDED AND RESTATED 2004 EQUITY
INCENTIVE PLAN (THE &#147;A&amp;R 2004 EIP&#148;) TO INCREASE THE NUMBER OF AUTHORIZED SHARES RESERVED FOR ISSUANCE UNDER THE A&amp;R 2004 EIP BY 3,900,000&nbsp;SHARES. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_5"></A>PROPOSAL&nbsp;FOUR </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_5a"></A>ADVISORY VOTE ON EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">At the 2011 Annual Meeting of Stockholders, our stockholders indicated their preference that the Company solicit an advisory (nonbinding)
vote on the compensation of our named executive officers commonly referred to as a &#147;say on pay&#148; vote, every three years. Our Board of Directors has adopted a policy that is consistent with that preference. In accordance with that policy,
we are seeking the stockholders&#146; approval, on an advisory basis, of the compensation of our named executive officers as disclosed pursuant to the SEC&#146;s compensation disclosure rules (which disclosure includes the Compensation Discussion
and Analysis, the related compensation tables and the narrative disclosure to those tables, on pages&nbsp;27 to 36 in this proxy statement). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Compensation and Talent Committee, which is responsible for designing and administering the Company&#146;s executive compensation
program, has designed our executive compensation program to provide a competitive and internally equitable compensation and benefits package that reflects Company performance, job complexity, and strategic value of the position while seeking to
ensure the individual&#146;s long-term retention and motivation and alignment with the long-term interests of the Company&#146;s stockholders. We believe the compensation program for our named executive officers has been instrumental in helping the
Company retain an executive team capable of managing the Company through the challenging business and economic environment over the past several years and enabling the Company to advance its research and development programs, including its clinical
development programs. We encourage you to carefully review the section entitled &#147;Compensation Discussion and Analysis&#148; of this proxy statement for additional details on the Company&#146;s executive compensation, including our compensation
philosophy and objectives, as well as the reasons and processes for how our Compensation and Talent Committee determined the structure and amounts of the 2016 compensation of our named executive officers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">We are asking our stockholders to indicate their support for our named executive officer compensation as described in this proxy
statement. This vote is not intended to address any specific item of compensation, but rather the overall 2016 compensation of our named executive officers (including the philosophy, policies and practices for setting such compensation) described in
this proxy statement. Accordingly, we are asking our stockholders to vote &#147;FOR&#148; the following resolution at the Annual Meeting: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">&#147;RESOLVED, that the Company&#146;s stockholders approve, on an advisory basis, the compensation of the Named Executive Officers, as
disclosed in the Company&#146;s proxy statement for the 2017 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the SEC, including the Compensation Discussion and Analysis, the related compensation tables and the
narrative disclosure to those tables in the proxy statement.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Vote Required </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Adoption of this resolution will require the affirmative vote of the majority of the shares of Common Stock represented in person or by
proxy and entitled to vote at the Annual Meeting. Abstentions will have the same effect as negative votes. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are counted towards a quorum, but are not counted for any purpose in determining
whether this matter has been approved. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The results of this advisory vote are not binding upon the Company. However, the Compensation
and Talent Committee values the opinions expressed by stockholders in their vote, and will consider the outcome of the vote in deciding whether any actions are necessary to address concerns raised by the vote and when making future compensation
decisions for named executive officers. Unless the Board of Directors decides to modify its policy regarding the frequency of soliciting advisory votes on the compensation of our named executive officers, the next scheduled &#147;say on pay&#148;
vote will be at our 2020 Annual Meeting of Stockholders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B></B><B><I>FOR </I></B><B>THE ADVISORY PROPOSAL&nbsp;ON EXECUTIVE COMPENSATION </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_6"></A>PROPOSAL&nbsp;FIVE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_6a"></A>ADVISORY VOTE ON FREQUENCY OF &#147;SAY ON PAY&#148; PROPOSAL </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Consistent with the requirements of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the Board of Directors is
providing the Company&#146;s stockholders with the opportunity to cast an advisory vote on how often the Company should submit a &#147;say on pay&#148; proposal, as provided for in Proposal&nbsp;Four, to stockholders. Currently, consistent with the
preference expressed by stockholders at the 2011 Annual Meeting of Stockholders, the policy of the Board of Directors is to solicit a &#147;say on pay&#148; advisory vote every three years. Accordingly, we are again providing stockholders with the
following choices: the choice of whether the &#147;say on pay&#148; advisory vote should be submitted to the stockholders annually, every two years, or every three years, or the choice to abstain from voting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Board of Directors believes that the &#147;say on pay&#148; advisory vote should be submitted to the stockholders once every three
years, and therefore the Board of Directors recommends that you vote for a three-year interval for the advisory vote on executive compensation, for the following reasons: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">A triennial approach provides regular input by stockholders, while allowing stockholders to better judge our compensation
programs in relation to our long-term performance. This benefits our institutional and other stockholders, who have historically held our stock over the long-term. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Our executive compensation program is designed to operate over the long-term and is designed to support long-term value
creation. Equity awards, mainly in the form of stock options, have historically represented a substantial portion of our executives&#146; compensation. Stock options provide significant leverage if our long-term growth objectives are achieved, while
placing a significant portion of our executives&#146; compensation at risk if our long-term objectives are not achieved. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">A triennial vote will provide our Compensation and Talent Committee and our Board of Directors sufficient time to
thoughtfully evaluate the results of the most recent advisory vote on executive compensation, discuss the implications of the vote with our stockholders and develop and implement any changes to our executive compensation program that may be
appropriate in light of the vote. A triennial vote will also allow for these changes to our executive compensation program to be in place long enough for stockholders to see and evaluate the effectiveness of these changes. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">The composition and level of compensation paid to executives in the market evolves over multiple years. A triennial
approach will allow us to review evolving practices in the market to ensure our compensation programs reflect best practices. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">We understand that our stockholders may have different views as to what is the best approach for the Board of Directors, and we look
forward to hearing from our stockholders on this Proposal. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">You may cast your vote on your preferred voting frequency by choosing the
option of one year, two years, three years or abstain from voting when you vote in response to the resolution set forth below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">&#147;RESOLVED, that the stockholders of the Company determine, on an advisory basis, that the frequency with which the stockholders of
the Company wish to have an advisory vote on the compensation of the Company&#146;s named executive officers as disclosed pursuant to the SEC&#146;s compensation disclosure rules (which disclosure includes the Compensation Discussion and Analysis,
the Summary Compensation Table, and the related tables and disclosure) is: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:1%; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Choice 1&nbsp;&#151; every three years;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:1%; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Choice 2&nbsp;&#151; every two years; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:1%; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Choice 3&nbsp;&#151; every year;&nbsp;or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:1%; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Choice 4&nbsp;&#151; abstain from voting.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Abstentions will not be counted as either votes cast for or against the Proposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Vote Required </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Stockholders are not voting to
approve or disapprove the Board of Directors&#146; recommendation. Stockholders may choose among the four choices included in the resolution above. While this is an advisory vote and, therefore, <FONT STYLE="white-space:nowrap">non-binding,</FONT>
the Board of Directors will give careful consideration to the choice which receives the most &#147;FOR&#148; votes before determining the action the Board deems most appropriate for the Company and its stockholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>THE BOARD OF DIRECTORS RECOMMENDS THAT YOU SELECT </B><B><I>&#147;EVERY THREE YEARS&#148; </I></B><B>AS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>THE FREQUENCY WITH WHICH THE COMPANY SHOULD PROVIDE ITS STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>WITH THE OPPORTUNITY TO CAST A &#147;SAY ON PAY&#148; ADVISORY VOTE. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_7"></A>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">This proxy statement, including the section entitled &#147;Compensation Discussion and Analysis&#148; set forth below, contains
&#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, Section&nbsp;21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995. These statements are based on our
current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. These forward-looking statements reflect management&#146;s current expectations concerning future results
and events and can generally be identified by the use of words such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;could,&#148; &#147;would,&#148; &#147;likely,&#148; &#147;potential,&#148; &#147;continue,&#148; &#147;future,&#148;
&#147;estimate,&#148; &#147;believe,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;assume,&#148; &#147;intend,&#148; &#147;plan,&#148; and other similar words or phrases, as well as statements in the future tense. Without limiting the
generality of the foregoing, forward-looking statements contained in this proxy statement include statements relating to compensation plans, strategies, objectives and our anticipated financial and operational performance. Except as required by law,
we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements should be evaluated together with the many risks and uncertainties that
affect our business, including those set forth in the risk factors in Item&nbsp;1A of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2016, as filed with the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_8"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The following table sets forth, as of February&nbsp;28, 2017, certain information with respect to the beneficial ownership of Common Stock
by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">any person (including any group as that term is used in Section&nbsp;13(d)(3) of the Exchange Act), known by us to be the
beneficial owner of more than 5% of our voting securities, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">each director and each nominee for director to the Company, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">each of the executive officers named in the Summary Compensation Table appearing herein, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">all such executive officers, directors and nominees for director of the Company as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The number and percentage of shares beneficially owned are based on the aggregate of 41,754,123 shares of Common Stock outstanding as of
February&nbsp;28, 2017, adjusted as required by the rules promulgated by the SEC. We do not know of any arrangements, including any pledge by any person of our securities, the operation of which may at a subsequent date result in a change of control
of the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD></TR>
<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Name and Address of Beneficial Owner</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Number&nbsp;of<BR>Shares</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Percent&nbsp;of&nbsp;Common<BR>Stock Outstanding</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" COLSPAN="8"><B>5% Stockholders:</B></TD>
<TD VALIGN="top"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Entities affiliated with FMR, LLC<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,249,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:8pt; font-family:ARIAL">245 Summer Street</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:8pt; font-family:ARIAL">Boston, MA
02210</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Entities affiliated with BVF Partners L.P.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,772,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:8pt; font-family:ARIAL">1 Sansome Street, 30<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:8pt; font-family:ARIAL">San Francisco, California 94104</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Eastern Capital Limited.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,607,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:8pt; font-family:ARIAL">10 Market Street, #773</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:8pt; font-family:ARIAL">Grand
Cayman <FONT STYLE="white-space:nowrap">KY1-9006,</FONT> Cayman Islands</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Entities affiliated with BlackRock, Inc.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,998,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:8pt; font-family:ARIAL">55 East 52<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> Street</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:8pt; font-family:ARIAL">New York, NY 10055</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Entities affiliated with Lansdowne Partners Limited Partnership<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,848,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:8pt; font-family:ARIAL">15 Davies Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:8pt; font-family:ARIAL">London W1K
3AG</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:8pt; font-family:ARIAL">England</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" COLSPAN="8"><B>Named Executive Officers:</B></TD>
<TD VALIGN="top"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Robert I. Blum<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">902,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Sharon A. Barbari<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">353,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Fady I. Malik, M.D., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">321,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Bradley P. Morgan, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Andrew A. Wolff, M.D., F.A.C.C.<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Santo J. Costa<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">L. Patrick Gage, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">John T. Henderson, M.B., Ch.B.<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Edward Kaye<SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">B. Lynne Parshall, Esq.<SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Sandford D. Smith<SUP STYLE="font-size:85%; vertical-align:top">(16).</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Wendell Wierenga, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(17)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.00pt solid #000000">All directors and executive officers as a group (16 persons)</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right">3,204,263</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">%&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Represents beneficial ownership of less than one percent (1%) of the outstanding shares of Common Stock.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT </B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Based on a Schedule 13G filed with the SEC on February&nbsp;13, 2017 which reflected 5,199,414 shares of Common Stock
held by FMR LLC; in addition to 1,050,500 shares of Common Stock underlying warrants exercisable as of February&nbsp;28, 2017. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Based on a Schedule 13G filed with the SEC on February&nbsp;14, 2017 which reflected 4,851,691 shares of Common Stock
held by BVF Partners L.P. and its Affiliates and 921,052 shares of Common Stock underlying warrants exercisable as of February&nbsp;28, 2017. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Based on a Schedule 13G filed with the SEC on February&nbsp;13, 2015 which reflected 3,607,529 shares of Common Stock
held by Eastern Capital Limited and includes 723,684 shares of Common Stock underlying warrants exercisable as of February&nbsp;28, 2017. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Based on a Schedule 13G filed with the SEC on January&nbsp;23, 2017. </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Based on a Schedule 13G filed with the SEC on February&nbsp;12, 2016 which reflected 2,321,865 shares of Common Stock
held by Lansdowne Partners (UK) LLP; in addition to 526,316 shares of Common Stock underlying warrants exercisable as of February&nbsp;28, 2017. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Represents: (a) 93,768 shares of Common Stock held by Mr.&nbsp;Blum; (b) 2,083 shares of Common Stock held by the
Brittany Blum 2003 Irrevocable Trust; (c) 2,083 shares of Common Stock held by the Bridget Blum 2003 Irrevocable Trust; and (d) 804,367 shares of Common Stock underlying options granted to Mr.&nbsp;Blum that are exercisable within 60 days of
February&nbsp;28, 2017. Mr.&nbsp;Blum disclaims beneficial ownership of the shares of Common Stock held by the trusts. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Represents: (a) 40,323 shares of Common Stock held by the Barbari Family Trust; and (b) 312,784 shares of Common Stock
underlying options granted to Ms.&nbsp;Barbari that are exercisable within 60 days of February&nbsp;28, 2017. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Represents: (a) 45,404 shares of Common Stock held by Dr.&nbsp;Malik; and (b) 275,596 shares of Common Stock underlying
options granted to Dr.&nbsp;Malik that are exercisable within 60 days of February&nbsp;28, 2017. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Represents: (a) 45,194 shares of Common Stock held by Dr.&nbsp;Morgan; and (b) 128,511 shares of Common Stock underlying
options granted to Dr.&nbsp;Morgan that are exercisable within 60 days of February&nbsp;28, 2017. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Represents: (a) 47,255 shares of Common Stock held by Dr.&nbsp;Wolff; and (b) 187,077 shares of Common Stock underlying
options granted to Dr.&nbsp;Wolff that are exercisable within 60 days of February&nbsp;28, 2017. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Represents: 66,664 shares of Common Stock underlying options granted to Mr.&nbsp;Costa that are exercisable within 60
days of February&nbsp;28, 2017. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Represents (a) 30,000 shares of Common Stock held by Dr.&nbsp;Gage; (b) 1,850 shares held by Dr.&nbsp;Gage&#146;s spouse;
and (c) 167,676 shares of Common Stock underlying options granted to Dr.&nbsp;Gage that are exercisable within 60 days of February&nbsp;28, 2017. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Represents (a) 250 shares of Common Stock held by Dr.&nbsp;Henderson; (b) 83 shares held by Dr.&nbsp;Henderson&#146;s
spouse; and (c) 146,859 shares of Common Stock underlying options granted to Dr.&nbsp;Henderson that are exercisable within 60 days of February&nbsp;28, 2017. Dr.&nbsp;Henderson disclaims beneficial ownership of the shares of Common Stock held by
his spouse. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Represents: 17,885 shares of Common Stock underlying options granted to Dr.&nbsp;Kaye that are exercisable within 60 days
of February&nbsp;28, 2017. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Represents: 83,458 shares of Common Stock underlying options granted to Ms.&nbsp;Parshall that are exercisable within 60
days of February&nbsp;28, 2017. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Represents: 94,780 shares of Common Stock underlying options granted to Mr.&nbsp;Smith that are exercisable within 60
days of February&nbsp;28, 2017. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Represents: 91,003 shares of Common Stock underlying options granted to Dr.&nbsp;Wierenga that are exercisable within 60
days of February&nbsp;28, 2017. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Except as otherwise noted above, the address of each person listed on the table is
c/o Cytokinetics, Incorporated, 280 East Grand Avenue, South San Francisco, CA 94080. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">We do not have a policy for stock ownership
guidelines for members of the Board of Directors or executive officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_9"></A>BOARD OF DIRECTORS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Our Board of Directors is composed of individuals whose knowledge, background, experience and judgment we believe to be valuable to the
Company. The primary functions of our Board of Directors are to: </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Review and approve our strategic direction and annual operating plan and monitor our performance; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Evaluate the President and Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Review management performance and compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Review management succession planning; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Advise and counsel management; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Monitor and manage potential conflicts of interests of management, board members and stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Oversee the integrity of financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Monitor the effectiveness of the governance practices under which the Board of Directors operates and make changes as
needed. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">We do not have a formal diversity policy for selecting Board of Directors members. However, we believe it
is important that the members of our Board of Directors collectively bring the experiences and skills appropriate to effectively carry out the Board of Directors&#146; responsibilities both as our business exists today and as we plan to develop an
organization capable of successfully conducting late-stage clinical development and commercialization of our products. We therefore seek as members of our Board of Directors individuals with a variety of perspectives and the expertise and ability to
provide advice and oversight in one or more of these areas: accounting controls, business strategy, risk management, strategic partnering, financial engineering, legal and regulatory compliance and compensation and retention practices. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The following table sets forth in alphabetical order the names of each member of our Board of Directors, their age, position, director
class and committee membership as of March&nbsp;31, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Director</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Age</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Position/Class</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Audit<BR>Committee</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Compensation<BR>and Talent<BR>Committee</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Nominating&nbsp;and<BR>Governance<BR>Committee</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Science&nbsp;&amp;<BR>Technology<BR>Committee</FONT></B></FONT></TD></TR>


<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Robert I. Blum</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">53</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">CEO, Class&nbsp;II</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Santo&nbsp;J.&nbsp;Costa</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">71</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Class&nbsp;III</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Chair</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman">&#10003;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">L. Patrick&nbsp;Gage, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">74</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Chairman,&nbsp;Class&nbsp;I</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman">&#10003;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Chair</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman">&#10003;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">John&nbsp;Henderson, M.B., Ch.B.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">72</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Class&nbsp;III</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman">&#10003;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman">&#10003;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman">&#10003;</FONT></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Edward M. Kaye, M.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">68</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Class&nbsp;I</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman">&#10003;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">B. Lynne&nbsp;Parshall, Esq.*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Class&nbsp;III</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Chair</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman">&#10003;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Sandford&nbsp;D.&nbsp;Smith</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">70</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Class&nbsp;II</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman">&#10003;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman">&#10003;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Wendell&nbsp;Wierenga, Ph.D</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">69</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Class&nbsp;I</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman">&#10003;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Chair</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" COLSPAN="5" STYLE="BORDER-TOP:1.00pt solid #000000; BORDER-BOTTOM:1.00pt solid #000000">Number of Committee Meetings Held in 2016</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1.00pt solid #000000; BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1.00pt solid #000000; BORDER-BOTTOM:1.00pt solid #000000">9</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1.00pt solid #000000; BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1.00pt solid #000000; BORDER-BOTTOM:1.00pt solid #000000">6</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1.00pt solid #000000; BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1.00pt solid #000000; BORDER-BOTTOM:1.00pt solid #000000">5</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1.00pt solid #000000; BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1.00pt solid #000000; BORDER-BOTTOM:1.00pt solid #000000">4</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Financial Expert </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><A NAME="toc307694_10"></A>Director Skills, Experience and Background </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>Robert I. Blum </I></B>was appointed as our President and Chief Executive Officer and as a member of our Board of Directors in
January 2007. Previous to that appointment, Mr.&nbsp;Blum served as our President from February 2006 to January 2007. He served as our Executive Vice President, Corporate Development and Commercial Operations and Chief Business Officer from
September 2004 to February 2006. From January 2004 to September 2004, he served as our Executive Vice President, Corporate Development and Finance and Chief Financial Officer. From October 2001 to December 2003, he served as our Senior Vice
President, Corporate Development and Finance and Chief Financial Officer. From July 1998 to September 2001, Mr.&nbsp;Blum was our Vice President, Business Development. Prior to joining us in July 1998, he was Director, Marketing at COR Therapeutics,
Inc. since 1996. From 1991 to 1996, he was Director, Business Development at COR Therapeutics. Prior to that, Mr.&nbsp;Blum performed roles of increasing responsibility in sales, marketing and other pharmaceutical business functions at Marion
Laboratories, Inc. and Syntex Corporation. Mr.&nbsp;Blum received B.A. degrees in Human Biology and Economics from Stanford University and an M.B.A. from Harvard Business School. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Mr.&nbsp;Blum brings to our Board of Directors a deep familiarity with our operations, strategy and vision, as well as a record of
successful corporate management, strategic partnering and financing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>BOARD OF DIRECTORS </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>Santo J. Costa </I></B>has served as a member of our Board of Directors since November 2010. Since 2007, Mr.&nbsp;Costa has served
as Of Counsel to the law firm of Smith, Anderson, Blount, Dorsett, Mitchell and Jernigan, L.L.P. of Raleigh, North Carolina, specializing in corporate law for healthcare companies. From 1994 to 2001, he held various positions at Quintiles
Transnational Corporation, including as Vice Chairman, President and Chief Operating Officer. Prior to joining Quintiles, Mr.&nbsp;Costa spent 23 years in the pharmaceutical industry, most recently as General Counsel and Senior Vice President,
Administration with Glaxo Inc. Prior to joining Glaxo, he served as U.S. Area Counsel with Merrell Dow Pharmaceuticals and as Food&nbsp;&amp; Drug Counsel with Norwich Eaton Pharmaceuticals, Inc. Mr.&nbsp;Costa has served as Chairman of the Board of
Alchemia Limited, a biopharmaceutical company, from March 2014 to June 2015. He served on the Board of Directors of Magor Corporation, formerly Biovest Corp. I, from March 2010 until March 2013. He served as Chairman of the Board of LaboPharm, Inc.
from 2006 to 2011 and a director of OSI Pharmaceuticals from 2006 to 2010, as well as serving as a director at other private companies. Mr.&nbsp;Costa earned both a B.S. in Pharmacy and a J.D. from St. John&#146;s University. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Mr.&nbsp;Costa brings to our Board of Directors broad operational leadership experience in the pharmaceutical and clinical services
industries, including relevant legal, regulatory, governance and policy expertise. He also has extensive experience as a public company executive and board member in the pharmaceutical and biotechnology industries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>L. Patrick Gage, Ph.D. </I></B>has served as a member of our Board of Directors since November 2009 and as Chairman of the Board of
Directors since March 2010. Since July 2002, Dr.&nbsp;Gage has served as a consultant to the biopharmaceutical industry, including serving as an advisor to venture capital firms. From 1998 to 2002, Dr.&nbsp;Gage was President of Wyeth Research and
subsequently also Senior Vice President, Science and Technology for American Home Products, parent company of Wyeth Research. From 1989 to 1998, he held roles of increasing responsibility at Genetics Institute, Inc., first as head of Research and
Development, then as Chief Operating Officer and eventually as President. From 1971 to 1989, Dr.&nbsp;Gage held various positions in research management with <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Inc., most recently serving as
Vice President responsible for U.S. drug discovery. Dr.&nbsp;Gage has served as the Chairman of the Board of Directors of Tetraphase Pharmaceuticals since April 2013. Dr.&nbsp;Gage earned a bachelor&#146;s degree in Physics from the Massachusetts
Institute of Technology and a Ph.D. in Biophysics from the University of Chicago. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Dr.&nbsp;Gage brings to our Board of Directors
extensive experience as a public company executive and board member in the pharmaceutical and biotechnology industries and in strategies for bringing breakthrough medicines to approval and commercialization. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>John T. Henderson, M.B., Ch.B.</I></B> has served as a member of our Board of Directors since February 2009. Since December 2000,
Dr.&nbsp;Henderson has served as a consultant to the pharmaceutical industry as president of Futurepharm LLC. Until his retirement in December 2000, Dr.&nbsp;Henderson was with Pfizer Inc. for over 25 years, most recently as a Vice President in the
Pfizer Pharmaceuticals Group. Dr.&nbsp;Henderson previously held Vice Presidential level positions with Pfizer in Research and Development in Europe and later in Japan. He was also Vice President, Medical for Pfizer&#146;s Europe, U.S. and
International Pharmaceuticals groups. Dr.&nbsp;Henderson has served on the Board of Directors of Myriad Genetics, Inc., a healthcare diagnostics company, since 2004, and has served as the Chairman of Myriad&#146;s Board of Directors since April
2005. He served on the Board of Directors of Myrexis, Inc. (formerly Myriad Pharmaceuticals, Inc.) from June 2009 until January 2013. Dr.&nbsp;Henderson earned his bachelor&#146;s of science and medical degrees from the University of Edinburgh and
is a Fellow of the Royal College of Physicians (Ed.) and the Faculty of Pharmaceutical Medicine. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Dr.&nbsp;Henderson brings to our
Board of Directors broad experience in matters relating to global pharmaceutical drug development in a wide range of therapeutic areas and stages of business development, and an extensive background as a public company executive, board member and
consultant in the pharmaceutical industry. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>Edward M. Kaye, M.D., </I></B>has served as a member of our Board of Directors since
since May 2016. Dr.&nbsp;Kaye currently serves as the Chief Executive Officer and a member of the Board of Sarepta Terapeutics, Inc., a biotechnology company. Prior to this, Dr.&nbsp;Kaye served as Interim Chief Executive Officer of Sarepta from
March&nbsp;31, 2015 to September&nbsp;19, 2016 and as the SVP, Chief Medical Officer since 2011. Dr.&nbsp;Kaye was Group Vice President of Clinical Development at Genzyme Corporation, a biotechnology company, from April 2007 to June 2011, where he
supervised the clinical research in the lysosomal storage disease programs and in the genetic neurological disorders. Prior to this, Dr.&nbsp;Kaye held various roles at Genzyme Corporation since 2001, including Vice President of Medical Affairs for
Lysosomal Storage Diseases, Vice President of Clinical Research and Interim Head of PGH Global Medical Affairs. Dr.&nbsp;Kaye earned his B.S. in Biology from Loyola University and earned his M.D. at Loyola University Stritch School of Medicine. He
received his Pediatric training at Loyola University Hospital, Child Neurology training at Boston City Hospital, Boston University, and completed his training as a Neurochemical Research Fellow (Geriatric Fellow) at Bedford VA Hospital, Boston
University. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Dr.&nbsp;Kaye brings to our Board of Directors extensive clinical research and development experience, particularly his
expertise in rare neuromuscular diseases which is highly relevant as we advance our clinical programs in ALS and SMA into late-stage development. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>BOARD OF DIRECTORS </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>B. Lynne Parshall, Esq. </I></B>has served as a member of our Board of Directors since February 2013. Ms.&nbsp;Parshall currently
serves on the Board of Directors and as the Chief Operating Officer of Ionis Pharmaceuticals, Inc. She has held various positions of increasing responsibilities at Ionis since 1991. Prior to joining Ionis, Ms.&nbsp;Parshall was a partner at the law
firm of Cooley LLP. Ms.&nbsp;Parshall served as a member of the Board of Directors of Regulus Therapeutics Inc. from January 2009 to June 2015, and prior to Regulus&#146; conversion to a corporation, from November 2007 to January 2009.
Ms.&nbsp;Parshall is a member of the Licensing Executives Society and a member of the American, California, and San Diego bar associations. Ms.&nbsp;Parshall holds a J.D. from Stanford Law School, California and B.A. from Harvard University,
Massachusetts. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Ms.&nbsp;Parshall brings to our Board of Directors extensive operational and business development experience,
particularly in the advancement and funding of potential products directed to specialty care and orphan drug designated indications. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>Sandford D. Smith</I></B> has served as a member of our Board of Directors since March 2012. Mr.&nbsp;Smith currently serves as
Chairman of Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, and has served on the Board of Directors since January 2012, and also served as Interim Chief Executive Officer from July 2015 to January 2016. From 1996 to 2011,
Mr.&nbsp;Smith held various positions at <FONT STYLE="white-space:nowrap">Sanofi-Genzyme</FONT> (formerly Genzyme Corporation), most recently leading the integration of Genzyme&#146;s international business into Sanofi&#146;s global organization.
Prior to that, he served as Executive Vice President of Genzyme Corporation, and President of Genzyme International. From 1986 to 1996, Mr.&nbsp;Smith was President, Chief Executive Officer and a member of the Board of Directors of RepliGen
Corporation. From 1977 to 1985, Mr.&nbsp;Smith held various positions at Bristol-Myers Squibb, most recently serving as Vice President of Business Development and Strategic Planning for the Pharmaceutical and Nutritional Division. He also has served
on the Board of Directors of Neuralstem, Inc. and Arpicus Biosciences, Inc. since May and August 2014, respectively. Mr.&nbsp;Smith earned a bachelor&#146;s degree from the University of Denver. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Mr.&nbsp;Smith brings to our Board of Directors broad experience in matters relating to the launch and commercialization of new drugs in a
wide range of therapeutic areas, and in particular drugs targeting rare disease indications. He also has extensive experience as a public company executive and board member in the pharmaceutical and biotechnology industries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>Wendell Wierenga, Ph.D. </I></B>has served as a member of our Board of Directors since February 2011. From June 2011 to January
2014, Dr.&nbsp;Wierenga served as Executive Vice President, Research and Development, at Santarus, Inc., which was acquired by Salix Inc., which was subsequently acquired by Valeant Pharmaceuticals International, Inc. From 2006 to 2011, he served as
Executive Vice President, Research and Development, at Ambit Biosciences Corporation. From 2003 to 2006, he served as Executive Vice President of Research and Development at Neurocrine Biosciences, Inc. From 2000 to 2003, Dr.&nbsp;Wierenga served as
Chief Executive Officer of Syrrx, Inc. (now part of Takeda Pharmaceutical Company). From 1990 to 2000, he was Senior Vice President of Worldwide Pharmaceutical Sciences, Technologies and Development at Parke-Davis/Warner Lambert (now Pfizer, Inc.)
Prior to that, Dr.&nbsp;Wierenga spent 16 years at Upjohn Pharmaceuticals in research and drug discovery roles, most recently as Executive Director of Discovery Research. Dr.&nbsp;Wierenga has served on the Board of Directors of XenoPort, Inc. from
2001 to August 2016, the Board of Directors of Ocera Therapeutics, Inc. since December 2013, the Board of Directors of Apricus Biosciences, Inc. and Concert Pharmaceuticals, Inc. since March 2014 and on the Board of Directors of Anacor
Pharmaceuticals, Inc. from 2014 to July 2016. He also serves as the chairman of the Board of Directors of a privately held pharmaceutical research and development company. Dr.&nbsp;Wierenga also served on the Board of Directors of Onyx
Pharmaceuticals, Inc. from 1996 to 2013. Dr.&nbsp;Wierenga holds a B.A. from Hope College and a Ph.D. in Chemistry from Stanford University. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Dr.&nbsp;Wierenga brings to our Board of Directors over thirty years of experience in matters relating to pharmaceutical drug discovery
and development in a wide range of therapeutic areas, and an extensive background as a public company executive and board member in the pharmaceutical and biotechnology industries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><A NAME="toc307694_11"></A>Board Leadership Structure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Our Board of Directors does not have a policy on whether the same person should serve as both the Chief Executive Officer and Chairman of
the Board or, if the roles are separate, whether the Chairman should be selected from the <FONT STYLE="white-space:nowrap">non-employee</FONT> directors or should be an employee. The Board of Directors believes that it should have the flexibility to
make these determinations in the way that it believes best provides appropriate leadership for us at a given time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Board believes
that its current leadership structure, with Mr.&nbsp;Blum serving as Chief Executive Officer and Dr.&nbsp;Gage serving as Chairman, is appropriate for us at this time. Both leaders are actively engaged on significant matters affecting us, such as
long-term strategy. The Chief Executive Officer has overall responsibility for all aspects of our operations, while the Chairman has a greater focus on governance of the Company, including oversight of the Board of Directors. We believe this balance
of shared leadership between the two positions is a strength for us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>BOARD OF DIRECTORS </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><A NAME="toc307694_12"></A>Board Role in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The role of our Board of Directors is to oversee the President and Chief Executive Officer and other senior management in the competent,
lawful and ethical operation of the Company, including management&#146;s establishment and implementation of appropriate practices and policies with respect to areas of potentially significant risk to us. The Board as a whole is responsible for such
risk oversight, but administers certain of its risk oversight functions through its committees, such as the Audit Committee, the Compensation and Talent Committee and the Nominating and Governance Committee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Audit Committee is responsible for the oversight of our accounting and financial reporting processes, including our internal control
systems. In addition, the Audit Committee oversees and reviews our financially related risk management practices, including our investment policy. At least quarterly, management reports to the Board of Directors and Audit Committee on our
significant risk areas, as identified by management. These reports include discussions of current and new areas of potential operational, legal or financial risk and status reports on risk mitigation programs undertaken by us. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">As part of the of the Compensation and Talent Committee&#146;s risk oversight function, it considers whether our compensation policies and
practices for our employees create risks that are reasonably likely to have a material adverse effect on us. In conducting this evaluation, the Compensation and Talent Committee has reviewed our current practices and procedures for awarding cash and
equity compensation to employees through the annual performance review process, particularly as such practices and procedures apply to the establishment of the goals that are taken into consideration in the payment of bonuses. The Compensation and
Talent Committee has determined that these practices do not encourage inappropriate risk-taking. In particular, because we are a development-stage company with no commercial sales, the Compensation and Talent Committee has concluded that our
employees are not incentivized to take inappropriate risks to meet short-term goals, such as quarterly earnings or sales projections. Further, the Compensation and Talent Committee believes that there is sufficient Board of Director oversight of our
processes for compensation determinations to avoid the establishment of incentives that are materially adverse to our interests. Accordingly, the Compensation and Talent Committee has determined that our compensation policies at this time do not
create risks that are reasonably likely to have a material adverse effect on the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Nominating and Governance Committee
oversees the risks associated with our corporate governance and operating practices, including those relating to the composition of Board of Directors, the structure and function of Board committees, and meeting logistics and policies. The
Nominating and Governance Committee regularly reviews issues and developments relating to corporate governance and formulates and recommends corporate governance standards to the Board of Directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><A NAME="toc307694_13"></A>Independence of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Each of our directors is independent as defined under the Nasdaq listing standards, except for Robert I. Blum, our President and Chief
Executive Officer, who is not independent by virtue of his employment with the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">There is no family relationship between any
director and executive officer of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><A NAME="toc307694_14"></A>Board of Directors Meetings and Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Our Board of Directors held twelve meetings during the fiscal year ended December&nbsp;31, 2016. Each of the directors serving during
fiscal year 2016 attended at least 75% of the aggregate of all meetings of the Board of Directors and the committees of the Board of Directors upon which such director served during his or her tenure. The Board of Directors has a standing Audit
Committee, a Compensation and Talent Committee, a Nominating and Governance Committee and a Science and Technology Committee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>Audit Committee.</I></B> The Audit Committee consists of directors B. Lynne Parshall, John T. Henderson and Sandford D. Smith. All
members of the Audit Committee are independent (as independence is currently defined in Rules 5605(c)(2)(A)(i) and (ii)&nbsp;of the Nasdaq listing standards). The Board of Directors determined that B. Lynne Parshall is an &#147;audit committee
financial expert&#148; as defined in the SEC rules, based on her experience as a Chief Operating Officer of a life science company. The Audit Committee operates under a written charter adopted by the Board of Directors. We maintain a copy of the
Audit Committee charter on our website, <I>cytokinetics.com. </I>The information found on our website is not part of this or any other report filed with or furnished to the SEC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Audit Committee reviews our critical accounting policies and practices, consults with and reviews the services provided by our
independent registered public accounting firm and selects our independent registered public accounting firm. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Audit Committee held
nine meetings during fiscal year 2016. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>Compensation and Talent Committee.</I></B> The Compensation and Talent Committee
consists of directors Santo J. Costa, L. Patrick Gage, Sandford D. Smith and Wendell Wierenga. All of the members of the Compensation and Talent Committee </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>BOARD OF DIRECTORS </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">are independent (as independence is currently defined in Rule 5605(a)(2) of the Nasdaq listing standards) and Rule 5605(d)(2), as applied to compensation
committee members. The Board of Directors has adopted a written charter for the Compensation and Talent Committee. We maintain a copy of the Compensation and Talent Committee charter on our website, <I>cytokinetics.com.</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Compensation and Talent Committee reviews and approves the salaries and incentive compensation of our executive officers and
administers our stock plans and employee benefit plans. The Compensation and Talent Committee, in consultation with the third-party executive compensation consultant and discussion with management, forms its own recommendations for all executive
compensation (base salary, bonus, equity and other benefits) and director compensation. All new hire stock option and stock award grants to employees above the senior director level, including our executive officers, are approved by the Compensation
and Talent Committee. In addition, the Compensation and Talent Committee approves the annual stock option grants for all employees as part of the annual performance review process. The Compensation and Talent Committee has delegated to Robert I.
Blum, as President and Chief Executive Officer, the authorization to approve new hire stock option grants, within <FONT STYLE="white-space:nowrap">pre-approved</FONT> new hire grant guidelines, for new hires at or below the senior director level.
Further discussion of the role and function of our Compensation and Talent Committee can be found in the section below entitled &#147;Compensation Discussion and Analysis.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Compensation and Talent Committee engages the services of nationally recognized third-party professional executive compensation
consulting firms to assist in benchmarking data from competitive peer group companies. The Compensation and Talent Committee engaged Radford Surveys + Consulting in 2015 and 2016 for this purpose. <B></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Compensation and Talent Committee held six meetings during fiscal year 2016. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>Nominating and Governance Committee.</I></B> The Nominating and Governance Committee consists of directors Santo&nbsp;J.&nbsp;Costa,
L. Patrick Gage, John T. Henderson, and B. Lynne Parshall. All members of the Nominating and Governance Committee are independent (as independence is currently defined in Rule 5605(a)(2) and 5605(d)(2) of the Nasdaq listing standards). The Board of
Directors has adopted a written charter for the Nominating and Governance Committee. We maintain a copy of the Nominating and Governance Committee charter on our website,<I> cytokinetics.com.</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Nominating and Governance Committee assists the Board of Directors in identifying qualified persons to serve as directors, evaluates
all proposed director nominees, evaluates incumbent directors before recommending renomination, and recommends approved candidates to the Board of Directors for appointment or renomination to Company stockholders. The Nominating and Governance
Committee also regularly reviews issues and developments relating to corporate governance and formulates and recommends corporate governance standards to the Board of Directors. If there is a change in a director&#146;s employment, the Nominating
and Governance Committee evaluates and makes a recommendation to the Board of Directors as to whether the potential termination of the director is appropriate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Nominating and Governance Committee has used search firms to assist in the identification and evaluation of qualified candidates to
join the Board of Directors and may elect to do so again in the future. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Nominating and Governance Committee held five meetings
during fiscal year 2016. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">To date, the Nominating and Governance Committee has not established a policy for considering candidates for
director nominated by our stockholders, and will consider director candidates nominated by stockholders on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis, as appropriate. Because those candidates
will receive substantially the same consideration that candidates recommended by members of the Board of Directors receive, the Board of Directors believes that it is appropriate for the Company to not have a formal policy for considering such
candidates at this time. Stockholders may nominate candidates for director in accordance with the advance notice and other procedures contained in our Bylaws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>Science and Technology Committee.</I></B> Our Board of Directors established the Science and Technology Committee in September 2014.
The Science and Technology Committee consists of directors L. Patrick Gage, John T. Henderson, Edward Kaye (effective May&nbsp;18, 2016) and Wendell Wierenga. All of the members of the Science and Technology Committee are independent (as
independence is currently defined in Rule 5605(a)(2) of the Nasdaq listing standards). The Board of Directors has adopted a written charter for the Science and Technology Committee. We maintain a copy of the Science and Technology Committee charter
on our website, <I>cytokinetics.com.</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Science and Technology Committee provides guidance to management and the Board of
Directors on emerging trends in healthcare, discovery research and clinical development, and reviews and advises management and the Board of Directors on the overall strategic direction and investment in the Company&#146;s research, development and
technology programs. The Science and Technology Committee regularly reviews research programs and progress against goals, assesses the capabilities of key scientific and medical personnel and the depth and breadth of the scientific resources
available to the Company, as well as reviewing and advising on regulatory strategy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>BOARD OF DIRECTORS </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Science and Technology Committee held four meetings during fiscal year 2016. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">We do not have a formal policy regarding stockholder communication with the Board of Directors. However, our stockholders may communicate
directly with the Board of Directors in writing, addressed to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Board of Directors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">c/o Corporate Secretary </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Cytokinetics, Incorporated </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">280 East Grand Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">South San Francisco, California
94080 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">or by email to: <I>investor@cytokinetics.com</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Corporate Secretary will review each stockholder communication. The Corporate Secretary will forward to the entire Board of Directors
(or to members of a Board of Directors&#146; committee, if the communication relates to a subject matter clearly within that committee&#146;s area of responsibility) each communication that relates to our business or governance, is not offensive, is
legible in form and reasonably understandable in content, and does not merely relate to a personal grievance against us or an individual or the purpose of which is to further a personal interest not shared by the other stockholders generally.
Stockholders who would like their submissions directed to an individual member of the Board of Directors may so specify, and the communication will be forwarded, as appropriate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">We do not have formal policies regarding attendance by members of the Board of Directors at our annual meetings of stockholders. Robert I.
Blum, Santo Costa, L. Patrick Gage, John T. Henderson and Wendell Wierenga attended the 2016 Annual Meeting of Stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_15"></A>EXECUTIVE OFFICERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The following table sets forth in alphabetical order the names of our executive officers and their ages and positions with us as of
March&nbsp;31, 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="61%"></TD></TR>
<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Name</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Age</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Position</FONT></B></FONT></TD></TR>


<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Robert I. Blum</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Sharon A. Barbari</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President, Finance and Chief Financial Officer</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Bonnie A. Charpentier, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President, Regulatory Affairs and Compliance</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">David W. Cragg</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President, Human Resources</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Fady I. Malik, M.D., Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President, Research and Development</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Caryn McDowell</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">General Counsel and Chief Compliance Officer</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Bradley P. Morgan, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President, Research and <FONT STYLE="white-space:nowrap">Non-Clinical</FONT> Development</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Elisabeth Schnieders, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President, Business Development</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Andrew A. Wolff, M.D., F.A.C.C.</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Senior Vice President and Chief Medical Officer</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><A NAME="toc307694_16"></A>Executive Skills, Experience and Background </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>Robert I. Blum&#146;s</I></B> biography is set forth under &#147;Board of Directors&#148; above. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>Sharon A. Barbari</I></B> has served as our Executive Vice President of Finance and Chief Financial Officer since July 2009. She
served as our Senior Vice President of Finance and Chief Financial Officer from September 2004 through June 2009. From September 2002 to August 2004, she served as Chief Financial Officer and Senior Vice President of Finance and Administration of
InterMune, Inc. From January 1998 to June 2002, she served at Gilead Sciences, Inc., most recently as Vice President and Chief Financial Officer. From 1996 to 1998, she served as Vice President, Strategic Planning at Foote, Cone&nbsp;&amp; Belding
Healthcare in San Francisco, an international advertising and marketing firm. From 1972 to 1995, she was employed by Syntex Corporation where she held various management positions in corporate finance, financial planning, marketing and commercial
planning. Ms.&nbsp;Barbari has served on the Board of Directors of Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences, Inc.), a specialty pharmaceutical company, since March 2014. Ms.&nbsp;Barbari received a B.S. in Accounting from San Jose
State University. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>Bonnie A. Charpentier, Ph.D.</I></B> joined the Company in January 2014 as our Senior Vice President of
Regulatory Affairs and Compliance. Prior to joining the Company, Dr.&nbsp;Charpentier served as Vice President of Regulatory and Quality at CymaBay Therapeutics, Inc. (formerly Metabolex, Inc.) where she provided strategic regulatory leadership from
May 2007 to January 2014. From 2001 to 2006 she served as Vice President of Regulatory and Quality at Genitope Corp. From 1995 to 2001, she held regulatory positions at Roche Global Development, a division of F.
<FONT STYLE="white-space:nowrap">Hoffman-La</FONT> Roche Ltd., including serving as Vice President and Regulatory Site Head in Palo Alto, CA. From 1991 to 1995 she held regulatory positions of increasing responsibility at Syntex Corporation.
Dr.&nbsp;Charpentier obtained her Ph.D. in Biology from the University of Houston. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>David W. Cragg</I></B> has served as our
Senior Vice President, Human Resources since July 2009. He served as our Vice President of Human Resources from February 2005 through June 2009. From October 2000 until January 2005, Mr.&nbsp;Cragg managed his own human resources consulting
practice. From March 2000 until its acquisition in September 2000 by Yahoo!, Inc., he was Vice President, Human Resources for eGroups Inc., an Internet email management company. Prior to October 2000, Mr.&nbsp;Cragg was a Principal Human Resources
Consultant at Genentech, Inc. Mr.&nbsp;Cragg received a B.A. in Industrial Psychology from the University of California, Santa Cruz. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>Fady I. Malik, M.D., Ph.D.</I></B>, has served as our Executive Vice President of Research and Development since November 2015.
Dr.&nbsp;Malik served as our Senior Vice President of Research and Development from August 2014 to November 2015. Dr.&nbsp;Malik served as our Senior Vice President of Research and Early Development from June 2012 to August 2014. He has been with
Cytokinetics since our inception in 1998, serving in a variety of roles, including Vice President, Biology from March 2008 to June 2012, all focused towards building our cardiovascular and muscle programs. Since 2000, Dr.&nbsp;Malik has held an
appointment in the Cardiology Division of the University of California, San Francisco, where he is currently a Clinical Professor and an Attending Interventional Cardiologist at the San Francisco Veterans Administration Medical Center.
Dr.&nbsp;Malik received a B.S. from the University of California at Berkeley, a Ph.D. from the University of California at San Francisco and his M.D. from the University of California at San Francisco. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>Caryn G. McDowell</I></B><I> </I>has served as our General Counsel and Chief Compliance Officer since May 2016. She served as our
General Counsel from May 2015 to May 2016. From January 2014 to February 2015, she served as Vice President, Deputy General Counsel and Assistant Secretary of InterMune, Inc., a biopharmaceutical company, where she was primarily
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>EXECUTIVE OFFICERS </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">responsible for securities matters and commercialization. From June through December 2013, Ms.&nbsp;McDowell served as Associate General Counsel, Head of
US Healthcare Law at Onyx Pharmaceuticals, Inc, a biopharmaceutical company (acquired by Amgen) where she lead a team of healthcare lawyers across several therapeutic areas. From 2012-2013, Ms.&nbsp;McDowell held the position of Executive Director,
Corporate Law at Affymax, Inc., a biopharmaceutical company where she counseled the company on legal risk associated with commercialization. Prior to these positions, she served in legal roles of increasing responsibility at Genentech, and
Millennium Pharmaceuticals. Prior to that, she served as Senior Counsel at the Office of the Inspector General (OIG) U.S. Department of Health and Human Services and as Assistant Attorney General Medicaid Fraud Control Unit of the Commonwealth of
Massachusetts. She began her career as a litigator at Morrison Mahoney, LLP. Ms.&nbsp;McDowell received a J.D. from Boston University School of Law and a B.A. from the University of Michigan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>Bradley P. Morgan, Ph.D.,</I></B> has served as our Senior Vice President of Research and
<FONT STYLE="white-space:nowrap">Non-Clinical</FONT> Development since February 2017. Dr.&nbsp;Morgan<B><I> </I></B>served as our Senior Vice President of Drug Discovery and Early Development from November 2015 to February 2016, and he served as our
Vice President of Drug Discovery and Early Development from June 2012 to November 2015. Dr.&nbsp;Morgan has been with Cytokinetics since 2002, serving in a variety of roles including Vice President, Chemistry, all focused towards discovery and early
development of our cardiovascular and muscle programs. Prior to joining Cytokinetics, Dr.&nbsp;Morgan held several scientific and management positions at Pfizer Global research and development from 1993 to 2002. During that time, he focused on
programs for treatments of obesity, diabetes, and related diseases, including nuclear receptor modulators and selective <FONT STYLE="white-space:nowrap">G-coupled</FONT> protein receptor modulators. Dr.&nbsp;Morgan is a member of the American
Chemical Society and of the Faculty of 1000 in Pharmacology and Drug Discovery. Dr.&nbsp;Morgan received his Ph.D. in Chemistry from the University of California, Berkeley and performed post-doctoral studies at the California Institute of
Technology. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>Elisabeth A. Schnieders, Ph. D.</I></B><I> </I>has served as our Senior Vice President, Business Development since
December 2016. She served as our Vice President, Business Development from November 2009 to December 2016. From January 2000 to November 2009, she held positions of increasing responsibility in business development and alliance management. From 1998
to 1999 she served as Manager, Business Development of Acacia Biosciences, a drug discovery technology company. Dr.&nbsp;Schnieders received a S.B. in Life Sciences from MIT and a Ph.D. in Molecular and Cell Biology from the University of
California, Berkeley. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>Andrew A. Wolff, M.D., F.A.C.C. </I></B>has served as our Senior Vice President and Chief Medical Officer
since August 2014. Dr.&nbsp;Wolff served as our Senior Vice President of Clinical Research and Development and Chief Medical Officer from September 2004 to August 2014. From September 1994 until September 2004, Dr.&nbsp;Wolff held various positions
of increasing responsibility at CV Therapeutics, most recently as Senior Vice President and Chief Medical Officer. From 1988 until 1994, he served in various drug development positions of increasing responsibility in both the United States and the
United Kingdom for Syntex Corporation, most recently as the Executive Director of Medical Research and New Molecules Clinical Programs Leader. Since 1986, Dr.&nbsp;Wolff has held an appointment in the Cardiology Division of the University of
California, San Francisco, where he is currently an Associate Clinical Professor, and is an Attending Cardiologist in the Coronary Care Unit at the San Francisco Veterans Administration Medical Center. Dr.&nbsp;Wolff received a B.A. in Chemistry and
Biology from the University of Dayton and an M.D. from Washington University Medical School. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_17"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_18"></A>Compensation Discussion and Analysis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">This Compensation Discussion and Analysis explains our compensation philosophy, policies and practices for 2016 for the following
executives, who we refer to in this Compensation Discussion and Analysis and in the following tables as our named executive officers: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="61%"></TD></TR>
<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Name</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Position</FONT></B></FONT></TD></TR>


<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Robert I. Blum</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President&nbsp;and&nbsp;Chief&nbsp;Executive&nbsp;Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Sharon A. Barbari</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Executive&nbsp;Vice&nbsp;President,&nbsp;Finance&nbsp;and&nbsp;Chief&nbsp;Financial&nbsp;Officer</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Fady Malik, M.D., Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President, Research and Development</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Bradley P. Morgan, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President, Research and <FONT STYLE="white-space:nowrap">Non-Clinical</FONT> Development</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Andrew A. Wolff, M.D.</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Senior Vice President, Chief Medical Officer</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Executive Summary </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">We design our executive compensation program to provide a competitive compensation package that focuses on corporate and individual
performance and long-term results, while maximizing retention. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The highlights of our 2016 executive compensation program include:
</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">We provided merit salary increases in the range of 2% to 3.5%, to all members of our executive team in 2016 and also
granted merit salary increases to other <FONT STYLE="white-space:nowrap">non-executive</FONT> employees in 2016 consistent with our past practices. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">We provided an annual discretionary bonus designed to reward executives for achieving corporate goals and, except for our
President and Chief Executive Officer, individual goals in their functional area. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Our equity program for our named executive officers has consisted of stock options and in 2015, performance stock units
(&#147;PSUs&#148;). The stock options were granted in February 2015 with exercise prices equal to 100% of the fair market value on the date of grant, each vesting monthly over four years based on continued service. No PSUs were granted in 2016, but
PSUs granted in August 2015 remain subject to achievement of certain performance goals. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">We held our second advisory
stockholder vote on executive compensation at our 2014 Annual Meeting. Approximately 97% of the shares voted were cast in favor of our executive compensation. We did not hold an advisory vote on executive compensation at either of our 2015 Annual
Meeting or at our 2016 Annual Meeting, as we solicit such advisory vote once every three years. The Compensation and Talent Committee of the Board of Directors, or the Committee, believes that this vote affirms our stockholders&#146; support for the
Company&#146;s compensation practices. After considering the outcome of the advisory vote, the Committee made no significant changes to the executive compensation program for 2015 or 2016. We will hold our next advisory vote on executive
compensation at the 2017 Annual Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Overview of Compensation Program </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Compensation Philosophy and Objectives </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Committee works to structure our executive compensation program to reward achievement of our business goals, align the executive
officers&#146; interests with those of our stockholders and encourage our executives to build a sustainable biopharmaceutical company. The Committee seeks to ensure that we maintain our ability to attract and retain superior employees in key
positions by providing our executives compensation that is competitive relative to the compensation paid to similarly situated executives in a defined group of peer companies and the broader marketplace from which we recruit and compete for talent.
The Committee seeks to ensure that the total compensation paid to our executive officers is fair, reasonable, competitive and reflective of their performance and contributions toward corporate goals and objectives. To meet these objectives, we
provide base salary, cash bonus opportunities, equity awards, broad-based employee benefits with limited prerequisites, and severance benefits upon a loss of position in connection with a change in control. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In determining the amount and form of these compensation elements, the Committee considers a number of factors, including: </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">compensation levels paid to similarly situated executives by our Peer Companies (as defined below), to attract and retain
executives in a competitive market for talent; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">corporate and individual performance, including performance in relation to our business plan, and execution of
individual, team and company-wide strategic initiatives, to focus executives on achieving our business objectives; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>EXECUTIVE COMPENSATION </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the experiences and knowledge of our executives; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">internal pay equity of the compensation paid to one executive officer as compared to another &#151; that is, the
compensation paid to each executive should reflect the importance of his or her role to the Company as compared to the roles of the other executives &#151; to promote teamwork and contribute to retention, while recognizing that compensation
opportunities should increase based on increased levels of responsibility among officers; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">broader economic conditions, to ensure that our pay strategies account for how the larger economic environment impacts
our business; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the potential dilutive effect of equity awards on our stockholders. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Role of the Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Committee is
generally responsible for reviewing, modifying, approving and otherwise overseeing the compensation policies and practices applicable to all of our employees, including the administration of our equity plans and employee benefit plans. As part of
its responsibilities, the Committee establishes and implements compensation decisions for our named executive officers and evaluates the success of those decisions in supporting the Company&#146;s compensation philosophy for our named executive
officers. The Committee reports its decisions regarding executive compensation matters to the entire Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">As part of its
deliberations, in any given year, the Committee may review and consider materials such as Company financial reports, financial projections, operational data and stock performance data. The Committee also reviews information such as total
compensation that may become payable to the named executive officers in various hypothetical scenarios, executive stock ownership information, analyses of historical executive compensation levels and current company-wide compensation levels and
benchmarking data provided by the independent compensation consultant. The Committee also seeks input from the Committee&#146;s independent compensation consultant and our President and Chief Executive Officer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Role of the Independent Compensation Consultant </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Committee retained Radford Surveys + Consulting, an Aon Hewitt Company, or Radford, as its independent compensation consultant for
compensation decisions in 2016. Pursuant to SEC rules, the Committee has assessed Radford&#146;s independence and concluded that no conflict of interest exists that would prevent Radford from independently advising the Committee. The Committee
intends to continue to assess the independence of any of our compensation advisors, consistent with applicable NASDAQ listing standards. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">For 2016, Radford provided the following services to the Committee: </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">reviewed and provided recommendations on the composition of our 2016 Peer Companies; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">provided compensation data related to executives at our 2016 Peer Companies based on data from SEC filings and
Radford&#146;s Life Science Survey; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">conducted a competitive review of the compensation of our named executive officers, including advising on the design and
structure of our equity incentive compensation program; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">conducted a detailed assessment of our 2016 Peer Companies board of directors&#146; compensation practices and developed
a summary report of findings and recommendations, including advising on the design and structure of our equity incentive compensation program; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">prepared an analysis of our share usage under our equity incentive plan in comparison to our 2016 Peer Companies based on
data from SEC filings. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Company pays for the costs of Radford&#146;s services. However, the Committee has the
authority to engage and terminate Radford&#146;s services. Although Radford makes recommendations to the Committee, it has no authority to make compensation decisions on behalf of the Committee or the Company. Radford attends Committee meetings
either in person or via conference call as deemed appropriate by the Committee Chair. The Company&#146;s management provides historical data, reviews reports for accuracy and interacts directly with Radford. The Committee, at its discretion, also
communicates and meets separately with Radford. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Radford did not provide any other executive compensation services to the Company in
2016; however, the Company did engage Radford to provide survey data for our broader employee base to our management. The fee for these services in 2016 was less than $10,000. The Committee approved of Radford providing these other <FONT
STYLE="white-space:nowrap">non-executive</FONT> compensation services as it determined that these services did not constitute a conflict of interest or prevent Radford from objectively performing its work for the Committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>EXECUTIVE COMPENSATION </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Role of Executive Officers in Compensation Decisions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">For compensation decisions in 2016, our President and Chief Executive Officer aided the Committee by providing recommendations regarding
the compensation of all executive officers other than himself. Each executive officer, with the exception of our President and Chief Executive Officer, participated in an annual performance review with our President and Chief Executive Officer to
provide input about his or her contributions to the Company&#146;s goals and objectives for 2016. Our President and Chief Executive Officer participated in a review process, with respect to his own performance review, with a representative from the
Board of Directors and Committee member. The Committee assessed the recommendations of our President and Chief Executive Officer (and, with respect to our President and Chief Executive Officer, the recommendations of the Board of Directors&#146;
representative) in the context of each executive officer&#146;s performance. No executive officer participated directly in the Committee&#146;s final determinations regarding the amount of any component of his or her own 2016 compensation package.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Our Human Resources, Finance and Legal departments work with our President and Chief Executive Officer to design and develop
compensation programs for our named executive officers, to recommend changes to existing compensation programs, to establish corporate and individual performance goals, to prepare peer data comparisons and other Committee briefing materials and
ultimately to implement the Committee&#146;s decisions. Our Senior Vice President, Human Resources and our President and Chief Executive Officer meet separately with Radford to convey information on proposals that management may make to the
Committee, as well as to assist Radford in collecting information about the Company to perform its duties for the Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Benchmarking </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Committee believes it is important when making its compensation-related decisions to be informed as to current compensation practices
of comparable publicly held companies in the life sciences industry. To obtain independent and expert advice on appropriate compensation, the Committee engages Radford to analyze the executive compensation practices of a number of comparable
publicly held companies in the life sciences industry, or our Peer Companies. The Committee, in consultation with Radford, reviews and adjusts the list of Peer Companies annually to ensure that the list provides a current and useful comparison of
companies for use as a means of comparing our executive compensation levels relative to the market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Committee approved the
following Peer Companies for use in making compensation decisions in 2016: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>


<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" NOWRAP STYLE="BORDER-TOP:1.00pt solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.67em; text-indent:-1.33em; font-size:9pt; font-family:ARIAL">&#149;&nbsp;&nbsp;&nbsp;Acceleron Pharma</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-TOP:1.00pt solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.67em; text-indent:-1.33em; font-size:9pt; font-family:ARIAL">&#149;&nbsp;&nbsp;&nbsp;Five Prime Therapeutics,
Inc.</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-TOP:1.00pt solid #000000">&#149;&nbsp;&nbsp;&nbsp;Rigel Pharmaceuticals, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.67em; text-indent:-1.33em; font-size:9pt; font-family:ARIAL">&#149;&nbsp;&nbsp;&nbsp;Amicus Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.67em; text-indent:-1.33em; font-size:9pt; font-family:ARIAL">&#149;&nbsp;&nbsp;&nbsp;Geron Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#149;&nbsp;&nbsp;&nbsp;Sangamo Biosciences, Inc.</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.67em; text-indent:-1.33em; font-size:9pt; font-family:ARIAL">&#149;&nbsp;&nbsp;&nbsp;Anthera Pharmaceuticals, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.67em; text-indent:-1.33em; font-size:9pt; font-family:ARIAL">&#149;&nbsp;&nbsp;&nbsp;Infinity&nbsp;Pharmaceuticals,&nbsp;Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#149;&nbsp;&nbsp;&nbsp;Synta Pharmaceuticals, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.67em; text-indent:-1.33em; font-size:9pt; font-family:ARIAL">&#149;&nbsp;&nbsp;&nbsp;ArQule, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.67em; text-indent:-1.33em; font-size:9pt; font-family:ARIAL">&#149;&nbsp;&nbsp;&nbsp;Omeros Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#149;&nbsp;&nbsp;&nbsp;Theravance Biopharma</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.67em; text-indent:-1.33em; font-size:9pt; font-family:ARIAL">&#149;&nbsp;&nbsp;&nbsp;Array Biopharma, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.67em; text-indent:-1.33em; font-size:9pt; font-family:ARIAL">&#149;&nbsp;&nbsp;&nbsp;OncoMed Pharmaceuticals, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#149;&nbsp;&nbsp;&nbsp;Threshold Pharmaceuticals, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.67em; text-indent:-1.33em; font-size:9pt; font-family:ARIAL">&#149;&nbsp;&nbsp;&nbsp;ChemoCentryx, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.67em; text-indent:-1.33em; font-size:9pt; font-family:ARIAL">&#149;&nbsp;&nbsp;&nbsp;Peregrine Pharmaceuticals, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#149;&nbsp;&nbsp;&nbsp;XenoPort, Inc.</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1.00pt solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.67em; text-indent:-1.33em; font-size:9pt; font-family:ARIAL">&#149;&nbsp;&nbsp;&nbsp;Concert Pharmaceuticals,
Inc.</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1.00pt solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.67em; text-indent:-1.33em; font-size:9pt; font-family:ARIAL">&#149;&nbsp;&nbsp;&nbsp;Regulus Therapeutics</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1.00pt solid #000000">&#149;&nbsp;&nbsp;&nbsp;Xoma Corporation</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Companies are evaluated and adjusted as appropriate for inclusion in these analyses based on business
characteristics similar to ours. Potential companies are selected based on criteria that include business model, stage of development, market capitalization, year of initial public offering, employee headcount, research and development expenditures,
cash reserves and revenue. The Committee selected the 2016 Peer Companies in November 2015. At the time of the determination, these companies had a market capitalization between $123&nbsp;million and $936&nbsp;million, had an employee head count
between 20 and 287, and were generally at a comparable stage to us in the development of their lead drug candidate. The Committee determined that the foregoing selection criteria were appropriate for selecting the 2016 Peer Companies because at such
time, Cytokinetics was a late-stage biopharmaceutical company with a market capitalization of approximately $274&nbsp;million and 92 employees. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">After the 2016 Peer Companies were selected, Radford prepared an extensive analysis of the compensation practices of the Peer Companies as
reported in their proxy statements, and offered additional analysis based on the compensation practices of a broader group of life science companies (a subset of what is included in the Radford Life Science Survey). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Committee reviewed the cash and equity components from these benchmarking analysis in setting a total compensation package for each
executive officer, while also reviewing each executive officer&#146;s past and anticipated contributions to the Company, current compensation package, compensation market trends for competitive positions, retention
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>EXECUTIVE COMPENSATION </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">risks and overall Company performance. While benchmarking information alone is not sufficient for setting compensation, the Committee believes that
considering this information is an important aspect of diligence in compensation-related decisions. Other factors, such as economic conditions, internal pay equity and individual negotiations may play an important role with respect to the
compensation offered to an executive in any given year. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In general and in line with the Company&#146;s general compensation
philosophy, when considering the Peer Company data, the Committee aims to provide target total cash and long-term equity compensation at or around the median of the compensation paid to similarly situated executives employed by the Peer Companies
for target level performance, with compensation above this level possible for exceptional performance. To achieve this positioning for target levels of compensation, the Committee generally sets the various compensation elements as follows: </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">base salaries between the 50<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> and 75<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> percentile for comparable positions; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">target cash bonus compensation at a level such that, when combined with base salary, the target total cash compensation
is at or around the median for comparable positions; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">target long-term equity compensation at a level such that, when combined with target total cash compensation, target
total cash and equity compensation is at or around the median for comparable positions. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">When reviewing base salary
the Committee takes into consideration the high cost of living and competitive life science marketplace in the Bay Area. In order to attract and retain key talent they believe it is appropriate to have a more meaningful level of fixed compensation
in the form of base salary (between the 50<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> and 75<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentiles of the Peer Companies) to achieve this objective. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Compensation Components </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>Base
Salary.</I></B> We provide base salary as a fixed source of compensation for our executive officers for the services they provide to us during the year and to balance the impact of having the remainder of their compensation &#147;at risk&#148; in
the form of discretionary annual cash bonuses and equity-based incentive compensation. The Committee recognizes the importance of base salaries as an element of compensation that helps to attract and retain talented executives. We believe that base
salaries should be consistent with the salaries provided by our Peer Companies. The Committee targets base salary between the 50<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> and 75<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>
percentiles of the Peer Companies. The Committee believes this positioning is necessary to attract and retain executives in the San Francisco Bay Area where the cost of living is higher than much of the country, and to enable us to recruit executive
talent from companies that are at a more mature stage of development and therefore may have greater resources to provide higher base compensation, higher total compensation, greater job security and increased employee benefits. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Committee generally reviews base salaries annually and adjusts base salaries if necessary to remain at the desired benchmark level as
compared to the Peer Company data. The Committee also takes into account each executive&#146;s individual responsibilities, performance during the prior fiscal year and experience in deciding whether the benchmark percentile is the correct
positioning for that executive that year. Additionally, in determining base salary increases, the Committee considers the Company&#146;s overall budget for merit salary increases for the year, and whether an executive officer was promoted or his or
her responsibilities were or are expected to be modified during the year. The Company&#146;s 2016 budget for merit salary increases for all employees was an aggregate increase of 3% over the 2015 salary base salaries. There was no separate merit
salary increase budget for our named executive officers. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The 2016 base salaries and the percentage increase of the prior year&#146;s
base salary for each of the named executive officers were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD></TR>
<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Named Executive Officer</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">2016&nbsp;Base&nbsp;Salary</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">%&nbsp;increase&nbsp;from<BR>2015</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD></TR>


<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Robert I. Blum</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$595,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Sharon A. Barbari</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$412,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Fady Malik, M.D., Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$449,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Bradley P. Morgan, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$332,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Andrew A. Wolff, M.D.</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$395,760</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">2.0%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>Annual Bonus.</I></B> We structure our annual cash bonuses to provide incentives for our executive
officers to achieve our annual corporate and individual performance objectives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Target Bonuses.</I> Each named executive
officer&#146;s annual target bonus is expressed as a percentage of his or her base salary and is set at a level that, upon 100% achievement of the Company&#146;s corporate goals and the named executive officer&#146;s
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>EXECUTIVE COMPENSATION </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">individual performance goals, falls at the median level for a similar executive position as compared to the Peer Company data. In determining the split of
the target bonus as between corporate and individual performance, the Committee believes that the more senior a named executive officer&#146;s position and operational responsibilities within the Company, the greater the percentage of his or her
bonus that should be weighted to corporate rather than individual achievement. For example, our President and Chief Executive Officer&#146;s bonus is based entirely on corporate achievement and not on individual achievement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Target bonus levels for 2016 performance for each of the named executive officers, expressed as a percentage of base salary, and the
relative weightings of individual goals and corporate goals, were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Named Executive Officer</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Target&nbsp;Bonus<BR>% of Salary</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Individual<BR>Goal<BR>Weighting</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Corporate<BR>Goal<BR>Weighting</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD></TR>


<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Robert I. Blum</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Sharon A. Barbari</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Fady Malik, M.D., Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Bradley P. Morgan, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Andrew A. Wolff, M.D.</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">35%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">25%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">75%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The 2016 target bonus levels were at the median level for similar executive positions as compared to the
2016 Peer Company data. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In the first quarter of each year, the Committee reviews and approves corporate goals presented by senior
management. The Committee does weigh the goals but does not establish a specific performance formula. Rather, the Committee determines actual bonuses in a subjective fashion at the end of the year, taking into account the original goals and any
other factors the Committee determines are material, in its discretion. The minimum bonus amount is zero, and the maximum is 120% of the target bonus amount. If the Committee determines that bonuses should not be awarded for corporate achievement
for any reason, bonuses will not be paid even if the individual achievements were met. We believe this fully discretionary bonus structure allows the Committee to be responsive to the uncertainties and lack of predictability associated with being a
biotechnology company dedicated to the discovery, development and commercialization of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutics with novel mechanisms of action. The individual and
corporate goals for 2016 are described in more detail in the section titled &#147;Corporate and Individual Achievement Assessment.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>Equity Awards.</I></B> The Committee believes that providing a material portion of our executive officers&#146; total compensation
in equity awards aligns the interests of our executive officers with our stockholders, by linking the value of compensation to the value of our Common Stock. In determining the form and size of equity awards, the Committee considers information
provided by Radford as to whether the complete compensation packages provided to each named executive officer, including prior equity awards, are sufficient to retain, motivate and adequately reward the executive for his or her contributions. In
addition, in determining the size of equity awards, the Committee considers the anticipated value of the named executive officer&#146;s contributions going forward. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><I>Stock Options. </I>We grant stock options to our named executive officers when they join us and annually, on a discretionary basis, as
part of our performance review and rewards process. All options have an exercise price equal to the fair market value of our Common Stock on the date of grant, and generally vest monthly based on continued service over a four-year period (with a <FONT
STYLE="white-space:nowrap">one-year</FONT> cliff for new hire grants). As a result of our option grant structure, the options provide a return to the executive officer only if the executive officer remains a service provider to the Company, and then
only if the market price of our Common Stock appreciates relative to the option exercise price over the period in which the option vests and beyond. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In determining the size of stock option grants to executive officers in a given year, the Committee may consider: </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">for each executive officer, the value of equity awards granted to executives in similar positions at our Peer Companies,
targeting long-term equity compensation at a level such that, when combined with target total cash compensation, the officer&#146;s target total compensation opportunity is at or around the median for comparable positions; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the equity budget for a given year for all of our employees, and the percentage of that budget allocated to be used for
awards to our named executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the retention and motivation value of equity awards that have been previously granted to each executive officer;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">each executive officer&#146;s total potential ownership as a percentage of our total outstanding shares; and
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">internal pay equity among our named executive officers, to reflect the importance of each officer&#146;s responsibilities
for the Company&#146;s success as compared to the other executive officers and our President and Chief Executive Officer. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>EXECUTIVE COMPENSATION </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The number of shares underlying stock options granted to our named executive officers in February 2016 was as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD></TR>
<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Named Executive Officer</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Option&nbsp;Shares</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD></TR>


<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Robert I. Blum</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Sharon A. Barbari</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Fady Malik, M.D., Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Bradley P. Morgan, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Andrew A. Wolff, M.D.</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Except for the PSU&#146;s granted in 2015, no other form of equity awards were granted to named executive
officers in 2016, 2015 or 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Corporate and Individual Achievement Assessment Impacting Compensation Components </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>Corporate Achievement.</I></B> Before the start of each calendar year, management prepares a set of corporate goals covering our
expected operating and financial performance for the fiscal year. Our corporate goals are focused on corporate metrics and objectives that are intended to provide both near- and long-term stockholder value. The Committee then reviews and approves
these corporate goals. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">For 2016, the Committee approved corporate goals related to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">completing patient enrollment in <FONT STYLE="white-space:nowrap">VITALITY-ALS,</FONT> the Phase 3 clinical trial of
tirasemtiv, in patients with ALS; initiating <FONT STYLE="white-space:nowrap">VIGOR-ALS,</FONT> the open-label clinical for patients who have completed <FONT STYLE="white-space:nowrap">VITALITY-ALS;</FONT> developing a New Drug Application/Marketing
Authorization Application and commercial readiness plan for tirasemtiv; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">collaborating with Regulatory Affairs and Amgen to complete End of Phase 2 regulatory interactions in North America and
Europe intended to result in a final agreed Phase 3 protocol and Special Protocol Assessment, for omecamtiv mecarbil, a novel investigational cardiac myosin activator and guide collaboration to start pivotal Phase 3 outcomes trial of omecamtiv
mecarbil in 2016; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">completing patient enrollment in the first cohort of CY 5021, the Phase 2 clinical trial of <FONT
STYLE="white-space:nowrap">CK-2127107</FONT> in patients with Spinal Muscular Atrophy; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">supplying material of our drug candidates for use in our skeletal muscle contractility development programs;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">advancing our research programs to lead optimization and candidate selection, and conducting a early research program
selection process; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">raising capital and corporate partnering for our programs, including receipt of funds; and </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">managing the budget to close the fiscal year with sufficient cash to cover projected expenditures for the following
eighteen months. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">At the end of each year, the Committee determines the overall level of corporate achievement,
including assessing our performance relative to these goals. The Committee does not use a rigid formula in determining the Company&#146;s level of achievement, but instead considers: </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the degree of success achieved for each corporate goal, comparing actual results against the <FONT
STYLE="white-space:nowrap">pre-determined</FONT> deliverables associated with each objective; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the difficulty of the goal; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">whether significant unforeseen obstacles or favorable circumstances altered the expected difficulty of achieving the
desired results; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">other factors that may have made the stated goals more or less important to our success; and </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">other accomplishments by us during the year or other factors which, although not included as part of the formal goals,
are nonetheless deemed important to our near- and long-term success. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Committee does assign weightings to the
goals by functional area, but uses its discretion and judgment to determine a percentage that it believes fairly represents our achievement level for the year. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B><I>Individual Achievement. </I></B>Individual goals for each named executive officer are derived from the corporate goals that relate
to his or her functional area, except for our President and Chief Executive Officer, who has no individual goals apart from the corporate goals. Our President and Chief Executive Officer establishes the individual goals with each other named
executive officer described below based on the relevant corporate goals and key functional area priorities for the year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>EXECUTIVE COMPENSATION </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Ms.&nbsp;Barbari&#146;s 2016 goals related to supporting partnering activities and providing financial analyses as needed
for deal structures, recruiting staff to ensure continuity in workflow and reduce dependency on outside consultants, raising capital, managing the implementation of upgrades to our financial systems, managing spending within the Board-approved net
operating budget and developing contingency plans to address future cash requirements, ensuring compliance with internal controls as required by COSO and <FONT STYLE="white-space:nowrap">AS-5,</FONT> managing the development of Information
Technology Commercial Readiness plans and meeting SEC reporting compliance requirements and supporting the presentation of key clinical data with appropriate investor events. </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Dr.&nbsp;Malik&#146;s 2016 goals related to advancing research programs to candidate selection and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">hit-to-lead</FONT></FONT> stages, collaborating with Amgen on the development program for omecamtiv mecarbil and the <FONT STYLE="white-space:nowrap">follow-on</FONT> research program
directed to next-generation compounds in our cardiac muscle contractility program, providing high quality, clinical trial supplies, directing the conduct of our <FONT STYLE="white-space:nowrap">VITALITY-ALS,</FONT>
<FONT STYLE="white-space:nowrap">VIGOR-ALS</FONT> and <FONT STYLE="white-space:nowrap">CK-2127107</FONT> clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Dr.&nbsp;Morgan&#146;s 2016 goals related to collaborating with Commercial Planning to develop a Strategic Plan and
Budget for the commercial supply of tirasemtiv to support a potential launch in <FONT STYLE="white-space:nowrap">mid-2018,</FONT> guiding our early research programs process and overseeing Medical Chemistry, Analytical Chemistry,
Automation&nbsp;&amp; Technology and the <FONT STYLE="white-space:nowrap">Non-Clinical</FONT> Development groups. His goals also included&nbsp;leading the efforts of candidate selection and to advance our Research programs and continued support of
both our collaborations and their drug development programs. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Dr.&nbsp;Wolff&#146;s 2016 goals related to providing clinical guidance and support to the
<FONT STYLE="white-space:nowrap">VITALITY-ALS</FONT> Phase 3 clinical study. Assisting the Regulatory team with strategy, document review and drafting and participating in Regulatory Agency meetings. Overseeing external collaborations with Amgen on
Phase 3 study protocol for omecamtiv mecarbil. As <FONT STYLE="white-space:nowrap">co-chair</FONT> of the Astellas Joint Development Committee continue to define the development of <FONT STYLE="white-space:nowrap">CK-2127107</FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">At the end of each year, the Committee, with input from our President and Chief Executive Officer, determines the
overall level of individual achievement for each named executive officer, which includes, but is not limited to, an assessment of the executive&#146;s performance relative to these goals. The Committee does not use a rigid formula in determining
each executive officer&#146;s level of achievement, but considers: </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the degree of success achieved against the specific deliverables associated with each objective; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the difficulty of the goal; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">whether significant unforeseen obstacles or favorable circumstances altered the expected difficulty of achieving the
desired results; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the overall performance of the functional areas for which the executive officer has responsibility;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the manner in which the executive officer contributes to the overall success of the Company, including areas outside of
his or her responsibility; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the overall management of the executive officer&#146;s staff; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">other factors that may have made the stated goals more or less important to our success; and </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">other accomplishments by the executive officer during the year which, although not included as part of the formal goals,
are nonetheless deemed important to our near- and long-term success. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Committee does not assign weights in these
assessments, but uses its discretion and judgment to determine, based on recommendations by the President and Chief Executive Officer, a percentage that it believes fairly represents the named executive officer&#146;s individual achievement level
for the year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>2016 Executive Compensation Decisions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Corporate
Achievement Level </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In February 2017, the Committee determined that the Company had an overall corporate achievement level of
95% for 2016. This determination was based on progress in the advancement of the Company&#146;s skeletal and cardiac muscle R&amp;D programs, the achievement of research program milestones, and the expansion of a collaboration agreement. The
Committee considers these achievements alongside progress toward achieving business development goals, and other financing objectives and certain research goals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Individual Achievement Levels </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Mr.&nbsp;Blum&#146;s individual achievement level is based solely on the corporate achievement level, which for 2016 was 95%, as discussed
above. In February 2017, the Committee determined that the other named executive officers had individual achievement levels for 2016, based on their individual goals for 2016 and achievements against them described above, as follows:
Ms.&nbsp;Barbari &#151; 95%; Dr.&nbsp;Malik &#151; 95%; Mr.&nbsp;Morgan &#151; 95%; and Dr.&nbsp;Wolff &#151; 87%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>EXECUTIVE COMPENSATION </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Robert I. Blum. </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt"><I><U>Salary</U></I><I>.</I> The Committee granted a merit salary increase to Mr.&nbsp;Blum in 2016 of 3.5%. Accordingly,
Mr.&nbsp;Blum&#146;s base salary for 2016 was $595,000. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt"><I><U>Bonus</U></I><I>.</I> In February 2017, the Committee awarded Mr.&nbsp;Blum a bonus for 2016 performance of
$350,000, or 59% of his 2016 base salary. This was based on a target bonus of 60% of his base salary, multiplied by the corporate achievement level of 95%, however the Board did exercise some discretion in determining the final bonus amount.
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt"><I><U>Equity</U></I><I>. </I>In February 2016, the Committee awarded Mr.&nbsp;Blum stock options to purchase 275,000
shares of common stock in consideration of his performance as President and Chief Executive Officer in 2015. This award was within the targeted equity award range based on an analysis of data from our 2016 Peer Companies, which resulted in targeted
cash and equity compensation at or around the median. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Sharon A. Barbari. </I></B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt"><I><U>Salary</U></I><I>.</I> The Committee granted a merit salary increase to Ms.&nbsp;Barbari in 2016 of 2.5%.
Accordingly, Ms.&nbsp;Barbari&#146;s base salary for 2016 was $412,798. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt"><I><U>Bonus</U></I><I>.</I> In February 2017, the Committee awarded Ms.&nbsp;Barbari a bonus for her 2016 performance of
$156,863, or 38% of her 2016 base salary. This was based on a target bonus of 40% of base salary, multiplied by an overall achievement level of 95% (based on a weighting of 25% for her individual achievement level of 95% and 75% for the corporate
achievement level of 95%). </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt"><I><U>Equity</U></I><I>.</I> In February 2016, the Committee awarded Ms.&nbsp;Barbari stock options to purchase 90,000
shares of common stock. In determining the size of the award, the Committee considered her contribution with managing financial resources in 2015 which resulted in cash reserves in excess of those required to cover capital expenditure in the months
following. This award was within the targeted equity award range based on an analysis of data from our 2016 Peer Companies which resulted in targeted cash and equity compensation at or around the median. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Fady Malik. </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt"><I><U>Salary</U></I><I>.</I> The Committee granted a merit salary increase to Dr.&nbsp;Malik in 2016 of 2.5%.
Accordingly, Dr.&nbsp;Malik&#146;s base salary for 2016 was $449,694. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt"><I><U>Bonus</U></I><I>.</I> In February 2017, the Committee awarded Dr.&nbsp;Malik a bonus for his 2016 performance of
$170,884 or 38% of his 2016 base salary. This was based on a target bonus of 40% of base salary, multiplied by an overall achievement level of 95% (based on a weighting of 25% for his individual achievement level of 95% and 75% for the corporate
achievement level of 95%). </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt"><I><U>Equity</U></I><I>. </I>In February 2016, the Committee awarded Dr.&nbsp;Malik stock options to purchase 100,000
shares of common stock. In determining the size of the award, the Committee considered his contributions in research, preclinical and nonclinical development areas in 2016. This award was within the targeted equity award range based on an analysis
of data from our 2016 Peer Companies which resulted in targeted cash and equity compensation at or around the median. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Bradley Morgan.
</I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt"><I><U>Salary</U></I><I>.</I> The Committee granted a merit salary increase to Mr.&nbsp;Morgan in 2016 of 3%. Accordingly,
Mr.&nbsp;Morgan&#146;s base salary for 2016 was $332,227. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt"><I><U>Bonus.</U></I><I> </I>In February 2017, the Committee awarded Mr.&nbsp;Morgan a bonus for his 2016 performance of
$110,465 or 33% of his 2016 base salary. This was based on a target bonus of 35% of base salary, multiplied by an overall achievement level of 95% (based on a weighting of 25% for his individual achievement level of 95% and 75% for the corporate
achievement level of 95%). </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt"><I></I><I></I><I><U>Equity.</U></I><I> </I>In February 2016, the Committee awarded Mr.&nbsp;Morgan stock options to
purchase 50,000 shares of common stock. In determining the size of the award, the Committee considered his contributions in 2016 in meeting the goals related to drug discovery and early development. This award was within the targeted equity award
range based on an analysis of data from our 2016 Peer Companies which resulted in targeted cash and equity compensation at or around the median. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Andrew Wolff. </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt"><I><U>Salary</U></I><I>.</I> The Committee granted a merit salary increase to Dr.&nbsp;Wolff in 2016 of 2%. Accordingly,
Dr.&nbsp;Wolff&#146;s base salary for 2016 was $395,760. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>EXECUTIVE COMPENSATION </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt"><I><U>Bonus.</U></I><I> </I>In February 2017, the Committee awarded Dr.&nbsp;Wolff a bonus for his 2016 performance of
$100,000 or 25% of his 2016 base salary. This was based on management discretion. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt"><I></I><I></I><I><U>Equity.</U></I><I> </I>In February 2016, the Committee awarded Dr.&nbsp;Wolff stock options to
purchase 40,000 shares of common stock. In determining the size of the award, the Committee considered his contributions in 2016 in meeting the goals related to medical affairs. This award was within the targeted equity award range based on an
analysis of data from our 2016 Peer Companies which resulted in targeted cash and equity compensation at or around the median. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>2017
Compensation Decisions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In February 2017, the Committee made the following decisions with respect to the compensation of the named
executive officers. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Named Executive Officer</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">2017<BR>Base&nbsp;Salary</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Option&nbsp;Shares</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">RSU&#146;s</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Target&nbsp;Bonus<BR>as a % of<BR>Base Salary</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD></TR>


<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Robert I. Blum</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$615,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Sharon A. Barbari</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$425,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Fady I. Malik</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$463,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Bradley P. Morgan, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$342,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Andrew A. Wolff, M.D.</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$403,675</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">35%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Severance Benefits and Employment Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">We have entered into Executive Employment Agreements with each of our named executive officers. These agreements provide for salary and
benefit continuation, bonus payments and accelerated vesting of equity awards upon the termination of their employment either by us without cause, or by the executive for good reason following a loss of position in connection with a change of
control of the Company. The terms of these agreements are described in more detail in the section entitled &#147;Potential Payments Upon Change of Control.&#148; In addition, our equity plan provides that all employee equity awards will be subject
to full acceleration if they are not assumed or replaced with comparable awards by the acquirer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Committee believes these
severance and change of control benefits are an essential element of our executive compensation package and assist it in recruiting and retaining talented executive officers. The Committee believes these benefits serve to minimize the distractions
to the executive, reduce the risk that the executive will depart the Company before an acquisition is consummated, and allow the executive to focus on continuing normal business operations and the success of a potential business combination, rather
than worrying about how business decisions that may be in the best interest of the Company and its stockholders will impact his or her own financial security. That is, these change of control arrangements help ensure stability among our executive
officer ranks and will enable our executives to maintain a balanced perspective in making overall business decisions during periods of uncertainty. Further, these agreements are in line with customary practices at an executive officer level at the
Peer Companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Other Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Our
executive officers are eligible to participate in our employee benefit plans, including medical, dental, life insurance, employee stock purchase and 401(k) plans. These benefits are available to our executives on the same terms and conditions as our
other employees. Our executive officers do not receive any perquisites other than those provided to all employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Equity Compensation Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Our policy is to make <FONT STYLE="white-space:nowrap">new-hire</FONT> and annual equity grants on
<FONT STYLE="white-space:nowrap">pre-determined</FONT> dates as follows: </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">The Committee <FONT STYLE="white-space:nowrap">pre-approves</FONT> new hire stock option grants above the senior director
level, including our executive officers, before an offer is made. The Committee has delegated to Robert I. Blum, as President and Chief Executive Officer, the authorization to approve new hire stock option grants, within <FONT
STYLE="white-space:nowrap">pre-approved</FONT> new hire grant guidelines, for new hires at or below the senior director level before an offer is made. New hire stock options are granted on the last day of the month in which the employee is hired.
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">We make annual equity grants, on a discretionary basis, as part of our performance review and reward process. The
Committee makes annual grants to employees at a Committee meeting held during the first quarter of each fiscal year. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>EXECUTIVE COMPENSATION </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The exercise price of the stock options is not less than the closing price of our Common Stock on the NASDAQ Capital Market on the grant
date of the option. Our policy is not to purposely accelerate or delay the public release of material information in consideration of a pending equity grant to allow the grantee to benefit from a more favorable stock price. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">We encourage our executive officers to hold a significant equity interest in the Company, but we have not set specific ownership
guidelines. We have a policy that prohibits our executive officers, directors and other members of management from engaging in short sales, transactions in put or call options, hedging transactions or other inherently speculative transactions with
respect to our stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Tax Deductibility of Executive Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Section&nbsp;162(m) of the Code limits the amount that a public company may deduct from federal income taxes for remuneration paid to the
chief executive officer and the three other most highly paid executive officers, other than the chief financial officer, to $1.0&nbsp;million per executive per year, unless certain requirements are met. Section&nbsp;162(m) provides an exception from
this deduction limitation for certain forms of &#147;performance-based compensation,&#148; including the gain recognized by executive officers upon the exercise of qualifying compensatory stock options. While the Committee is mindful of the benefit
to us of the full deductibility of compensation, the Committee believes that it should not be constrained by the requirements of Section&nbsp;162(m) where those requirements would impair flexibility in compensating our executive officers in a manner
that can best promote our corporate objectives. Accordingly, although our grants of stock options to our executive officers will be considered &#147;performance-based compensation&#148; under Section&nbsp;162(m), their annual cash bonuses, if any,
will not. We intend to continue to compensate our executive officers in a manner consistent with what we believe are the best interests of the Company and our stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Accounting Considerations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In determining the
size and type of equity awards, the Committee considers the potential impact of the accounting guidance for stock-based compensation. However, we do not set a specific budget for equity compensation based on the accounting cost. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Compensation Recovery Policy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">One of the
objectives of our compensation program for our named executive officers is to make a substantial portion of compensation paid to our executive officers dependent on the Company&#146;s overall financial performance. In order to ensure that our named
executive officers take full account of risks to the Company and its stockholders in their decision-making, and to reduce such risks wherever practicable, our Board adopted a clawback policy and delegated authority to its Compensation Committee to
administer it. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Our clawback policy allows the Company to seek repayment of incentive compensation that was erroneously paid. The
policy provides that if the Board, or Compensation Committee as applicable, determines that there has been a material misstatement of publicly issued financial results from those previously issued to the public [due to a knowing violation of rules
and regulations of the Securities and Exchange Commission or Company policy, or the willful commission of an act of fraud, dishonesty, gross recklessness or gross negligence], our Board or Compensation Committee will review all incentive
compensation made to our [executive] officers during the [three] year period prior to the restatement on the basis of having met or exceeded specific performance targets. If such payments would have been lower had they been calculated based on such
restated results, our Board or Compensation Committee will (to the extent permitted by governing law) seek to recoup the payments in excess of the amount that would have been paid based on the restated results. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In addition, as a public company subject to Section&nbsp;304 of the Sarbanes-Oxley Act of 2002, if we are required as a result of
misconduct to restate our financial results due to the material noncompliance with any financial reporting requirements under the federal securities laws, our President and Chief Executive Officer and Executive Vice President, Finance and Chief
Financial Officer may be legally required to reimburse us for any bonus or other incentive-based or equity-based compensation they received. In addition, we will comply with the requirements of the Dodd-Frank Wall Street Reform and Consumer
Protection Act and will adopt a compensation recovery policy once the SEC adopts final regulations on the subject. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>EXECUTIVE COMPENSATION </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_19"></A>Compensation and Talent Committee Report </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Compensation and Talent Committee of the Company has reviewed and discussed the Compensation Discussion and Analysis required by
Item&nbsp;402(b) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> with management and, based on such review and discussions, the Compensation and Talent Committee recommended to the Board of Directors that the Compensation Discussion and
Analysis be included in this proxy statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:9pt; font-family:ARIAL">MEMBERS OF THE COMPENSATION AND </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:9pt; font-family:ARIAL">TALENT COMMITTEE </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:9pt; font-family:ARIAL">Santo J. Costa </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:9pt; font-family:ARIAL">L.
Patrick Gage </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:9pt; font-family:ARIAL">Sandford D. Smith </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:9pt; font-family:ARIAL">Wendell Wierenga </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">Dated:
March&nbsp;31, 2017 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">During fiscal year 2016, directors Santo J. Costa, L. Patrick Gage, Sandford D. Smith and Wendell Wierenga served on the Compensation and
Talent Committee. No current or former member of the Compensation and Talent Committee or executive officer of the Company has served as a member of the board of directors or compensation committee of any entity that has one or more executive
officers serving as a member of our Board of Directors or Compensation and Talent Committee. The current and former members of the Compensation and Talent Committee were not officers or employees of the Company while a member of the Compensation and
Talent Committee during fiscal year 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Risk Analysis of the Compensation Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Committee has reviewed our compensation policies as generally applicable to our employees and believes that our policies do not
encourage excessive and unnecessary risk-taking and that the level of risk that they do encourage is not reasonably likely to have a material adverse effect on us. The design of our compensation policies and programs is intended to encourage our
employees to remain focused on both our short- and long-term goals. For example, while our cash bonus plans measure corporate and individual performance on an annual basis, the stock options typically vest over a number of years, which the Committee
believes encourages employees to focus on sustained stock price appreciation, thus limiting the potential value of excessive risk-taking. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>EXECUTIVE COMPENSATION </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_20"></A>Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The following table summarizes the total compensation earned by or paid to each of the named executive officers for the fiscal years ended
December&nbsp;31, 2016, 2015 and 2014: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Name and Principal Position</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Year</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Salary</FONT><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP><SUP
STYLE="font-size:85%; vertical-align:top">&nbsp;</SUP></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Bonus</FONT><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Stock<BR>Awards</FONT><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Option<BR>Awards</FONT><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">All
Other</FONT></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Compensation</FONT><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Total</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ROWSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Robert I. Blum</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">President and Chief</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL">Executive Officer</P></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">591,667</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">1,236,290</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">2,177,957</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">571,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">310,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,259,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,122,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,264,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">555,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">323,010</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">1,310,900</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">2,188,910</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ROWSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Sharon A. Barbari</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Executive Vice President, Finance</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL">and Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">411,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">404,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">980,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">402,730</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">144,983</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">524,925</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">420,893</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">7,950</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">1,501,481</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">400,775</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">153,886</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">458,815</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">7,800</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">1,021,276</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ROWSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Fady Malik, M.D., Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Executive Vice President,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL">Research and Development</P></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">447,866</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">170,884</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">449,560</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">7,950</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">1,076,260</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">415,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">699,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">561,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,842,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">384,583</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">131,891</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">655,450</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">7,800</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">1,179,724</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ROWSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Bradley P. Morgan, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top"> (6)</SUP></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Senior Vice President,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL">Research and
<FONT STYLE="white-space:nowrap">Non-Clinical</FONT> Development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">330,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">224,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">673,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">307,142</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">88,782</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">419,940</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">168,357</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">7,950</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">992,171</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ROWSPAN="3" STYLE="BORDER-BOTTOM:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Andrew Wolff, M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Senior Vice President,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL">Chief Medical Officer</P></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">394,467</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">179,824</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">674,291</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">388,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">349,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">196,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,024,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">388,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">85,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">473,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Includes amounts earned but deferred at the election of the named executive officers pursuant to our 401(k) employee
savings and retirement plan. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Represents amounts earned in 2016 pursuant to our Employee Bonus Plan and paid on March&nbsp;10, 2017.
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Amounts in this column reflect the grant date fair value of PSUs granted pursuant to our equity incentive plans
calculated in accordance with the accounting guidance for stock compensation. Assumptions used for the valuation of performance units are set forth in Note 11 to our audited financial statements for the fiscal year ended December&nbsp;31, 2016,
included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for each of such years. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Amounts in this column reflect the grant date fair value of awards granted pursuant to our equity incentive plans,
calculated in accordance with the accounting guidance for stock compensation. Assumptions used for the valuation of option grants are set forth in Note 11 to our audited financial statements for each of the fiscal years ended December&nbsp;31, 2016,
2015 and 2014, included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for each of such years. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Represents matching contributions under the Company&#146;s 401(k) plan. </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Dr.&nbsp;Morgan was became an executive officer of the Company in 2015 and therefore has no compensation disclosed for
2014. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Employment and Other Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">We have entered into Executive Employment Agreements with each named executive officer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Executive Employment Agreements provide for such officers to remain <FONT STYLE="white-space:nowrap">at-will</FONT> employees of the
Company and to receive salary, bonus and benefits as determined at the discretion of the Board of Directors. Such agreements also provide for such officers to receive certain benefits if, within the eighteen-month period following a change of
control of the Company, they resign for good reason or are terminated by us or our successor other than for cause &#151; see &#147;Potential Payments Upon Change of Control&#148; below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>EXECUTIVE COMPENSATION </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_21"></A>Grants of Plan Based Awards in 2016 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The following table sets forth information regarding plan-based awards to each of the named executive officers during 2016. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#737374">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #ffffff" BGCOLOR="#737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Estimated Future Payouts Under<BR>Employee Bonus Plan</FONT><SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374" BGCOLOR="#737374"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT
 COLOR="#ffffff">All Other<BR>Option</FONT></B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Awards:</FONT></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Number
of<BR>Securities<BR>Underlying<BR>Options<BR>(#)</FONT><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374" BGCOLOR="#737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Exercise<BR>or Base<BR>Price of<BR>Option<BR>Awards<BR>($)</FONT></B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374" BGCOLOR="#737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Grant&nbsp;Date<BR>Fair&nbsp;Value&nbsp;of<BR>Stock
and<BR>Option<BR>Awards<BR>($)</FONT></B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" BGCOLOR="#737374">&nbsp;</TD></TR>
<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Name</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Grant<BR>Date</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Threshold<BR>($)</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Target<BR>($)</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Maximum<BR>($)</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD></TR>


<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff">Robert I. Blum</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">357,000</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">428,400</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">02/23/16</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">275,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">6.67</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">1,236,290</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff">Sharon A. Barbari</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">165,119</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">198,143</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">02/23/16</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">6.67</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">404,604</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff">Fady I. Malik, M.D., Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">179,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">215,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">02/23/16</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">6.67</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">449,560</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff">Bradley P. Morgan, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">139,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">02/23/16</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">6.67</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">224,780</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff">Andrew A. Wolff, M.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">138,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">166,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right">02/23/16</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right">6.67</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right">179,824</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Reflects each named executive officer&#146;s participation in our Employee Bonus Plan, calculated based on each
officer&#146;s respective base salary and position as of December&nbsp;31, 2016. Amounts actually earned under the plan in 2016, if any, are reflected in the Summary Compensation Table above. </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">All stock options granted to the named executive officers in 2016 were granted under the Amended and Restated 2004 Equity
Incentive Plan. Each option vests monthly over a four-year period. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>EXECUTIVE COMPENSATION </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_22"></A>Outstanding Equity Awards at December&nbsp;31, 2016 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The following table sets forth information regarding outstanding equity awards held by each named executive officer as of
December&nbsp;31, 2016. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #fcfcfc"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Option Awards</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #fcfcfc"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Stock Awards</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>



<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #ffffff" BGCOLOR="#737374"><FONT COLOR="#ffffff"><B>Number of Securities<BR>Underlying Unexercised<BR>Options</B></FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" BGCOLOR="#737374"><FONT COLOR="#ffffff"><B>Option<BR>Exercise<BR>Price</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" BGCOLOR="#737374"><FONT COLOR="#ffffff"><B>Option<BR>Expiration<BR>Date</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" BGCOLOR="#737374"><FONT COLOR="#ffffff"><B>Number&nbsp;of<BR>Shares or<BR>Units That<BR>Have Not<BR>Vested<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" BGCOLOR="#737374"><FONT COLOR="#ffffff"><B>Market<BR>Value of<BR>Shares or<BR>Units That<BR>Have Not<BR>Vested<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" BGCOLOR="#737374">&nbsp;</TD></TR>


<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Exercisable</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Unexercisable</FONT><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff">Robert I. Blum</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">41,666</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">40.86</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">03/14/2017</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/28/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">45,832</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">11.10</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">02/26/2019</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/24/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">83,332</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">9.42</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">02/28/2021</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/05/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">125,000</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">8,333</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">6.00</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">03/05/2023</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/24/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">91,667</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">108,333</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">7.96</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">02/26/2025</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">217,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/23/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#ffffff"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">180,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">2,187,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff">Sharon A. Barbari</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/14/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">20,499</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">20.22</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">02/28/2018</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/26/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">22,499</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">18.48</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">02/24/2020</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/28/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">29,166</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">6.30</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">03/05/2022</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/05/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">49,583</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">20,417</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">9.65</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">02/24/2024</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/26/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">18,750</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">71,250</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">6.67</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">02/23/2026</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#ffffff"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">911,250</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff">Fady I. Malik, M.D., Ph.D.</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">3,299</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">40.86</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">03/14/2017</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/28/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">6,666</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">11.10</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">02/26/2019</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/24/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">12,500</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">9.42</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">02/28/2021</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/05/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">46,875</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">3,125</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">6.00</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">03/05/2023</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/24/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">45,833</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">54,167</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">7.96</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">02/26/2025</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/23/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#ffffff"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">1,215,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>EXECUTIVE COMPENSATION </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>

<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #fcfcfc"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Option Awards</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #fcfcfc"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Stock Awards</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #ffffff" BGCOLOR="#737374"><FONT COLOR="#ffffff"><B>Number of Securities<BR>Underlying Unexercised<BR>Options</B></FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" BGCOLOR="#737374"><FONT COLOR="#ffffff"><B>Option<BR>Exercise<BR>Price</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" BGCOLOR="#737374"><FONT COLOR="#ffffff"><B>Option<BR>Expiration<BR>Date</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" BGCOLOR="#737374"><FONT COLOR="#ffffff"><B>Number&nbsp;of<BR>Shares or<BR>Units That<BR>Have Not<BR>Vested<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" BGCOLOR="#737374"><FONT COLOR="#ffffff"><B>Market<BR>Value of<BR>Shares&nbsp;or<BR>Units&nbsp;That<BR>Have
Not<BR>Vested<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" BGCOLOR="#737374">&nbsp;</TD></TR>


<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Exercisable</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Unexercisable</FONT><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff">Morgan Bradley, Ph.D.</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">3,299</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">40.86</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">03/14/2017</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/28/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">6,666</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">11.10</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">02/26/2019</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/24/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">12,500</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">9.42</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">02/28/2021</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/05/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">23,437</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">1,562</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">6.00</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">03/05/2023</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/24/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">13,750</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">16,250</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">7.96</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">02/26/2025</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/23/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#ffffff"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">729,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff">Andrew Wolff, M.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/14/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">20,832</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">20.22</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">02/28/2018</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/26/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">18.48</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">02/24/2020</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/28/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">7,291</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">6.30</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">03/05/2022</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/05/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">16,042</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">18,958</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">7.96</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" ALIGN="right">02/26/2025</TD>
<TD NOWRAP VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#ffffff"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/23/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#ffffff"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e5e5e5" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5" ALIGN="right">607,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" BGCOLOR="#e5e5e5">&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">All currently unexercisable options in this table vest monthly over a four-year period from the date of grant.
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">The performance stock units have specific clinical development milestone vesting triggers as well as additional time
based vesting conditions. Vesting of 25% occurs March&nbsp;31, 2017, 50% occurs March&nbsp;31, 2018 and 25% on March&nbsp;31, 2019, and only upon Compensation Committee certification of performance achievement. No stock units are earned if the goals
are not met. The market value of the stock units is based on the closing stock price of $12.15 per share of our Common Stock as of December&nbsp;31, 2016. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_23"></A>Option Exercises and Vesting of Stock in 2016 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">There were no stock options exercised and no stock awards vested during the fiscal year ending December&nbsp;31, 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Pension Benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">We do not
provide our employees, including our named executive officers, with a defined benefit pension plan or any supplemental executive retirement plans or retiree health benefits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Nonqualified Deferred Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">We do not have a nonqualified defined contribution plan or other nonqualified deferred compensation plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_24"></A>Potential Payments Upon Termination or Change of Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">We have entered into Executive Employment Agreements with each of the named executive officers. Such agreements provide for such officers
to receive certain benefits if, within the eighteen-month period following a change of control of the Company, the executive officer resigns for good reason or is terminated by us or our successor other than for cause (a &#147;qualifying resignation
or termination&#148;) and such officer signs a standard release of claims with us. In addition, our executives will receive accelerated vesting of equity awards upon a change of control in which the acquirer does not assume all equity awards.
However, we do not have any other agreements, plans or arrangements that provide for severance or other benefits upon termination for other reasons. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>EXECUTIVE COMPENSATION </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">&#147;Good reason&#148; includes a material reduction in salary; a material decrease in duties or responsibilities; a material decrease in
the duties or responsibilities of the supervisor to whom the executive officer is required to report; a material decrease in the budget over which the executive officer has authority; relocation of the place of employment to a location more than
fifty miles from our location at the time of the change in control; or a material breach of the Executive Employment Agreement by us or our successor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">&#147;Cause&#148; includes failure to substantially perform the duties of the job other than due to physical or mental illness; engaging
in conduct that is materially injurious to us or constitutes gross misconduct; material breach of the Executive Employment Agreement by the executive officer; material breach of Company policies that have been adopted by the Board of Directors;
conviction of a felony; or fraud against us. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Under their Executive Employment Agreements, upon a qualifying resignation or
termination, Ms.&nbsp;Barbari, Dr.&nbsp;Malik, Dr.&nbsp;Morgan and Dr.&nbsp;Wolff will become entitled to receive: continuing severance payments at a rate equal to their base salary for a period of eighteen months; a lump sum payment equal to their
full target annual bonus; acceleration in full of vesting of equity awards held by them; and continued employee benefits until the earlier of eighteen months following the date of termination or resignation or the date they obtain employment with
generally similar employee benefits. In the event that such payments constitute &#147;parachute payments&#148; within the meaning of Section&nbsp;280G of the Code and become subject to the excise tax imposed under Section&nbsp;4999 of the Code, the
Executive Employment Agreements of Ms.&nbsp;Barbari, Dr.&nbsp;Malik, Dr.&nbsp;Morgan and Dr.&nbsp;Wolff each provide that the benefit amount may be reduced so that no portion of the payment is subject to the excise tax. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Under his Executive Employment Agreement, upon a qualifying resignation or termination, Mr.&nbsp;Blum will become entitled to receive:
continuing severance payments at a rate equal to his base salary for a period of twenty-four months; a lump sum payment equal to his full target annual bonus; acceleration in full of vesting of equity awards held by him; and continued employee
benefits until the earlier of twenty-four months following the date of termination or resignation or the date he obtains employment with generally similar employee benefits. In the event that such payments constitute &#147;parachute payments&#148;
within the meaning of Section&nbsp;280G of the Code and become subject to the excise tax imposed under Section&nbsp;4999 of the Code, Mr.&nbsp;Blum is eligible to receive a payment from us sufficient to pay the excise tax, and a tax <FONT
STYLE="white-space:nowrap">gross-up</FONT> payment, which is an additional payment sufficient to pay the excise tax and other income taxes resulting from the initial excise tax payment. This excise tax and tax
<FONT STYLE="white-space:nowrap">gross-up</FONT> payment has been a benefit we have historically offered at the Chief Executive Officer level based on the uniqueness and importance of that role to our business. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The provisions of each Executive Employment Agreement are intended to comply with the requirements of Section&nbsp;409A so that none of
the severance payments or benefits to be provided under the agreements will be subject to the additional tax imposed under Section&nbsp;409A. If severance payments to an executive officer at the time of termination would trigger the additional tax
imposed under Section&nbsp;409A, then such payments will instead become payable to the executive officer starting six months and one day after the termination date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Severance payments and benefits provided to an executive officer under an Executive Employment Agreement following a qualifying
resignation or termination are subject to certain conditions including adherence to existing confidentiality, proprietary information and invention assignment agreements, and <FONT STYLE="white-space:nowrap">non-competition</FONT> clauses. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The following table summarizes the potential benefits the named executive officers would receive in the circumstances described above
assuming their employment had been terminated on December&nbsp;31, 2016: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Name</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Salary</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Bonus</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Acceleration&nbsp;of<BR>Vesting of<BR>Performance&nbsp;Stock<BR>Units</FONT><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></FONT></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Acceleration&nbsp;of<BR>Vesting of<BR>Stock<BR>Options</FONT><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Continuation<BR>of&nbsp;Employee<BR>Benefits</FONT><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Excise&nbsp;Tax<BR>Gross&nbsp;Up</FONT><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Total</FONT><SUP STYLE="font-size:85%; vertical-align:top">(5) </SUP></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Robert I. Blum</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,190,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">357,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,187,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,844,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,292,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,951,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Sharon A. Barbari</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">619,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">911,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">630,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,386,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Fady I. Malik, M.D., Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">674,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,215,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">752,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,882,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Bradley Morgan, Ph. D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">498,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">729,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">316,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,720,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.00pt solid #000000">Andrew Wolff, M.D.</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right">593,640</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right">138,516</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right">607,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right">268,984</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right">42,499</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right">1,651,139</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">The value of the acceleration of vesting of the PSUs is calculated using the closing market price of the Company&#146;s
Common Stock as of December&nbsp;31, 2016 of $12.15 and assumes all of the performance goals have been met. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">The value of the acceleration of vesting of stock options is calculated as the amount by which the closing market price
of the Company&#146;s Common Stock as of December&nbsp;31, 2016 of $12.15 exceeds the exercise price for unvested stock options as of December&nbsp;31, 2016. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Represents the cost of premiums for medical, dental, vision, life and disability insurance coverage under our group
employee benefit plans. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Based on the payment amounts reflected above, Mr.&nbsp;Blum would be subject to excise taxes under Sections 280G and 4999
of the Code. Under his Executive Employment Agreement, Mr.&nbsp;Blum is entitled to receive a payment from the Company sufficient to pay the excise tax, and an excise tax <FONT STYLE="white-space:nowrap">gross-up</FONT> payment, which is an
additional payment sufficient to pay the excise tax and other income taxes resulting from the initial excise tax payment. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Other than Mr.&nbsp;Blum, our named executive officers are not entitled to an excise tax
<FONT STYLE="white-space:nowrap">gross-up</FONT> payment with respect to their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-in-control</FONT></FONT> payments and benefits. However, the payments and benefits may be reduced
to avoid excise tax if such reduction would enable the executive to net more on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis than they would in the absence of a reduction. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_25"></A>DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_26"></A>Director Summary Compensation Table for 2016 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The following table summarizes the total compensation earned by our Directors for the fiscal year ended December&nbsp;31, 2016. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Name</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Fees&nbsp;Earned&nbsp;or<BR>Paid in
Cash<BR>($)</FONT><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Option<BR>Awards<BR>($)</FONT><SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:2.00pt solid #737374"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Total<BR>($)</FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #737374">&nbsp;</TD></TR>


<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Robert I. Blum<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Santo J. Costa<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$57,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$101,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$159,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">L. Patrick Gage, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$32,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$202,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$235,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">John T. Henderson, M.B., Ch.B.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$160,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$185,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Edward M.Kaye.<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$3,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$211,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$214,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">B. Lynne Parshall, Esq.<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$131,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$176,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Sandford D. Smith<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$37,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$131,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$168,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Wendell Wierenga, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$52,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$131,132</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$183,632</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Mr.&nbsp;Gage, Dr.&nbsp;Henderson and Dr.&nbsp;Kaye made an annual election to receive 100% of their retainer fee for
2016 in stock options. Ms.&nbsp;Parshall, Mr.&nbsp;Smith and Dr.&nbsp;Wierenga each made an annual election to receive 50% of their retainer fees for 2016 in stock options. </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Amounts in this column reflect the grant date fair value of awards granted in 2016, calculated in accordance with the
accounting guidance for stock compensation. Assumptions used for the valuation of option grants are set forth in Note 11 to our audited financial statements for the fiscal year ended December&nbsp;31, 2016, included in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Employee Directors receive no separate compensation for their services as members of the Board of Directors. Refer to
summary compensation table, for the employee director&#146;s compensation earned fir the fiscal year ended December&nbsp;31, 2016. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">As of December&nbsp;31, 2016, Mr.&nbsp;Costa had outstanding options to purchase 68,331 shares of Common Stock, of which
59,997 were exercisable. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">As of December&nbsp;31, 2016, Dr.&nbsp;Gage had outstanding options to purchase 169,343 shares of Common Stock, of which
159,759 were exercisable. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">As of December&nbsp;31, 2016, Dr.&nbsp;Henderson had outstanding options to purchase 146,510 shares of Common Stock, of
which 137,446 were exercisable. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">As of December&nbsp;31, 2016, Dr.&nbsp;Kaye had outstanding options to purchase 40,175 shares of Common Stock, of which
11,117 were exercisable. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">As of December&nbsp;31, 2016, Ms.&nbsp;Parshall had outstanding options to purchase 84,117 shares of Common Stock, of
which 75,418 were exercisable. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">As of December&nbsp;31, 2016, Mr.&nbsp;Smith had outstanding options to purchase 95,439 shares of Common Stock, of which
86,740 were exercisable. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">As of December&nbsp;31, 2016, Dr.&nbsp;Wierenga had outstanding options to purchase 91,662 shares of Common Stock, of
which 82,963 were exercisable. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">We reimburse our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for
their expenses incurred in connection with attending Board of Directors and committee meetings. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><FONT STYLE="white-space:nowrap">Non-employee</FONT> directors receive a base retainer for service on the Board of Directors and an
additional retainer for each committee on which they serve. <FONT STYLE="white-space:nowrap">Non-employee</FONT> directors no longer receive <FONT STYLE="white-space:nowrap">per-meeting</FONT> fees. Annual retainers are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Annual Base Retainer</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">Chairman</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Lead outside director (if any)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Other directors</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Committee Chairperson Retainer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Audit Committee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Compensation and Talent Committee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Nominating and Governance Committee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Science and Technology Committee</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Committee Member Retainer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Audit Committee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Compensation and Talent Committee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Nominating and Governance Committee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Science and Technology Committee</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>DIRECTOR COMPENSATION </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Each independent outside director may continue to make an annual
election to receive his or her annual base retainer in cash or to receive either 50% or 100% of the retainer in stock options. The grant date of the stock options is the first business day of the fiscal calendar year. The number of stock options is
calculated at a rate of 2.5 times the cash retainer amount, divided by the closing price of our Common Stock on the date of grant. For example, if a director elects to receive 100% of the retainer in stock options, $100,000 (2.5 times $40,000) is
divided by the closing stock price on the date of grant to determine the number of stock options. The stock options vest monthly over a <FONT STYLE="white-space:nowrap">one-year</FONT> vesting period. This election is not available for the committee
retainers. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Company reimburses its <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for their <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with attending Board of Directors and committee meetings. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">We have in the past granted <FONT STYLE="white-space:nowrap">non-employee</FONT> directors options to purchase our Common Stock pursuant
to the terms of our 2004 Equity Incentive Plan and our Board of Directors continues to have the discretion to grant options to new and continuing <FONT STYLE="white-space:nowrap">non-employee</FONT> Directors. In May 2015, our Board of Directors and
stockholders, respectively, approved our Amended and Restated 2004 Equity Incentive Plan, which provides for automatic grants of stock options to directors who are not our officers or employees. Effective May&nbsp;20, 2015, new directors received an
initial option grant of 35,000 shares on joining the Board of Directors, and continuing directors received an annual option grant 20,000 shares. Generally, grants to new directors vested monthly over three years and grants to continuing directors
vest monthly over one year. Also effective May&nbsp;20, 2015, the timeframe within which a <FONT STYLE="white-space:nowrap">non-employee</FONT> director resigning from the Board is able to exercise vested options following the resignation date is
extended to one year. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Employee directors who meet the eligibility requirements may participate in our 2015 Employee Stock Purchase
Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">We maintain director and officer indemnification insurance coverage. This insurance covers directors and officers individually.
The policies currently run from June&nbsp;1, 2016 through June&nbsp;1, 2017 at a total annual cost of $421,502. The primary carrier is Old Republic Insurance Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_28"></A>REPORT OF THE AUDIT COMMITTEE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>OF THE BOARD OF DIRECTORS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The
Audit Committee operates under a written charter adopted by the Board of Directors and reviewed and approved annually by the Audit Committee. The purpose of the Audit Committee is to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Select the Company&#146;s independent auditors and oversee the accounting and financial reporting processes of the
Company and audits of the financial statements of the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Assist the Board of Directors in oversight and monitoring of (i)&nbsp;the integrity of the Company&#146;s financial
statements, (ii)&nbsp;the Company&#146;s financial reporting process, (iii)&nbsp;the Company&#146;s compliance with legal and regulatory requirements under applicable securities law, (iv)&nbsp;the independent auditors&#146; qualifications,
independence and performance, (v)&nbsp;the Company&#146;s systems of internal accounting and financial controls, and (vi)&nbsp;other areas of current or potential risk to the Company&#146;s finances; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Provide the Board of Directors with the results of its monitoring and recommendations derived therefrom;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Prepare a report in the Company&#146;s annual proxy statement in accordance with SEC rules; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Provide to the Board of Directors such additional information and materials as it may deem necessary to make the Board of
Directors aware of significant financial matters that come to its attention and that require the attention of the Board of Directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Management has the primary responsibility for the financial statements and the reporting process including the system of internal
controls. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In fulfilling its responsibilities during 2016, the Audit Committee has: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Reviewed and discussed the audited financial statements and the Company&#146;s financial reporting processes with
management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Discussed with the Company&#146;s independent registered public accounting firm, PricewaterhouseCoopers LLP, matters
required to be discussed under Statements of Auditing Standards No.&nbsp;1301, <I>Communications with Audit Committees</I>, and Statements of Auditing Standards No.&nbsp;90, <I>Communication with Audit Committees</I>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Received from PricewaterhouseCoopers LLP written disclosures and a letter regarding their independence as required by the
rules of the Public Company Accounting Oversight Board, and discussed with PricewaterhouseCoopers LLP their independence from management and the Company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Discussed with PricewaterhouseCoopers LLP the overall scope and plans for the audit. The Audit Committee met with
PricewaterhouseCoopers LLP, with and without management present, to discuss the results of its examinations, its evaluations of the Company&#146;s internal controls and the overall quality of the Company&#146;s financial reporting.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Based on the foregoing, the Audit Committee recommended to the Board of Directors that the audited financial
statements be included in the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016 for filing with the SEC. The Audit Committee and the Board of Directors have also recommended,
subject to stockholder ratification, the selection of PricewaterhouseCoopers LLP as the Company&#146;s independent registered public accounting firm for the year ending December&nbsp;31, 2017. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:27.78em; text-indent:-1.11em; font-size:9pt; font-family:ARIAL">Respectfully submitted,</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:27.78em; text-indent:-1.11em; font-size:9pt; font-family:ARIAL">MEMBERS OF THE AUDIT COMMITTEE</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:27.78em; text-indent:-1.11em; font-size:9pt; font-family:ARIAL">B. Lynne Parshall</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:27.78em; text-indent:-1.11em; font-size:9pt; font-family:ARIAL">John T. Henderson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:27.78em; text-indent:-1.11em; font-size:9pt; font-family:ARIAL">Sandford D. Smith</P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">Dated: March&nbsp;31, 2017 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_31"></A>SECTION&nbsp;16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Section&nbsp;16(a) of the Exchange Act requires our officers and directors, and persons who own more than ten percent of a registered
class of our equity securities, to file reports of ownership and changes in ownership with the SEC. Such officers, directors and <FONT STYLE="white-space:nowrap">ten-percent</FONT> stockholders are also required by SEC rules to furnish us with
copies of all forms that they file pursuant to Section&nbsp;16(a). Based solely on its review of the copies of such forms received by it, or written representations from certain reporting persons, we believe that during 2016, our executive officers
and directors complied with all applicable filing requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_33"></A>CERTAIN BUSINESS RELATIONSHIPS AND RELATED PARTY
TRANSACTIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Review, Approval or Ratification of Transactions with Related Party </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Our policy is that any transaction with a related party that is required to be reported under applicable SEC rules, other than
compensation-related matters and waivers of our Code of Ethics, must be reviewed and approved according to an established procedure. Such a transaction is reviewed by the Audit Committee as required by the Audit Committee&#146;s charter, and if
approved, is then submitted to the full Board of Directors where it is subject to review and approval or ratification by a majority of the independent, disinterested directors. We have not adopted specific standards for approval of these
transactions, but instead review each such transaction on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis. Our policy is to require that all such compensation-related matters be reviewed by the
Compensation and Talent Committee and, if approved, submitted to the Board of Directors for review and approval. Any waiver of our Code of Ethics must be reviewed by the Nominating and Governance Committee and, if approved, must be reported as
required under applicable SEC rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Amgen, Inc. (&#147;Amgen&#148;) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In December 2006, the Company entered into a collaboration and option agreement with Amgen to discover, develop and commercialize novel
small molecule therapeutics, including omecamtiv mecarbil, that activate cardiac muscle contractility for potential applications in the treatment of heart failure (the &#147;Amgen Agreement&#148;). The agreement granted Amgen an option to obtain an
exclusive license worldwide, except Japan, to develop and commercialize omecamtiv mecarbil and other drug candidates arising from the collaboration. In May 2009, Amgen exercised its option. As a result, Amgen became responsible for the development
and commercialization of omecamtiv mecarbil and related compounds at its expense worldwide (excluding Japan), subject to the Company&#146;s development and commercialization participation rights. Amgen reimburses the Company for certain research and
development activities it performs under the collaboration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In June 2013, Cytokinetics and Amgen executed an amendment to the Amgen
Agreement to include Japan, resulting in a worldwide collaboration (the &#147;Amgen Agreement Amendment&#148;). Under the terms of the Amgen Agreement Amendment, the Company received a <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront
license fee of $15.0&nbsp;million in June 2013. Under the Amgen Agreement Amendment, the Company conducted a Phase 1 pharmacokinetic study intended to support inclusion of Japan in a potential Phase 3 clinical development program and potential
global registration dossier for omecamtiv mecarbil. Amgen reimbursed the Company for the costs of this study. In addition, the Company is eligible to receive additional <FONT STYLE="white-space:nowrap">pre-commercialization</FONT> milestone payments
relating to the development of omecamtiv mecarbil and royalties on sales of omecamtiv mecarbil in Japan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In conjunction with the
Amgen Agreement Amendment, the Company also entered into a common stock purchase agreement which provided for the sale of 1,404,100 shares of its common stock to Amgen at a price per share of $7.12 and an aggregate purchase price of
$10.0&nbsp;million, which was received in June 2013. The Company determined the fair value of the stock issued to Amgen to be $7.5&nbsp;million. The excess of cash received over fair value of $2.5&nbsp;million was initially deferred and allocated
between the license and services based on their relative selling prices using best estimate of selling price. The allocated consideration was recognized as revenue as revenue criteria were satisfied, or as services were performed over approximately
12 months. Pursuant to this agreement, Amgen agreed to certain trading and other restrictions with respect to the Company&#146;s common stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Company determined that the license to the Japan territory granted under the Amgen Agreement Amendment was a separate, <FONT
STYLE="white-space:nowrap">non-contingent</FONT> deliverable under the amendment. The Company determined that the license has stand-alone value based on Amgen&#146;s internal product development capabilities since all relevant manufacturing <FONT
STYLE="white-space:nowrap">know-how</FONT> related to omecamtiv mecarbil was previously delivered to Amgen. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In October 2013, the
Company determined that the revenue recognition requirements under ASC <FONT STYLE="white-space:nowrap">605-10</FONT> had been met and accordingly, recognized $17.2&nbsp;million in license revenue attributable to the Amgen Agreement Amendment in the
fourth quarter of 2013. In year ended December&nbsp;31, 2014, the Company recognized the remaining $0.3&nbsp;million of the previously deferred consideration attributable to the Amgen Agreement Amendment as research and development revenues from
related parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>CERTAIN BUSINESS RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Amgen and the Company continued the research program in 2016.
Under the amended Amgen Agreement, the Company is entitled to receive reimbursements of internal costs of certain full-time employee equivalents during 2016, as well as potential additional milestone payments related to the research activities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Under the Amgen Agreement, as amended, the Company is eligible to receive over $300.0&nbsp;million in additional development milestone
payments which are based on various clinical milestones, including the initiation of certain clinical studies, the submission of a drug candidate to certain regulatory authorities for marketing approval and the receipt of such approvals.
Additionally, the Company is eligible to receive up to $300.0&nbsp;million in commercial milestone payments provided certain sales targets are met. Due to the nature of drug development, including the inherent risk of development and approval of
drug candidates by regulatory authorities, it is not possible to estimate if and when these milestone payments would become due. The achievement of each of these milestones is dependent solely upon the results of Amgen&#146;s development and
commercialization activities. During the year ended December&nbsp;31, 2016, the Company recognized $26.7&nbsp;million in development milestone payments related to the start of <FONT STYLE="white-space:nowrap">GALACTIC-HF,</FONT> the Phase 3
cardiovascular outcomes clinical trial of omecamtiv mecarbil which is being conducted by Amgen. During the years ended December&nbsp;31, 2015 and 2014, no revenue for milestones achieved under the Amgen Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Amgen Agreement also provides for the Company to receive increased royalties by <FONT STYLE="white-space:nowrap">co-funding</FONT>
Phase 3 development costs of omecamtiv mecarbil and other drug candidates under the collaboration. If the Company elects to <FONT STYLE="white-space:nowrap">co-fund</FONT> such costs at the $40.0&nbsp;million level, it would be entitled to <FONT
STYLE="white-space:nowrap">co-promote</FONT> the <FONT STYLE="white-space:nowrap">co-funded</FONT> drug in North America and participate in agreed commercialization activities in institutional care settings, at Amgen&#146;s expense. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In July 2013, Amgen announced that it had granted an option to commercialize omecamtiv mecarbil in Europe to Servier, with the
Company&#146;s consent, pursuant to an Option, License and Collaboration Agreement (the &#147;Servier Agreement&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In August
2016, the Company entered into a Letter Agreement with Amgen and Servier (the &#147;Letter Agreement&#148;), which (i)&nbsp;expands the territory of the sublicense to Servier to include specified countries in the Commonwealth of Independent States
(&#147;CIS&#148;) and (ii)&nbsp;provides that, if Amgen&#146;s rights under the Amgen Agreement, as amended, are terminated with respect to the territory of such sublicense, the sublicensed rights previously granted by Amgen to Servier under the
Servier Agreement will remain in effect and become a direct license or sublicense of such rights by us to Servier, on substantially the same terms as set forth in the Servier Agreement, including but not limited to Servier&#146;s payment of its
share of agreed development costs and future milestone and royalty payments to us. The Letter Agreement does not otherwise modify our rights and obligations under the Amgen Agreement, as amended, or create any additional financial obligations of the
Company, unless we otherwise agree in writing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In September 2016, Amgen and Servier announced Servier&#146;s decision to exercise its
option to commercialize omecamtiv mecarbil in Europe as well as the CIS, including Russia. The option and related commercialization sublicense to Servier is subject to the terms and conditions of the Amgen Agreement. Amgen remains responsible for
the performance of its obligations under the Amgen Agreement relating to Europe and the CIS, including the payment of milestones and royalties relating to the development and commercialization of omecamtiv mecarbil in Europe and the CIS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In December 2016, the Company provided notice of its exercise of its option under the Amgen Agreement to
<FONT STYLE="white-space:nowrap">co-invest</FONT> in the Phase 3 development program of omecamtiv mecarbil at the level of $10.0&nbsp;million. In connection with exercising its <FONT STYLE="white-space:nowrap">co-investment</FONT> option at
$10.0&nbsp;million, the Company will be eligible to receive an incremental royalty of up to 1% on annual net sales worldwide excluding Japan. The payment of $10.0&nbsp;million is due to Amgen in eight quarterly installments with the first payment
due at the time of providing notice of the option exercise and is contingent on Amgen continuing the Phase 3 development program of omecamtiv mecarbil. As of December&nbsp;31, 2016, the Company recorded a payment of $1.3&nbsp;million as a reduction
in collaboration revenue, related to the option to <FONT STYLE="white-space:nowrap">co-invest</FONT> in the Phase 3 development program of omecamtiv mecarbil as a reduction of revenue from Amgen, as it concluded the benefit to be received in
exchange for the <FONT STYLE="white-space:nowrap">co-investment</FONT> payment to Amgen, was not sufficiently separable from Amgen Agreement. In February 2017, the Company provided notice of its further exercise of its
<FONT STYLE="white-space:nowrap">co-invest</FONT> option in the additional amount of $30.0&nbsp;million (i.e. to fully <FONT STYLE="white-space:nowrap">co-invest</FONT> $40.0 million) in the Phase 3 development program of omecamtiv mecarbil. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Pursuant to the Amgen Agreement, the Company has recognized research and development revenue from Amgen for reimbursements of internal
costs of certain full-time employee equivalents, supporting a collaborative research program directed to the discovery of next-generation cardiac sarcomere activator compounds and of other costs related to that research program. These reimbursements
were recorded as research and development revenues from related parties. During the years ended December&nbsp;31, 2016, 2015 and 2014, the Company recorded net research and development revenue from Amgen of $27.9&nbsp;million, $2.5&nbsp;million and
$4.5&nbsp;million, respectively, under the Amgen Agreement. There were no accounts receivable due from Amgen during the years ended December&nbsp;31, 2016 and 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>CERTAIN BUSINESS RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Revenue from Amgen was as follows (in thousands): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #ffffff"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Years Ended<BR>December&nbsp;31,</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">2016</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">2015</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">2014</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Research and development revenues from related parties, net:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Reimbursement of internal costs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:8pt; font-family:ARIAL">Research and development milestone fees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:8pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Co-invest</FONT> option payment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:8pt; font-family:ARIAL">Allocated consideration</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:8pt; font-family:ARIAL">Total Research and development revenues from related parties, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Total net revenues from Amgen</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">27,882</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">2,481</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">4,538</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Astellas Pharma, Inc. (&#147;Astellas&#148;) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I></I></B><I>Original Astellas Agreement <FONT STYLE="white-space:nowrap">(Non-neuromuscular</FONT> license)</I><B><I> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In June 2013, the Company entered into a license and collaboration agreement with Astellas (the &#147;Original Astellas Agreement&#148;).
The primary objective of the collaboration with Astellas is to advance novel therapies for diseases and medical conditions associated with muscle weakness. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Under the Original Astellas Agreement, the Company granted Astellas an exclusive license to
<FONT STYLE="white-space:nowrap">co-develop</FONT> and jointly commercialize <FONT STYLE="white-space:nowrap">CK-2127107,</FONT> a fast skeletal troponin activator, for potential application in
<FONT STYLE="white-space:nowrap">non-neuromuscular</FONT> indications worldwide. The Company was primarily responsible for the conduct of Phase 1 clinical trials and certain Phase 2 readiness activities for
<FONT STYLE="white-space:nowrap">CK-2127107</FONT> and Astellas was primarily responsible for the conduct of subsequent development and commercialization activities for <FONT STYLE="white-space:nowrap">CK-2127107.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In July 2013, the Company received an upfront, <FONT STYLE="white-space:nowrap">non-refundable</FONT> license fee of $16.0&nbsp;million in
connection with the execution of the Original Astellas Agreement. Under the agreement, the Company was eligible to potentially receive over $24.0&nbsp;million in reimbursement of sponsored research and development activities during the initial two
years of the collaboration. The Original Astellas Agreement also provided for research and early and late stage development milestone payments based on various research and clinical milestones, including the initiation of certain clinical studies,
the submission for approval of a drug candidate to certain regulatory authorities for marketing approval and the commercial launch of collaboration products, and royalties on sales of commercialized products. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">At the inception of the Original Astellas Agreement, the Company deferred revenue related to the Original Astellas Agreement in accordance
with ASC <FONT STYLE="white-space:nowrap">605-25.</FONT> The Company evaluated whether the delivered elements under the arrangement have value on a stand-alone basis. Upfront, <FONT STYLE="white-space:nowrap">non-refundable</FONT> licensing payments
are assessed to determine whether or not the licensee is able to obtain stand-alone value from the license. Where this is not the case, the Company does not consider the license deliverable to be a separate unit of accounting, and the revenue for
the license fee is deferred and recognized in conjunction with the other deliverables that constitute the combined unit of accounting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Company determined that the license and the research and development services are a single unit of accounting as the license was
determined to not have stand-alone value. Accordingly, the Company is recognizing this revenue using the proportional performance model over the initial research term of the Original Astellas Agreement. During the years ended December&nbsp;31, 2016,
2015 and 2014, the Company recorded zero, $2.3&nbsp;million and $9.8&nbsp;million, respectively, in license revenue based on the proportional performance model under the Original Astellas Agreement. No license revenue remains deferred under the
Original Astellas Agreement as of December&nbsp;31, 2016. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Pursuant to the Original Astellas Agreement, the Company recognized
research and development revenue from Astellas for reimbursements of internal costs of certain full-time employee equivalents, supporting collaborative research and development programs, and of other costs related to those programs. During the years
ended December&nbsp;31, 2016, 2015 and 2014, the Company recorded research and development revenue from Astellas of zero, $3.5&nbsp;million and $15.4&nbsp;million, respectively, under the Original Astellas Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I></I></B><I>2014 Astellas Agreement (Expansion to include neuromuscular indications)</I><B><I> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In December 2014, the Company entered into an amended and restated license and collaboration agreement with Astellas (the &#147;2014
Astellas Agreement&#148;). This agreement superseded the Original Astellas Agreement. The 2014 Astellas Agreement expanded the objective of the collaboration of advancing novel therapies for diseases and medical conditions associated with muscle
weakness to include spinal muscular atrophy (SMA) and potentially other neuromuscular indications for <FONT STYLE="white-space:nowrap">CK-2127107</FONT> and other fast skeletal troponin activators, in addition to the
<FONT STYLE="white-space:nowrap">non-neuromuscular</FONT> indications provided for in the Original Astellas Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>CERTAIN BUSINESS RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Under the 2014 Astellas Agreement, the Company received a <FONT
STYLE="white-space:nowrap">non-refundable</FONT> upfront license fee of $30.0&nbsp;million in January 2015. Concurrently, the Company received $15.0&nbsp;million as a milestone payment relating to Astellas&#146; decision to advance <FONT
STYLE="white-space:nowrap">CK-2127107</FONT> into Phase 2 clinical development. Under the 2014 Astellas Agreement, the Company is conducting the initial Phase 2 clinical trial of <FONT STYLE="white-space:nowrap">CK-2127107</FONT> in patients with
SMA. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Company determined that the license and the research and development services relating to the 2014 Astellas Agreement are a
single unit of accounting as the license was determined to not have stand-alone value. Accordingly, the Company is recognizing this revenue over the research term of the 2014 Astellas Agreement using the proportional performance model. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">During the years ended December&nbsp;31, 2016 and 2015, the Company recorded $12.1&nbsp;million and $11.6&nbsp;million, respectively, in
license revenue based on the proportional performance model under the 2014 Astellas Agreement. No such revenues were recognized during the year ended December&nbsp;31, 2014. As of December&nbsp;31, 2016, $7.2&nbsp;million license revenue remains
deferred under the 2014 Astellas Agreement. Pursuant to the 2014 Astellas Agreement, the Company recognized research and development revenue from Astellas for reimbursements of internal costs of certain full-time employee equivalents, supporting
collaborative research and development programs, and of other costs related to those programs. The Company was eligible to potentially receive over $20.0&nbsp;million in reimbursement of sponsored research and development activities during the two
years of the collaboration following the execution of the 2014 Astellas Agreement. During the years ended December&nbsp;31, 2016 and 2015, the Company recorded research and development revenue from Astellas of $13.0&nbsp;million and
$8.7&nbsp;million, respectively, under the 2014 Astellas Agreement. No such revenues were recognized during the year ended December&nbsp;31, 2014. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In conjunction with the 2014 Astellas Agreement, the Company also entered into a common stock purchase agreement which provided for the
sale of 2,040,816 shares of its common stock to Astellas at a price per share of $4.90 and an aggregate purchase price of $10.0&nbsp;million which was received in December 2014. Pursuant to this agreement, Astellas agreed to certain trading and
other restrictions with respect to the Company&#146;s common stock. The Company determined the fair value of the stock issued to Astellas to be $9.1&nbsp;million. The excess of cash received over fair value of $0.9&nbsp;million was deferred along
with the license and research and development services. Allocated consideration will be recognized as revenue for the single unit of accounting above, as services are performed following the proportional performance model over the research term of
the 2014 Astellas Agreement. Following the common stock purchase, Astellas was determined to be a related party. As such, all revenue earned following the common stock purchase is classified as related party revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I></I></B><I>2016 Astellas Amendment (Inclusion of ALS as an Added Indication and Option on Tirasemtiv)</I><B><I> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In September 2016, the Company and Astellas executed an amendment (the &#147;2016 Amendment&#148;) to expand their collaboration on the
research, development and commercialization of skeletal muscle activators under the 2014 Astellas Agreement (collectively, the &#147;Current Astellas Agreement&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Under the 2016 Astellas Amendment, the Company granted Astellas the Option on Tirasemtiv. If Astellas exercises the option, Astellas will
receive exclusive worldwide commercialization rights outside of the Company&#146;s commercialization territory of North America, Europe and other select countries. Tirasemtiv is the Company&#146;s fast skeletal troponin activator being evaluated in
the ongoing Phase 3 clinical trial, <FONT STYLE="white-space:nowrap">VITALITY-ALS,</FONT> in people living with amyotrophic lateral sclerosis (&#147;ALS&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In addition, the 2016 Astellas Amendment expands the Company&#146;s collaboration with Astellas to include the development of <FONT
STYLE="white-space:nowrap">CK-2127107,</FONT> a next-generation fast skeletal troponin activator, for the potential treatment of ALS, as well the possible development in ALS of other fast skeletal regulatory activators licensed to Astellas under the
2014 Astellas Agreement (&#147;ALS License&#148;). Finally, the 2016 Astellas Amendment extends the existing joint research program focused on the discovery of additional next-generation skeletal muscle activators through 2017, including sponsored
research at Cytokinetics. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I></I></B><I>Astellas&#146; Option on Tirasemtiv</I><B><I> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In connection with the execution of the 2016 Astellas Amendment, the Company received a $15.0&nbsp;million
<FONT STYLE="white-space:nowrap">non-refundable</FONT> option fee for the grant of the Option on Tirasemtiv in October 2016. Prior to Astellas&#146; exercise of the option, the Company will continue the development of tirasemtiv, including the <FONT
STYLE="white-space:nowrap">VITALITY-ALS</FONT> trial, at its own expense to support regulatory approval in the U.S., EU and certain other jurisdictions and will retain the final decision making authority on the development of tirasemtiv. If Astellas
exercises the option, the Company will grant Astellas an exclusive license to develop and commercialize tirasemtiv outside the Company&#146;s own commercialization territory of North America, Europe and other select countries (&#147;License on
tirasemtiv&#148;) under a tirasemtiv License and Collaboration Agreement (&#147;tirasemtiv License Agreement&#148;). Each party would be primarily responsible for the further development of tirasemtiv in its territory and have the exclusive right to
commercialize tirasemtiv in its territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>CERTAIN BUSINESS RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">If Astellas exercises its option for a global collaboration for
the development and commercialization of tirasemtiv, the Company will receive an option exercise payment ranging from $25.0&nbsp;million (if exercise occurs following receipt of data from the <FONT STYLE="white-space:nowrap">VITALITY-ALS</FONT>
trial) to $80.0&nbsp;million (if exercise occurs following receipt of FDA approval) and a milestone payment of $30.0&nbsp;million from Astellas associated with the Company&#146;s initiation of the open-label extension trial for tirasemtiv <FONT
STYLE="white-space:nowrap">(VIGOR-ALS).</FONT> The Company will be responsible for the development costs of tirasemtiv during the option period, but if Astellas exercises the option after the defined review period following receipt of data from <FONT
STYLE="white-space:nowrap">VITALITY-ALS,</FONT> Astellas will at the time of option exercise reimburse the Company for a share of any additional costs incurred after such review period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">If Astellas exercises the option for tirasemtiv, the parties will share the future development costs of tirasemtiv in North America,
Europe and certain other countries (with Cytokinetics bearing 75% of such shared costs and Astellas bearing 25% of such costs), and Astellas will be solely responsible for the development costs of tirasemtiv specific to its commercialization
territory. Contingent upon the successful development of tirasemtiv, the Company may receive milestone payments up to $100.0&nbsp;million for the initial indication and up to $50.0&nbsp;million for each subsequent indication. If tirasemtiv is
commercialized, Astellas will pay the Company royalties (at rates ranging from the <FONT STYLE="white-space:nowrap">mid-teens</FONT> to twenty percent) on sales of tirasemtiv in Astellas&#146; territory, and the Company will pay Astellas royalties
(at rates up to the <FONT STYLE="white-space:nowrap">mid-teens)</FONT> on sales of tirasemtiv in the Company&#146;s territory, in each case subject to various possible adjustments. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Company concluded that the option to obtain the License on Tirasemtiv is a substantive option, and is therefore not considered a
deliverable at the execution of the 2016 Amendment. The Company determined that the Tirasemtiv License Agreement is contingent upon the exercise of the Option on Tirasemtiv, and is therefore not effective during the periods presented, since the
option has not been exercised as of the latest balance sheet date. In addition, the Company did evaluate the consideration set to be received for the License on Tirasemtiv in relation to the fair value of the License on tirasemtiv, and determined
that it was not being provided at a significant incremental discount. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Company further determined that the Option Fee of
$15.0&nbsp;million was deemed to be a prepayment towards the License on tirasemtiv, and therefore deferred revenue recognition either until the option is exercised, or until the option expires unexercised. If the Option on Tirasemtiv expires
unexercised, the $15.0&nbsp;million receipt would be added to the 2016 Amendment consideration, to be allocated to the units of accounting. The Option on Tirasemtiv expires, if not exercised by Astellas, following the receipt of the approval letter
for tirasemtiv from the FDA. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Prior to Astellas&#146; exercise of the option, the Company will continue the development of tirasemtiv,
including the <FONT STYLE="white-space:nowrap">VITALITY-ALS</FONT> trial, at its own expense to support regulatory approval in the U.S., EU and certain other jurisdictions, and the Company has complete discretion to continue to conduct clinical
trials, and will retain the final decision making authority on the development of tirasemtiv. Therefore, the Company concluded that there was no obligation related to any development services during the option period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I></I></B><I>Addition of ALS as an Added Indication <FONT STYLE="white-space:nowrap">(CK-2127107and</FONT> other fast skeletal activators)</I><B><I> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In connection with the execution of the 2016 Astellas Amendment, the Company received a
<FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront amendment fee of $35&nbsp;million. In addition, the Company received an accelerated $15.0&nbsp;million milestone payment that would have been payable upon the initiation of the first
Phase 2 clinical trial of <FONT STYLE="white-space:nowrap">CK-2127107</FONT> as the lead compound in ALS, as if such milestone had been achieved upon the execution of the 2016 Astellas Amendment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Company and Astellas are collaborating to develop <FONT STYLE="white-space:nowrap">CK-2127107</FONT> in ALS. Astellas is primarily
responsible for the development of <FONT STYLE="white-space:nowrap">CK-2127107</FONT> in ALS, but the Company will conduct the Phase 2 clinical trial of <FONT STYLE="white-space:nowrap">CK-2127107</FONT> in ALS and will share in the operational
responsibility for later clinical trials. Subject to specified guiding principles, decision making will be by consensus, subject to escalation and, if necessary, Astellas&#146; final decision making authority on the development (including regulatory
affairs), manufacturing, medical affairs and commercialization of <FONT STYLE="white-space:nowrap">CK-2127107</FONT> and other fast skeletal regulatory activators in ALS. The Company and Astellas will share equally the costs of developing <FONT
STYLE="white-space:nowrap">CK-2127107</FONT> in ALS for potential registration and marketing authorization in the U.S. and Europe, provided that (i)&nbsp;Astellas has agreed to solely fund Phase 2 development costs of
<FONT STYLE="white-space:nowrap">CK-2127107</FONT> in ALS subject to a right to recoup the Company&#146;s share of such costs plus a 100% premium by reducing future milestone and royalty payments to the Company and (ii)&nbsp;the Company may defer
(but not eliminate) a portion of its <FONT STYLE="white-space:nowrap">co-funding</FONT> obligation for development activities after Phase 2 for up to 18 months, subject to certain conditions. The Company has the right to <FONT
STYLE="white-space:nowrap">co-fund</FONT> its share of such Phase 2 development costs on a current basis, in which case there would not be a premium due to Astellas. Cytokinetics will also receive approximately $41.8&nbsp;million in additional
sponsored research and development funding through 2018 which includes Astellas&#146; funding of Cytokinetics&#146; conduct of the Phase 2 clinical development of <FONT STYLE="white-space:nowrap">CK-2127107</FONT> in ALS (approximately $36.6
million) as well as the continuing research collaboration (approximately $5.2 million). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Pursuant to the 2016 Astellas Amendment, the
Company and Astellas will collaborate to develop <FONT STYLE="white-space:nowrap">CK-2127107</FONT> in ALS. Astellas will be primarily responsible for the development of <FONT STYLE="white-space:nowrap">CK-2127107</FONT> in ALS, but the Company will
conduct the Phase 2 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>CERTAIN BUSINESS RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">clinical trial of <FONT STYLE="white-space:nowrap">CK-2127107</FONT> in ALS and
will share in the operational responsibility for later clinical trials. Subject to specified guiding principles, decision making will be by consensus, subject to escalation and, if necessary, Astellas&#146; final decision making authority on the
development (including regulatory affairs), manufacturing, medical affairs and commercialization of <FONT STYLE="white-space:nowrap">CK-2127107</FONT> and other fast skeletal regulatory activators in ALS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Company determined that the deliverables under the 2016 Astellas Amendment included (1)&nbsp;the ALS License, <FONT
STYLE="white-space:nowrap">(2)&nbsp;CK-2127107</FONT> development services in ALS through Phase 2 activities (&#147;ALS Development Services&#148;), and (3)&nbsp;research services added (&#147;Additional Research Services&#148;). Deliverables that
do not provide standalone value have been combined with other deliverables to form a unit of accounting that collectively has standalone value, with revenue being recognized on the combined unit of accounting, rather than the individual
deliverables. There are no rights of return provisions for the delivered items in the Current Astellas Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Company
considered the 2016 Astellas Amendment to be a modification of the 2014 Astellas Agreement. The remaining deliverables under the 2014 Astellas Agreement are: (1)&nbsp;the SMA license; (2)&nbsp;Research Services in connection with the Research Plan
(through 2016); and (3)&nbsp;SMA Development Services in connection with the Development Plan. The Company evaluated the components and consideration of the 2016 Astellas Amendment against other Phase 2 collaboration arrangements, and determined
that the new 2016 deliverables had standalone value and are delivered at fair value. Therefore no reallocation of consideration to the 2014 deliverables was performed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Company concluded that there are two units of accounting; the ALS License, and the Additional Research Services and ALS Development
Services (&#147;Research and ALS Development Services&#148;). The Company also determined that the ALS License has standalone value since (1)&nbsp;Astellas received a worldwide license for ALS, to perform further research in the field of ALS, to
develop and use <FONT STYLE="white-space:nowrap">CK-2127107</FONT> to make, have make, sell or otherwise commercialize <FONT STYLE="white-space:nowrap">CK-2127107</FONT> in ALS; (2)&nbsp;Astellas has the right to sublicense the rights to <FONT
STYLE="white-space:nowrap">CK-2127107</FONT> in ALS to a third party; and (3)&nbsp;Astellas has the technical capabilities to advance further development on <FONT STYLE="white-space:nowrap">CK-2127107</FONT> in ALS, without the continued involvement
of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Arrangement Consideration under the 2016 Astellas Amendment related to
<FONT STYLE="white-space:nowrap">CK-2127107</FONT> and research is comprised of the following (in millions): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD></TR>
<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Arrangement<BR>Consideration</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Amendment Fee</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$35.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Accelerated milestone payment</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:8pt; font-family:ARIAL">Total Upfront Consideration</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Additional Research Services</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">ALS Development Services</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:8pt; font-family:ARIAL">Total Committed Consideration</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Total Consideration</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$94.2</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Company allocated the $50.0&nbsp;million in upfront consideration along with the $44.2&nbsp;million in
then committed research and development consideration, among the two units of accounting, on a relative fair value basis, using the best estimated selling price (&#147;BESP&#148;). The BESP of the ALS License was determined using a discounted cash
flow, risk adjusted for probability of success; while the BESP of the research and development services were determined using estimated research and development cost, included in the research and development programs approved by Astellas. Based on
this allocation of consideration, the Company stands to recognize $74.9&nbsp;million in license revenue and $19.3 in research and development revenue, under the 2016 Astellas Amendment. Since the upfront consideration of $50.0&nbsp;million is less
than the allocated consideration of the ALS License, the Company recognized $50.0&nbsp;million in license revenue on the Amendment Effective Date, in September 2016, and record the remaining $24.9&nbsp;million as an allocation from research and
development services, when those services are performed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Allocation of arrangement consideration, and revenue recognition (in
millions): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Allocated<BR>Consideration</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Upfront<BR>Revenue<BR>Recognition</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Revenue<BR>Recognition<BR>over<BR>Performance<BR>Period</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Units of Accounting:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">ALS License</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Research and ALS Development Services</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.00pt solid #000000">Total consideration</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right">94.2</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right">50.0</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right">44.2</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>CERTAIN BUSINESS RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">During the year ended December&nbsp;31, 2016, the Company recorded
$50.1&nbsp;million in license revenue under the 2016 Astellas Amendment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Company will recognize the research and development
services using the proportional performance model over the initial development term, through the completion of the ALS Development Services. Pursuant to the 2016 Astellas Amendment, the Company receives payment for research and development revenue
from Astellas for reimbursements of internal costs of certain full-time employee equivalents, supporting collaborative research and development programs, and of other costs related to those programs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">During the year ended December&nbsp;31, 2016, the Company recorded $0.1&nbsp;million research and development revenue from Astellas, under
the 2016 Astellas Amendment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Company believes that each of the milestones related to research under the Current Astellas
Agreement is substantive and can only be achieved with the Company&#146;s past and current performance and each milestone will result in additional payments to the Company. During the year ended December&nbsp;31, 2016, the Company recorded $2.0
million&nbsp;in milestone revenue for research under this agreement, related to the initiation of <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for a fast skeletal troponin activator. The Company is eligible to receive up to
$2.0&nbsp;million in research milestone payments under the collaboration for each future potential drug candidate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The achievement of
each of the late stage development milestones and the commercialization milestones are dependent solely upon the results of Astellas&#146; development activities and therefore these milestones were not deemed to be substantive. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Under the Current Astellas Agreement, additional research and early and late state development milestone payments which are based on
various research and clinical milestones, including the initiation of certain clinical studies, the submission for approval of a drug candidate to certain regulatory authorities for marketing approval and the commercial launch of collaboration
products could total over $600.0&nbsp;million, including up to $95.0&nbsp;million relating to <FONT STYLE="white-space:nowrap">CK-2127107</FONT> in <FONT STYLE="white-space:nowrap">non-neuromuscular</FONT> indications, and over $100.0&nbsp;million
related to <FONT STYLE="white-space:nowrap">CK-2127107</FONT> in each of SMA, ALS and other neuromuscular indications. Additionally, $200.0&nbsp;million in commercial milestones could be received under the Current Agreement provided certain sales
targets are met. Due to the nature of drug development, including the inherent risk of development and approval of drug candidates by regulatory authorities, it is not possible to estimate if and when these milestone payments could become due. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">In the event Astellas commercializes any collaboration products, the Company will receive royalties on sales of such collaboration
products, including royalties ranging from the high single digits to the high teens on sales of products containing <FONT STYLE="white-space:nowrap">CK-2127107.</FONT> Cytokinetics can <FONT STYLE="white-space:nowrap">co-fund</FONT> certain
development costs for <FONT STYLE="white-space:nowrap">CK-2127107</FONT> and other compounds in exchange for increased milestone payments and royalties; such royalties may increase under certain scenarios to exceed twenty percent. Under the Current
Astellas Agreement, Cytokinetics retains an option to <FONT STYLE="white-space:nowrap">co-promote</FONT> collaboration products containing fast skeletal muscle activators for neuromuscular indications in the U.S., Canada and Europe, in addition to
its option to <FONT STYLE="white-space:nowrap">co-promote</FONT> other collaboration products in the U.S. and Canada as provided for in the Original Astellas Agreement. Astellas will reimburse Cytokinetics for certain expenses associated with its <FONT
STYLE="white-space:nowrap">co-promotion</FONT> activities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Research and development revenue from Astellas was as follows (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR BGCOLOR="#737374" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Year Ended</FONT></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">December&nbsp;31,</FONT></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">2016</FONT></B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Year Ended</FONT></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">December&nbsp;31,</FONT></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">2015</FONT></B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Year Ended</FONT></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">December&nbsp;31,</FONT></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">2014</FONT></B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">License Revenues from Related Parties</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Research and development revenues with related parties:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:8pt; font-family:ARIAL">Reimbursement of internal costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:8pt; font-family:ARIAL">Reimbursement of other costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:8pt; font-family:ARIAL">Research and development milestone fees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:8pt; font-family:ARIAL">Total research and development revenue with related parties from Astellas</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Research and development revenues:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:8pt; font-family:ARIAL">Reimbursement of internal costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:8pt; font-family:ARIAL">Reimbursement of other costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:8pt; font-family:ARIAL">Research and development milestone fees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:8pt; font-family:ARIAL">Total research and development revenue from Astellas</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.00pt solid #000000">Total Revenue from Astellas</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right">77,281</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right">26,102</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000" ALIGN="right">42,226</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>CERTAIN BUSINESS RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">At December&nbsp;31, 2016 and December&nbsp;31, 2015, the Company
had $23.1&nbsp;million and $20.4&nbsp;million, respectively, of deferred revenue under the Current Astellas Agreement, reflecting the unrecognized portion of the license revenue, option fee and payment of expenses. There were no accounts receivable
due from Astellas at December&nbsp;31, 2016 and 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><A NAME="toc307694_35"></A>Indemnification of Directors and Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The Company provides indemnification for its directors and officers so that they will be free from undue concern about personal liability
in connection with their service to the Company. Under the Company&#146;s Bylaws, the Company is required to indemnify its directors and officers to the extent not prohibited under Delaware or other applicable law. We have also entered into
indemnification agreements with each of our directors and officers, which require us to indemnify its directors and officers to the fullest extent permitted by Delaware law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_37"></A>HOUSEHOLDING OF PROXY MATERIALS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for Notices of
Internet Availability of Proxy Materials or other Annual Meeting materials with respect to two or more stockholders sharing the same address by delivering a single Notice of Internet Availability of Proxy Materials or other Annual Meeting materials
addressed to those stockholders. This process, which is commonly referred to as &#147;householding,&#148; potentially means extra convenience for stockholders and cost savings for companies. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">This year, a number of brokers with account holders who are Cytokinetics stockholders will be &#147;householding&#148; the Company&#146;s
proxy materials. A single Notice of Internet Availability of Proxy Materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice
from your broker that they will be &#147;householding&#148; communications to your address, &#147;householding&#148; will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate
in &#147;householding&#148; and would prefer to receive a separate Notice of Internet Availability of Proxy Materials, please notify us or your broker. Direct your written request to Investor Relations, Cytokinetics, Incorporated, 280 East Grand
Avenue, South San Francisco, California 94080 or contact Investor Relations at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">650-624-3283.</FONT></FONT> Stockholders who currently receive multiple copies of the Notices of
Internet Availability of Proxy Materials at their addresses and would like to request &#147;householding&#148; of their communications should contact their brokers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_39"></A>OTHER MATTERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The information contained above under the captions &#147;Compensation and Talent Committee Report&#148; and &#147;Report of the Audit
Committee of the Board of Directors&#148; shall not be deemed to be soliciting material or to be filed with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or the
Exchange Act, except to the extent that we specifically incorporate it by reference into such filing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">We know of no other matters to
be submitted to the meeting. If any other matters properly come before the meeting, it is the intention of the persons named in the Proxy to vote the shares they represent as the Board of Directors may recommend. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:9pt; font-family:ARIAL">THE BOARD OF DIRECTORS </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">Dated:
March&nbsp;31, 2017 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B><A NAME="toc307694_40"></A>APPENDIX A </B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>CYTOKINETICS, INCORPORATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc307694_41"></A>AMENDED AND RESTATED 2004 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>AMENDED BY THE BOARD OF DIRECTORS: FEBRUARY&nbsp;6, 2013 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>APPROVED BY STOCKHOLDERS: MAY&nbsp;22, 2013 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>AMENDED TO REFLECT THE REVERSE STOCK SPLIT: JUNE&nbsp;25, 2013 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: FEBRUARY&nbsp;3, 2015 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>APPROVED BY STOCKHOLDERS: MAY&nbsp;20, 2015 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>APPROVED BY STOCKHOLDERS: [MAY&nbsp;18, 2017] </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>1. PURPOSES OF
THE PLAN AND PERMITTED AWARDS. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The purposes of this Plan are to attract and retain the best available personnel for positions of
substantial responsibility, to provide additional incentive to Employees, Directors and Consultants, and to promote the success of the Company&#146;s business. The Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options,
Restricted Stock, Restricted Stock Units, Stock Appreciation Rights, Performance Units and Performance Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>2. SHARES SUBJECT TO THE PLAN. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(a) Shares Subject to the Plan.</B> Subject to adjustments as specified in Section&nbsp;12 of the Plan, the maximum aggregate number of
Shares that may be issued under the Plan is 11,637,190&nbsp;Shares. The Shares may be authorized, but unissued, or reacquired Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(b) Treatment of Lapsed Awards.</B> To the extent that an Award terminates, expires, or lapses for any reason, any shares of Stock
subject to the Award shall again be available for the grant of an Award pursuant to the Plan. Any shares of Stock tendered or withheld to satisfy the grant or exercise price or tax withholding obligation pursuant to any Award shall be treated as
issued under this Plan and shall be deducted from the aggregate number of shares which may be issued under Section&nbsp;2(a). Shares of Stock repurchased on the open market with the proceeds of an exercise price shall not again be available for the
grant of an Award pursuant to the Plan. Notwithstanding that a Stock Appreciation Right may be settled by the delivery of a net number of shares of Stock, the full number of shares of Stock underlying such Stock Appreciation Right shall not again be
available for the grant of an Award pursuant to the Plan. In addition, no shares of Stock may again be optioned, granted or awarded if such action would cause an Incentive Stock Option to fail to qualify as such under Section&nbsp;422 of the Code.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(c) Calculation of Share Reserve Under the Fungible Ratio.</B> For purposes of determining the number of shares of Stock issuable
or transferred pursuant to Section&nbsp;2(a), each share of Stock which is issued or transferred pursuant to a Full Value Award (i)&nbsp;prior to May&nbsp;20, 2015, shall be treated as if two shares of Stock had been so issued or transferred, and
(ii)&nbsp;on and after May&nbsp;20, 2015, shall be treated as if 1.17 shares of Stock had been so issued or transferred. To the extent there is issued a share of Stock pursuant to a Full Value Award that counted as more than one share against the
number of shares available for issuance under this Section and such share of Stock again becomes available for issuance under the Plan pursuant to this Section, then the number of shares of Stock available for issuance under the Plan shall increase
by (A)&nbsp;two shares of Stock for shares returning prior to May&nbsp;20, 2015, and (B)&nbsp;1.17 shares of Stock for shares returning on and after May&nbsp;20, 2015. To the extent permitted by Applicable Law or any exchange rule, shares of Stock
issued in assumption of, or in substitution for, any outstanding awards of any entity acquired in any form of combination by the Company or any Subsidiary shall not be counted against shares of Stock available for grant pursuant to this Plan. The
settlement of any Award in cash shall not be counted against the shares available for issuance under the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(d) Incentive Stock
Option Limit.</B> Subject to the provisions of Section&nbsp;12 relating to capitalization adjustments, the aggregate maximum number of shares of Stock that may be issued pursuant to the exercise of Incentive Stock Options will be
11,637,190&nbsp;shares of Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(e) Section</B><B></B><B>&nbsp;162(m) Limitations.</B> Subject to the provisions of
Section&nbsp;12 relating to capitalization adjustments: (i)&nbsp;a maximum of 500,000 shares of Stock subject to Options and SARs (such shares of Stock subject to adjustment to reflect any stock split on or before the effective date of the Plan)
whose value is determined by reference to an increase over an exercise or strike price of at least 100% of the Fair Market Value on the date the Award is granted may be granted to any one Participant during any one calendar year, and (ii)&nbsp;a
maximum of 500,000 shares of Stock subject to Awards of Performance Units or Awards of Performance Shares may be granted to any one Participant during any one calendar year (whether the grant, vesting or exercise is contingent upon the attainment
during the Performance Period of the Performance Goals). If an Award is subject to vesting or exercise contingent on the attainment during the Performance Period of Performance Goals, then such Award will count only against the limit applicable to
Awards of Performance Units and Performance Shares. If a Performance Unit could (but is not required to) be paid out in cash, it will count only against the limit applicable to Awards of Performance Shares and Performance Units. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">A-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>APPENDIX A </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(f) Share Reserve.</B> The Company, during the term of this Plan, will at all times reserve and keep available such number of Shares as
will be sufficient to satisfy the requirements of the Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>3. ADMINISTRATION OF THE PLAN. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(a) Procedure.</B> Unless and until the Board delegates administration to a Committee as set forth below, the Plan shall be
administered by the Board. The Board may delegate administration of the Plan to a Committee or Committees of one or more members of the Board. If administration is delegated to a Committee, the Committee shall have the powers theretofore possessed
by the Board, including the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise. The Board may designate different Committees to administer the Plan with respect to different groups of Service
Providers. To the extent that the Administrator determines it to be desirable to qualify Awards granted hereunder as <B><I>&#147;performance-based compensation&#148;</I></B> within the meaning of Section&nbsp;162(m) of the Code, the Plan will be
administered by a Committee of two or more <B><I>&#147;</I></B> <B><I>outside directors&#148;</I></B> within the meaning of Section&nbsp;162(m) of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(b) Powers of the Administrator.</B> Subject to the provisions of the Plan, and in the case of a Committee, subject to the specific
duties delegated by the Board to such Committee, the Administrator will have the authority, in its discretion: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(i) </B>to
determine the Fair Market Value; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(ii)</B> to select the Service Providers to whom Awards may be granted hereunder; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(iii) </B>to determine the number of Shares to be covered by each Award granted hereunder and the date of grant; the date of grant of
an Award will be, for all purposes, the date on which the Administrator makes the determination granting such Award, or such later date as is determined by the Administrator; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(iv) </B>to approve forms of agreement for use under the Plan; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(v) </B>to determine the terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder. Such terms
and conditions include, but are not limited to, the exercise price, the time or times when Awards may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture restrictions, and any restriction or
limitation regarding any Award or the Shares relating thereto, based in each case on such factors as the Administrator will determine; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(vi) </B>to construe and interpret the terms of the Plan and Awards granted pursuant to the Plan; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(vii)</B> to prescribe, amend and rescind rules and regulations relating to the Plan, including rules and regulations relating to <FONT
STYLE="white-space:nowrap">sub-plans</FONT> established for the purpose of satisfying applicable foreign laws; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(viii) </B>to
modify or amend each Award (subject to Section&nbsp;19(c) of the Plan); <I>provided, however</I>, that Board may amend the terms of an Award without the affected Participant&#146;s consent if necessary (A)&nbsp;to maintain the qualified status of
the Award as an Incentive Stock Option, (B)&nbsp;to clarify the manner of exemption from, or to bring the Award into compliance with, Section&nbsp;409A of the Code, or (C)&nbsp;to comply with other Applicable Law; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(ix)</B> to determine the terms and conditions of any, and with the approval of the Company&#146;s stockholders, to institute an
Exchange Program; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(x) </B>to authorize any person to execute on behalf of the Company any instrument required to effect the grant
of an Award previously granted by the Administrator; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(xi)</B> to allow a Participant to defer the receipt of the payment of cash
or the delivery of Shares that would otherwise be due to such Participant under an Award; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(xii) </B>to make all other
determinations deemed necessary or advisable for administering the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(c) Prohibition Against Repricing.</B> Subject to
adjustments made pursuant to Section&nbsp;14, in no event shall the Administrator have the right to amend the terms of any Award to reduce the exercise price of such outstanding Award or cancel an outstanding Award in exchange for cash or other
Awards with an exercise price that is less than the exercise price of the original Award without stockholder approval. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(d) Effect
of Administrator&#146;s Decision.</B> The Administrator&#146;s decisions, determinations and interpretations will be final and binding on all Participants and any other holders of Awards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>4. ELIGIBILITY. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Nonstatutory Stock Options,
Restricted Stock, Restricted Stock Units, Stock Appreciation Rights, Performance Units and Performance Shares may be granted to Service Providers. Incentive Stock Options may be granted only to Employees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">A-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>APPENDIX A </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>5. TERMS RELATING TO STOCK OPTIONS AND STOCK APPRECIATION RIGHTS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Each Option or SAR will be in such form and will contain such terms and conditions as the Board deems appropriate. All Options will be
separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Stock purchased on exercise of each type of
Option. If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable
rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option. The provisions of separate Options or SARs need not be identical; <I>provided, however</I>, that each Award Agreement will conform to (through incorporation of
provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(a) Term of Option.</B> The term of each Option or SAR will be stated in the Award Agreement and will not exceed ten years from the
date of grant, except that in the case of an Incentive Stock Option granted to a Participant who is a Ten Percent Stockholder, the term of the Incentive Stock Option may not be more than five years from the date of grant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(b) Exercise Price.</B> The exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the
Stock on the date the Award is granted, except that for Options or SARs granted to a Ten Percent Stockholder, the exercise or strike price of each Option or SAR will not be less than 110% of the Fair Market Value of the Stock on the date of grant.
Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Stock subject to the Award if such Award is granted pursuant to an assumption of or substitution for
another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section&nbsp;409A and, if applicable, Section&nbsp;424(a) of the Code. Each SAR will be denominated in shares of Stock
equivalents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(c) Waiting Period and Exercise Dates.</B> At the time an Option or SAR is granted, the Administrator will fix the
period within which the Option or SAR may be exercised and will determine the vesting requirements and any other conditions that must be satisfied before the Option or SAR may be exercised. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(d) Exercise of an Option.</B> The Administrator will determine the acceptable method (which may be electronic) and form of
consideration for exercising an Option, including the method of payment. Such consideration may include: (i)&nbsp;cash; (ii)&nbsp;check; (iii)&nbsp;promissory note, to the extent permitted by Applicable Laws; (iv)&nbsp;other Shares, provided that
such Shares have a Fair Market Value on the date of surrender equal to the aggregate exercise price of the Shares as to which said Option will be exercised and provided that accepting such Shares, in the sole discretion of the Administrator, shall
not result in any adverse accounting consequences to the Company; (iv)&nbsp;consideration received by the Company under a cashless exercise program implemented by the Company in connection with the Plan; (vi)&nbsp;such other consideration and method
of payment for the issuance of Shares to the extent permitted by Applicable Laws; or (vii)&nbsp;any combination of the foregoing methods of payment. In the case of an Incentive Stock Option, the Administrator will specify in the Award Agreement the
acceptable forms of consideration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(e) Exercise and Payment of a SAR.</B> The Administrator will determine the acceptable method
(which may be electronic) to exercise any outstanding SAR. The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (i)&nbsp;the aggregate Fair Market Value (on the date of the exercise
of the SAR) of a number of shares of Stock equal to the number of Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (ii)&nbsp;the strike price. The
appreciation distribution may be paid in Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Award Agreement evidencing such SAR. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(f) Termination of Relationship as a Service Provider.</B> Except as otherwise provided in the applicable Award Agreement, if a
Participant ceases to be a Service Provider, other than for Cause or upon the Participant&#146;s death or Disability, any unvested portion of the Option or SAR shall terminate and will revert to the Plan, and the Participant may exercise the vested
portion of his or her Option or SAR until the earlier of three months following the Participant&#146;s termination, or expiration of the Option or SAR. If the Participant does not exercise his or her Option or SAR within the time specified, the
Option or SAR will terminate, and the Shares covered by such Option or SAR will revert to the Plan. In the case of a Participant terminated for Cause, the Option or SAR will terminate immediately upon such Participant&#146;s termination as a Service
Provider, and the Participant will be prohibited from exercising his or her Option or SAR from and after the date of such termination for Cause. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(g) Disability of Participant.</B> Except as otherwise provided in the applicable Award Agreement, if a Participant ceases to be a
Service Provider as a result of the Participant&#146;s Disability, any unvested portion of the Option or SAR shall terminate and will revert to the Plan, and the Participant may exercise the vested portion of his or her Option or SAR until the
earlier of 12 months following the Participant&#146;s termination, or expiration of the Option or SAR. If the Participant does not exercise his or her Option or SAR within the time specified, the Option or SAR will terminate, and the Shares covered
by such Option or SAR will revert to the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">A-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>APPENDIX A </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(h) Death of Participant.</B> Except as otherwise provided in the applicable Award Agreement, if a Participant dies while a Service
Provider, any unvested portion of the Option or SAR shall terminate and will revert to the Plan, and the Participant&#146;s properly designated beneficiary may exercise the Option or SAR until the earlier of 12 months following Participant&#146;s
death, or until expiration of the term of such Option or SAR. If no such beneficiary has been designated by the Participant, then such Option or SAR may be exercised by the personal representative of the Participant&#146;s estate or by the person(s)
to whom the Option or SAR is transferred pursuant to the Participant&#146;s will or in accordance with the laws of descent and distribution. If the Option or SAR is not so exercised within the time specified herein, the Award will terminate, and the
Shares covered by such Option or SAR will revert to the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(i) Rights of Holder of Option. </B>Unless otherwise stated in the
applicable Award Agreement, an individual holding or exercising an Option or SAR shall have none of the rights of a stockholder (for example, the right to receive cash or dividend payments or distributions attributable to the subject Shares or to
direct the voting of the subject Shares) until the Shares covered thereby are fully paid and issued to him. In no case shall an individual holding an Option receive cash or dividend payments or distributions or dividend equivalents attributable to
unvested Shares underlying an Option. Except as provided in <B>Section</B><B></B><B>&nbsp;12(a) </B>hereof, no adjustment shall be made for dividends, distributions or other rights for which the record date is prior to the date of such issuance.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>6. RESTRICTED STOCK. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(a) Grant of
Restricted Stock.</B> The Administrator may grant Shares of Restricted Stock to Service Providers in such amounts as the Administrator, in its sole discretion, will determine. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(b) Restricted Stock Agreement.</B> Each Award of Restricted Stock will be evidenced by an Award Agreement that will specify the Period
of Restriction, the number of Shares granted, and such other terms and conditions as the Administrator will determine. Unless the Administrator determines otherwise, Shares of Restricted Stock will be held by the Company as escrow agent until the
restrictions on such Shares have lapsed. The Administrator may impose such other restrictions on Shares of Restricted Stock as it may deem advisable or appropriate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(c) Transferability.</B> Except as provided in this Section&nbsp;6, Shares of Restricted Stock may not be sold, transferred, pledged,
assigned, or otherwise alienated or hypothecated until the end of the applicable Period of Restriction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(d) Removal of
Restrictions.</B> Except as otherwise provided in this Section&nbsp;6, Shares of Restricted Stock covered by each Restricted Stock grant made under the Plan will be released from escrow as soon as practicable after the last day of the Period of
Restriction. The Administrator, in its discretion, may accelerate the time at which any restrictions will lapse or be removed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(e)
Voting Rights.</B> During the Period of Restriction, Service Providers holding Shares of Restricted Stock granted hereunder may exercise full voting rights with respect to those Shares, unless the Administrator determines otherwise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(f) Dividends and Other Distributions.</B> During the Period of Restriction, Service Providers holding Shares of Restricted Stock will
be entitled to receive all dividends and other distributions paid with respect to such Shares unless otherwise provided in the Award Agreement. Any such dividends will be subject to the same restrictions on transferability and forfeitability as the
Shares of Restricted Stock with respect to which they were paid. For clarity, Service Providers holding Shares of Restricted Stock shall have the right to vote such Shares and the right to receive any dividends declared or paid with respect to such
Shares provided that any such dividends shall be subject to the same vesting restrictions as the underlying Shares subject to the Restricted Stock during the Period of Restriction. Such dividends so accrued with respect to the Shares subject to any
Award of Restricted Stock, whether subject to time-based and/or performance-based vesting criteria, shall become payable no earlier than the date the applicable vesting criteria have been satisfied and the Period of Restriction with respect to such
Shares has lapsed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(g) Return of Restricted Stock to Company.</B> On the date set forth in the Award Agreement, the Restricted
Stock for which restrictions have not lapsed will revert to the Company and again will become available for grant under the Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>7. RESTRICTED STOCK UNITS.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(a) Grant of Restricted Stock Units; Vesting and Other Terms.</B> Restricted Stock Units may be granted to Service Providers
at any time with the number of Units to be determined by the Administrator. The Administrator will set service-based or other vesting provisions in its discretion which, depending on the extent to which they are met, will determine the number of
Shares to be issued to the Service Providers. Each Award of Restricted Stock Units will be evidenced by an Award Agreement that will specify the vesting schedule, and such other terms and conditions as the Administrator, in its sole discretion, will
determine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">A-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>APPENDIX A </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(b) Earning of Restricted Stock Units; Form and Timing of Payment.</B> Upon vesting of Restricted Stock Units, the holder thereof will
be issued that the number of shares of Stock. Issuance of Shares upon the vesting of Restricted Stock Units will be made as soon as practicable after vesting, but in no event later than the time required to avoid adverse tax consequences under
Section&nbsp;409A of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(c) Cancellation of Restricted Stock Units.</B> If a holder of Restricted Stock Units terminates
service prior to the vesting of all Units or as otherwise provided in an Award Agreement, all unvested Restricted Stock Units will be forfeited and will again be available for grant under the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(d)</B> <B>Dividend Equivalents. </B>Dividend equivalents may be credited in respect of Shares covered by an Award Agreement covering a
Restricted Stock Unit, as determined by the Board and contained in such Award Agreement. At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the Restricted Stock Unit in
such manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit credited by reason of such dividend equivalents will be subject to all of the same terms and conditions (including forfeiture restrictions) of the
underlying Restricted Stock Unit to which they relate, and such dividend equivalent shall not be paid unless and until the time that the Shares underlying the Restricted Stock Unit are vested and are distributed to the Service Provider. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>8. PERFORMANCE UNITS AND PERFORMANCE SHARES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(a) Grant of Performance Units and Performance Shares.</B> Performance Units and Performance Shares may be granted to Service Providers
at any time as determined by the Administrator, in such numbers and subject to such other terms and conditions as determined by the Administrator, in its discretion. For Performance Units or Performance Shares intended to qualify as
<I>&#147;</I>performance-based compensation&#148; within the meaning of Section&nbsp;162(m) of the Code, (i)&nbsp;no Participant will receive Performance Units/Shares having an initial value greater than $4,000,000, and (ii)&nbsp;no Participant will
receive more than 500,000 Performance Units/Shares. Notwithstanding the foregoing limitation, for Performance Units/Shares intended to qualify as &#147;performance-based compensation&#148; within the meaning of Section&nbsp;162(m) of the Code, in
connection with his or her initial service, a Service Provider may be granted up to an additional 500,000 Performance Units/Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(b) Section</B><B></B><B>&nbsp;162(m) Performance Restrictions.</B> For purposes of qualifying grants of Performance Units/Shares as
&#147;performance-based compensation&#148; under Section&nbsp;162(m) of the Code, the Administrator, in its discretion, may set restrictions based upon the achievement of Performance Goals. The Performance Goals will be set by the Administrator on
or before the Determination Date. In granting Performance Units/Shares which are intended to qualify under Section&nbsp;162(m) of the Code, the Administrator will follow any procedures determined by it from time to time to be necessary or
appropriate to ensure qualification of the Award under Section&nbsp;162(m) of the Code (e.g., in determining the Performance Goals). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(c) Value of Performance Units/Shares.</B> Each Performance Unit will have an initial value that is established by the Administrator on
or before the date of grant. Each Performance Share will have an initial value equal to the Fair Market Value of a Share on the date of grant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(d) Performance Objectives and Other Terms.</B> The Administrator will set performance objectives or other vesting provisions in its
discretion which, depending on the extent to which they are met, will determine the number or value of Performance Units/Shares that will be paid out to the Service Providers. Each Award of Performance Units/Shares will be evidenced by an Award
Agreement that will specify the Performance Period, and such other terms and conditions as the Administrator will determine. The Administrator may set performance objectives based upon the achievement of Company-wide, divisional, or individual
goals, applicable federal or state securities laws, or any other basis determined by the Administrator in its discretion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(e)
Earning of Performance Units/Shares.</B> After the applicable Performance Period has ended, the holder of Performance Units/Shares will be entitled to receive a payout of the number of Performance Units/Shares earned by the Participant over the
Performance Period, to be determined as a function of the extent to which the corresponding performance objectives or other vesting provisions have been achieved. After the grant of a Performance Unit/Share, the Administrator, in its sole
discretion, may reduce or waive any performance objectives or other vesting provisions for such Performance Unit/Share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(f) Form
and Timing of Payment of Performance Units/Shares.</B> Payment of earned Performance Units/Shares will be made as soon as practicable after the expiration of the applicable Performance Period. The Administrator may pay earned Performance
Units/Shares in the form of cash, in Shares (which have an aggregate Fair Market Value equal to the value of the earned Performance Units/Shares at the close of the applicable Performance Period) or in a combination thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(g) Cancellation of Performance Units/Shares.</B> On the date set forth in the Award Agreement, all unearned or unvested Performance
Units/Shares will be forfeited and will again be available for grant under the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">A-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>APPENDIX A </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(h) Dividends and Other Distributions. </B>No cash dividends or distributions declared with respect to Shares subject to the
Performance Units/Shares shall be paid to any Participant unless and until the Participant vests in such underlying Performance Units/Shares. Upon the vesting of a Performance Units/Shares, any cash dividends or distributions declared but not paid
during the vesting period with respect to such Performance Units/Shares shall be paid to the Participant at the same time or times as the Shares underlying the Performance Units/Shares. Any stock dividends declared on Shares subject to a Performance
Units/Shares shall be subject to the same restrictions and shall vest at the same time as the Performance Units/Shares from which said dividends were derived. All unvested dividends shall be forfeited by the Participants to the extent their
underlying Performance Units/Shares are forfeited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>9. PERFORMANCE GOALS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">The granting and/or vesting of Awards of Restricted Stock, Restricted Stock Units, Performance Shares and Performance Units and other
incentives under the Plan may be made subject to the attainment of performance goals relating to one or more business criteria within the meaning of Section&nbsp;162(m) of the Code and may provide for a targeted level or levels of achievement
(<B><I>&#147;Performance Goals&#148;</I></B>) including, with respect to the Company or any business unit: (a)&nbsp;cash position, (b)&nbsp;clinical progression, (c)&nbsp;collaboration arrangements, (d)&nbsp;collaboration progression,
(e)&nbsp;earnings per share, (f)&nbsp;a financing event, (g)&nbsp;net income, (h)&nbsp;operating cash flow, (i)&nbsp;market share, (j)&nbsp;operating expenses, (k)&nbsp;operating income, (l)&nbsp;product approval, (m)&nbsp;product revenues,
(n)&nbsp;profit after tax, (o)&nbsp;projects in development, (p)&nbsp;regulatory filings, (q)&nbsp;return on assets, (r)&nbsp;return on equity, (s)&nbsp;revenue growth, and (t)&nbsp;total stockholder return, (u)&nbsp;implementation of, progression
in or completion of projects or processes (including, without limitation, progress in research or development programs, progress in regulatory or compliance initiatives, clinical trial initiation, clinical trial enrollment, clinical trial results,
new or supplemental indications for existing products, regulatory filing submissions, regulatory filing acceptances, regulatory or advisory committee interactions, regulatory approvals, product supply and systems development and implementation),
(v)&nbsp;completion of a joint venture or other corporate transaction, (w)&nbsp;employee retention, (x)&nbsp;budget management and (y)&nbsp;to the extent that an Award is not intended to comply with Section&nbsp;162(m) of the Code, other measures of
performance selected by the Board. Prior to the Determination Date, the Administrator will determine whether any significant element(s) will be included in or excluded from the calculation of any Performance Goal with respect to any Participant. Any
Performance Goals may be used to measure the performance of the Company as a whole or a business unit of the Company and may be measured relative to a peer group or index or to another Performance Goal. With respect to any Award, Performance Goals
may be used alone or in combination. The Performance Goals may differ from Participant to Participant and from Award to Award. Prior to the Determination Date, the Administrator will determine whether any significant element(s) will be included in
or excluded from the calculation of any Performance Goal with respect to any Participant. In all other respects, Performance Goals will be calculated in accordance with the Company&#146;s financial statements, generally accepted accounting
principles, or under a methodology established by the Administrator prior to the issuance of an Award. In determining the amounts earned by a Participant pursuant to an Award intended to qualified as &#147;performance-based compensation&#148; under
Section&nbsp;162(m) of the Code, the Administrator will have the right to reduce or eliminate (but not to increase) the amount payable at a given level of performance to take into account additional factors that the Administrator may deem relevant
to the assessment of individual or corporate performance for the Performance Period. A Participant will be eligible to receive payment pursuant to an Award intended to qualify as &#147;performance-based compensation&#148; under Section&nbsp;162(m)
of the Code for a Performance Period only if the Performance Goals for such period are achieved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>10. LEAVES OF ABSENCE. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Unless the Administrator provides otherwise, vesting of Awards granted hereunder will be suspended during any unpaid leave of absence. A
Service Provider will not cease to be an Employee in the case of (a)&nbsp;any leave of absence approved by the Company or (b)&nbsp;transfers between locations of the Company or between the Company, its Parent, or any Subsidiary. For purposes of
Incentive Stock Options, no such leave may exceed 90 days, unless reemployment upon expiration of such leave is guaranteed by statute or contract. If reemployment upon expiration of a leave of absence approved by the Company is not so guaranteed,
then six months and a day following the 1st day of such leave any Incentive Stock Option held by the Participant will cease to be treated as an Incentive Stock Option and will be treated for tax purposes as a Nonstatutory Stock Option. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>11. TRANSFERABILITY OF AWARDS. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">Unless
determined otherwise by the Administrator, an Award may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution and may be exercised, during the lifetime of
the Participant, only by the Participant. If the Administrator makes an Award transferable, such Award will contain such additional terms and conditions as the Administrator deems appropriate; provided, however, that the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">A-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>APPENDIX A </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">Administrator may only make an Award transferable to one or more of the following: (a)&nbsp;a &#147;family member&#148; (as defined pursuant to Rule 701
of the Securities Act of 1933, as amended) of the Participant; (b)&nbsp;a trust for the benefit of one or more of the Participant or the persons referred to in clause (a); (c)&nbsp;a partnership, limited liability company or corporation in which the
Participant or the persons referred to in clause (a)&nbsp;are the only partners, members or stockholders; or (d)&nbsp;charitable donations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>12. ADJUSTMENTS;
DISSOLUTION OR LIQUIDATION; MERGER OR CHANGE IN CONTROL. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(a) Adjustments.</B> In order to prevent diminution or enlargement of
the benefits or potential benefits intended to be made available under the Plan, in the event that any dividend or other distribution (whether in the form of cash, Shares, other securities, or other property), recapitalization, stock split, reverse
stock split, reorganization, merger, consolidation, <FONT STYLE="white-space:nowrap">split-up,</FONT> <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination, repurchase, or exchange of Shares or other securities of the Company, or other
change in the corporate structure of the Company affecting the Shares occurs, the Administrator shall appropriately adjust the number and class of Shares that may be delivered under the Plan and/or the number, class, and price of Shares covered by
each outstanding Award, the numerical Share limits as specified throughout the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(b) Dissolution or Liquidation.</B> In the
event of the proposed dissolution or liquidation of the Company, the Administrator will notify each Participant as soon as practicable prior to the effective date of such proposed transaction. To the extent it has not been previously exercised, an
Award will terminate immediately prior to the consummation of such proposed action. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(c) Change in Control.</B> In the event of a
Change in Control, each outstanding Award will be assumed or an equivalent option or right substituted by the successor corporation or a Parent or Subsidiary of the successor corporation. In the event that the successor corporation refuses to assume
or substitute for the Award, the Participant will fully vest in and have the right to exercise all of his or her outstanding Options and SARs, including Shares as to which such Awards would not otherwise be vested or exercisable, all restrictions on
Restricted Stock shall lapse, and, with respect to Performance Shares, Restricted Stock Units and Performance Units, all performance goals or other vesting criteria will be deemed achieved at target levels and all other terms and conditions met.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(i)</B> For the purposes of this subsection (c), an Award will be considered assumed if, following the Change in Control, the
Award confers the right to purchase or receive, for each Share subject to the Award immediately prior to the Change in Control, the fair market value of the consideration received in the merger or Change in Control by holders of Stock for each Share
held on the effective date of the transaction; provided, however, that if such consideration received in the Change in Control is not solely stock of the successor corporation or its Parent, the Administrator may, with the consent of the successor
corporation, provide for the consideration to be received to be solely stock of the successor corporation or its Parent equal in fair market value to the per share consideration received by holders of Stock in the Change in Control. The continuation
or imposition of vesting terms or other restrictions on Awards in connection with a Change of Control shall not prevent such Awards from being considered assumed for purposes of this Section. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(ii) </B>Notwithstanding the above, an Award that vests, is earned or <FONT STYLE="white-space:nowrap">paid-out</FONT> upon the
satisfaction of one or more performance goals will not be considered assumed if the Company or its successor modifies any of such performance goals without the Participant&#146;s consent; <I>provided, however</I>, a modification to such performance
goals only to reflect the successor corporation&#146;s post-Change in Control corporate structure will not be deemed to invalidate an otherwise valid Award assumption. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(iii)</B> If an Option or SAR is not assumed or substituted for in the event of a Change in Control, the Administrator will notify the
Participant that the Option or SAR will be fully vested and exercisable for a stated period of time prior to the Change of Control, as determined by the Administrator, and the Option or SAR will terminate upon the expiration of such period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(iv) </B>With respect to Awards granted to an Outside Director that are assumed or substituted for, if on the date of or following such
assumption or substitution the Participant&#146;s status as a Director or a director of the successor corporation, as applicable, is terminated other than upon a voluntary resignation by the Participant not at the request of the successor, then the
Participant will fully vest in all Awards, and shall have the right to exercise Options and SARs for such periods as provided in the applicable Award Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>13. TAX WITHHOLDING. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(a) Withholding
Requirements.</B> Prior to the delivery of any Shares or cash pursuant to an Award (or exercise thereof), the Company will have the power and the right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to
satisfy federal, state, local, foreign or other taxes (including the Participant&#146;s FICA obligation) required to be withheld with respect to such Award (or exercise thereof). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">A-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>APPENDIX A </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(b) Withholding Arrangements.</B> The Administrator, in its sole discretion and pursuant to such procedures as it may specify from time
to time, may permit a Participant to satisfy such tax withholding obligation, in whole or in part by (without limitation) (i)&nbsp;paying cash, (ii)&nbsp;electing to have the Company withhold otherwise deliverable cash or Shares having a Fair Market
Value equal to the amount required to be withheld, (iii)&nbsp;delivering to the Company already-owned Shares having a Fair Market Value equal to the amount required to be withheld, or (iv)&nbsp;selling a sufficient number of Shares otherwise
deliverable to the Participant through such means as the Administrator may determine in its sole discretion (whether through a broker or otherwise) equal to the amount required to be withheld. The amount of the withholding requirement will be deemed
to include any amount which the Administrator agrees may be withheld at the time the election is made, not to exceed the amount determined by using the maximum federal, state or local marginal income tax rates applicable to the Participant with
respect to the Award on the date that the amount of tax to be withheld is to be determined. The Fair Market Value of the Shares to be withheld or delivered will be determined as of the date that the taxes are required to be withheld. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>14. CLAWBACK AND RECOVERY OF AWARDS. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">All
Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#146;s
securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Board has adopted a clawback policy that allows the Company to seek repayment of incentive
compensation that was erroneously paid. The policy provides that if the Board, or Compensation Committee as applicable, determines that there has been a material misstatement of publicly issued financial results from those previously issued to the
public due to a knowing violation of rules and regulations of the Securities and Exchange Commission or Company policy, or the willful commission of an act of fraud, dishonesty, gross recklessness or gross negligence, our Board or Compensation
Committee will review all incentive compensation made to our named executive officers during the three year period prior to the restatement on the basis of having met or exceeded specific performance targets. If such payments would have been lower
had they been calculated based on such restated results, our Board or Compensation Committee will (to the extent permitted by governing law) seek to recoup the payments in excess of the amount that would have been paid based on the restated results.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>15. CONDITIONS UPON ISSUANCE OF SHARES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(a) Legal Compliance.</B> Shares will not be issued pursuant to the exercise of an Award unless the exercise of such Award and the
issuance and delivery of such Shares will comply with Applicable Laws and will be further subject to the approval of counsel for the Company with respect to such compliance. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(b) Investment Representations.</B> As a condition to the exercise of an Award, the Company may require the person exercising such
Award to represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a
representation is required. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>16. AMENDMENT AND TERMINATION OF THE PLAN. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(a) Amendment and Termination.</B> The Administrator may at any time amend, alter, suspend or terminate the Plan. The Company will
obtain stockholder approval of any Plan amendment to the extent necessary and desirable to comply with Applicable Laws. Unless earlier terminated or extended, the Plan will continue in effect until May&nbsp;20, 2025, at which time it shall terminate
without further action on the part of the Board or the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(b) Effect of Amendment or Termination.</B> No amendment,
alteration, suspension or termination of the Plan will impair the rights of any Participant, without the consent of the Participant. Termination of the Plan will not affect the Administrator&#146;s ability to exercise the powers granted to it
hereunder with respect to Awards granted under the Plan prior to the date of such termination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>17. MISCELLANEOUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(a) Not An Employment or Service Contract.</B> Neither the Plan nor any Award will confer upon a Participant any right with respect to
continuing the Participant&#146;s relationship as a Service Provider with the Company, nor will they interfere in any way with the Participant&#146;s right or the Company&#146;s right to terminate such relationship at any time, with or without
cause, to the extent permitted by Applicable Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">A-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>APPENDIX A </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(b) Inability to Obtain Authority.</B> The inability of the Company to obtain authority from any regulatory body having jurisdiction,
which authority is deemed by the Company&#146;s counsel to be necessary to the lawful issuance and sale of any Shares hereunder, will relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such
requisite authority will not have been obtained. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(c) Electronic Delivery</B>. Any reference herein to a &#147;written&#148;
agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#146;s intranet (or other shared electronic medium controlled by the
Company to which the Participant has access). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(d) Compliance with Section</B><B></B><B>&nbsp;409A of the Code.</B> Unless
otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section&nbsp;409A of the Code,
and, to the extent not so exempt, in compliance with Section&nbsp;409A of the Code. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section&nbsp;409A of the Code, the Award Agreement evidencing
such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section&nbsp;409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby
incorporated by reference into the Award Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Stock are publicly traded, and if a Participant holding an
Award that constitutes &#147;deferred compensation&#148; under Section&nbsp;409A of the Code is a &#147;specified employee&#148; for purposes of Section&nbsp;409A of the Code, no distribution or payment of any amount that is due because of a
&#147;separation from service&#148; (as defined in Section&nbsp;409A of the Code without regard to alternative definitions thereunder) will be issued or paid before the date that is six months following the date of such Participant&#146;s
&#147;separation from service&#148; (as defined in Section&nbsp;409A of the Code without regard to alternative definitions thereunder) or, if earlier, the date of the Participant&#146;s death, unless such distribution or payment can be made in a
manner that complies with Section&nbsp;409A of the Code, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(e) Choice of Law.</B> The law of the State of Delaware will govern all questions concerning the construction, validity and
interpretation of this Plan, without regard to that state&#146;s conflict of laws rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>18. DEFINITIONS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify">As used herein, the following definitions will apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(a) </B><B><I>&#147;Administrator&#148;</I></B> means the Board or any of its Committees as will be administering the Plan, in
accordance with Section&nbsp;3 of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(b) </B><B><I>&#147;Affiliate&#148;</I></B> means, at the time of determination, any
&#147;parent&#148; or &#147;subsidiary&#148; of the Company as such terms are defined in Rule 405 of the Securities Act. The Board will have the authority to determine the time or times at which &#147;parent&#148; or &#147;subsidiary&#148; status is
determined within the foregoing definition. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(c) </B><B><I>&#147;Applicable Law&#148;</I></B> means the requirements relating to
the administration of equity-based awards under U.S. federal and state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Stock is listed or quoted and the applicable laws of any
foreign country or jurisdiction where Awards are, or will be, granted under the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(d) </B><B><I>&#147;Award&#148;</I></B>
means, individually or collectively, a grant under the Plan of Options, SARs, Restricted Stock, Restricted Stock Units, Performance Units or Performance Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(e) </B><B><I>&#147;Award Agreement&#148;</I></B> means the written or electronic agreement setting forth the terms and provisions
applicable to each Award granted under the Plan. The Award Agreement is subject to the terms and conditions of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(f)
</B><B><I>&#147;Board&#148;</I></B> means the Board of Directors of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(g) </B><B><I>&#147;Cause&#148;</I></B> means, in
the absence of any written agreement between the Participant and the Company defining such term, with respect to a Participant, the occurrence of any of the following events: (i)&nbsp;such Participant&#146;s commission of any felony or any crime
involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii)&nbsp;such Participant&#146;s attempted commission of, or participation in, a fraud or act of dishonesty against the Company;
(iii)&nbsp;such Participant&#146;s intentional, material violation of any contract or agreement between the Participant and the Company or of any statutory duty owed to the Company; (iv)&nbsp;such Participant&#146;s unauthorized use or disclosure of
the Company&#146;s confidential information or trade secrets; or (v)&nbsp;such Participant&#146;s gross misconduct. The determination that a termination of the Participant is either for Cause or without Cause will be made by the Company, in its sole
discretion. Any determination by the Company that the service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant under the Plan will have no effect upon any determination of the
rights or obligations of the Company or such Participant for any other purpose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">A-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>APPENDIX A </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(h) </B><B><I>&#147;Change in Control&#148;</I></B> means the occurrence of any of the following events: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(i) </B>Any <B><I>&#147;person&#148;</I></B> (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the
<B><I>&#147;beneficial owner&#148;</I></B> (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%)&nbsp;or more of the total voting
power represented by the Company&#146;s then outstanding voting securities; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(ii)</B> The consummation of the sale or
disposition by the Company of all or substantially all of the Company&#146;s assets; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(iii) </B>A change in the composition of the
Board occurring within a <FONT STYLE="white-space:nowrap">two-year</FONT> period, as a result of which less than a majority of the directors are Incumbent Directors. <B><I>&#147;Incumbent Directors&#148;</I></B> means directors who either
(A)&nbsp;are Directors as of the effective date of the Plan, or (B)&nbsp;are elected, or nominated for election, to the Board with the affirmative votes of at least a majority of the Incumbent Directors at the time of such election or nomination
(but will not include an individual whose election or nomination is in connection with an actual or threatened proxy contest relating to the election of directors to the Company); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(iv)</B> The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation
which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least
fifty percent (50%)&nbsp;of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(i) </B><B><I>&#147;Code&#148;</I></B> means the Internal Revenue Code of 1986, as amended. Any reference to a section of the Code will
be a reference to any successor or amended section of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(j) </B><B><I>&#147;Committee&#148;</I></B> means a committee of
Directors appointed by the Board in accordance with Section&nbsp;3 of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(k) </B><B><I>&#147;Company&#148;</I></B> means
Cytokinetics, Incorporated, a Delaware corporation, or any successor thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(l) </B><B><I>&#147;Consultant&#148;</I></B> means
any person, including an advisor, engaged by the Company or a Parent or Subsidiary to render services to such entity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(m)
</B><B><I>&#147;Determination Date&#148;</I></B> means the latest possible date that will not jeopardize the qualification of an Award granted under the Plan as &#147;performance-based compensation&#148; under Section&nbsp;162(m) of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(n) </B><B><I>&#147;Director&#148;</I></B> means a member of the Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(o) </B><B><I>&#147;Disability&#148;</I></B> means total and permanent disability as defined in Section&nbsp;22(e)(3) of the Code,
provided that in the case of Awards other than Incentive Stock Options, the Administrator in its discretion may determine whether a permanent and total disability exists in accordance with <FONT STYLE="white-space:nowrap">non-discriminatory</FONT>
standards. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(p) </B><B><I>&#147;Employee&#148;</I></B> means any person employed by the Company or any Parent or Subsidiary of the
Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(q) </B><B><I>&#147;Exchange Act&#148;</I></B> means the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(r) </B><B><I>&#147;Exchange Program&#148;</I></B> means a program under which (i)&nbsp;outstanding Awards are surrendered or cancelled
in exchange for Awards of the same type (which may have lower exercise prices and different terms), Awards of a different type, and/or cash, (ii)&nbsp;Participants would have the opportunity to transfer any outstanding Awards to a financial
institution or other person or entity selected by the Administrator, and/or (iii)&nbsp;the exercise price of an outstanding Award is reduced. The Administrator will determine the terms and conditions of any Exchange Program in its sole discretion,
subject to the provisions of Section&nbsp;4(c). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(s) </B><B><I>&#147;Fair Market Value&#148;</I></B> means, as of any date, the
value of Stock determined as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(i) </B>If the Stock is listed on any established stock exchange or a national market
system, including without limitation the NASDAQ Global Market, the NASDAQ Global Select Market or the NASDAQ Capital Market, its Fair Market Value will be the closing sales price for such stock (or the closing bid, if no sales were reported) as
quoted on such exchange or system on the day of determination, as reported in The Wall Street Journal or such other source as the Administrator deems reliable; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(ii) </B>If the Stock is regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value
of a Share of Stock will be the mean between the high bid and low asked prices for the Stock on the day of determination, as reported in The Wall Street Journal or such other source as the Administrator deems reliable; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(iii)</B> In the absence of an established market for the Stock, the Fair Market Value will be determined in good faith by the
Administrator. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(t) </B><B><I>&#147;Fiscal Year&#148;</I></B> means the fiscal year of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">A-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>APPENDIX A </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(u) </B><B><I>&#147;Full Value Award&#148;</I></B> means any Award other than an Option, SAR or other Award for which the Participant
pays the intrinsic value (whether directly or by forgoing a right to receive a payment from the Company). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(v)</B>
<B><I>&#147;Incentive Stock Option&#148;</I></B> means an Option intended to qualify as an incentive stock option within the meaning of Section&nbsp;422 of the Code and the regulations thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(w) </B><B><I>&#147;Nonstatutory Stock Option&#148;</I></B> means an Option that by its terms does not qualify or is not intended to
qualify as an Incentive Stock Option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(x) </B><B><I>&#147;Officer&#148;</I></B> means a person who is an officer of the Company
within the meaning of Section&nbsp;16 of the Exchange Act and the rules thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(y) </B><B><I>&#147;Option&#148;</I></B> means
a stock option granted pursuant to the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(z) </B><B><I>&#147;Outside Director&#148;</I></B> means a Director who is not an
Employee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(aa) </B><B><I>&#147;Parent&#148;</I></B> means a <B><I>&#147;parent corporation,&#148;</I></B> whether now or hereafter
existing, as defined in Section&nbsp;424(e) of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(bb) </B><B><I>&#147;Participant&#148;</I></B> means the holder of an
outstanding Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(cc) </B><B><I>&#147;Performance Period&#148;</I></B> means any Fiscal Year or such other period as determined
by the Administrator in its sole discretion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(dd) </B><B><I>&#147;Performance Share&#148;</I></B> or <B><I>&#147;Performance
Unit&#148;</I></B> means an Award granted to a Participant pursuant to Section&nbsp;8. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(ee) </B><B><I>&#147;Period of
Restriction&#148;</I></B> means the period during which the transfer of Shares of Restricted Stock are subject to restrictions and therefore, the Shares are subject to a substantial risk of forfeiture. Such restrictions may be based on the passage
of time, the achievement of target levels of performance, or the occurrence of other events as determined by the Administrator. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(ff) </B><B><I>&#147;Plan&#148;</I></B> means this Amended and Restated 2004 Equity Incentive Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(gg) </B><B><I>&#147;Restricted Stock&#148;</I></B> means shares of Stock issued pursuant to a Restricted Stock Award under
Section&nbsp;6 of the Plan, or issued pursuant to the early exercise of an Option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(hh) </B><B><I>&#147;Restricted Stock
Unit&#148;</I></B> shall mean a bookkeeping entry representing an amount equal to the Fair Market Value of one Share, granted pursuant to Section&nbsp;7. Each Restricted Stock Unit represents an unfunded and unsecured obligation of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(ii) </B><B><I>&#147;Rule <FONT STYLE="white-space:nowrap">16b-3&#148;</FONT></I></B> means Rule
<FONT STYLE="white-space:nowrap">16b-3</FONT> of the Exchange Act or any successor to Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> as in effect when discretion is being exercised with respect to the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(jj) </B><B><I>&#147;Section 16(b)&#148;</I></B> means Section&nbsp;16(b) of the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(kk) </B><B><I>&#147;Service Provider&#148;</I></B> means an Employee, Director or Consultant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(ll) </B><B><I>&#147;Share&#148;</I></B> means a share of the Stock, as adjusted in accordance with Section&nbsp;12 of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(mm) </B><B><I>&#147;Stock&#148;</I></B> means the Common Stock of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(nn) </B><B><I>&#147;Stock Appreciation Right&#148;</I></B> or <B><I>&#147;SAR&#148;</I></B> means an Award, granted alone or in
connection with an Option, that pursuant to Section&nbsp;5 is designated as a SAR. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(oo) </B><B><I>&#147;Subsidiary&#148;</I></B>
means a <B><I>&#147;subsidiary corporation&#148;</I></B>, whether now or hereafter existing, as defined in Section&nbsp;424(f) of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:ARIAL" ALIGN="justify"><B>(pp) </B><B><I>&#147;Ten Percent Stockholder&#148;</I></B> means a person who Owns (or is deemed to Own pursuant to Section&nbsp;424(d)
of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">A-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g307694im001.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">C123456789 IMPORTANT ANNUAL MEETING INFORMATION 000004 000000000.000000 ext 000000000.000000 ext ENDORSEMENT_LINE SACKPACK
000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext MR A SAMPLE Electronic Voting Instructions DESIGNATION (IF ANY) Available 24 hours a day, 7 days a week! ADD 1 ADD 2 Instead of mailing your proxy, you may choose
one of the voting ADD 3 methods outlined below to vote your proxy. ADD 4 VALIDATION DETAILS ARE LOCATED BELOW IN THE TITLE BAR. ADD 5 Proxies submitted by the Internet or telephone must be received by ADD 6 11:59 p.m., Eastern Time, on May&nbsp;17,
2017. Vote by Internet &#149; Go to www.investorvote.com/CYTK &#149; Or scan the QR code with your smartphone &#149; Follow the steps outlined on the secure website Vote by telephone &#149; Call toll free <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-652-VOTE</FONT></FONT></FONT> (8683)&nbsp;within the USA, US territories&nbsp;&amp; Canada on a touch tone telephone &#149; Follow the instructions provided by the recorded message
Using a black ink pen, mark your votes with an X as shown in X this example. Please do not write outside the designated areas. Annual Meeting Proxy Card 1234 5678 9012 345 IF YOU HAVE NOT VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE
PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. A Proposals The Board of Directors recommends a vote &#147;FOR ALL&#148; for Proposal 1, and &#147;FOR&#148; Proposals 2, 3 and 4. 1. Election of Directors: 01&#151;L.
Patrick Gage 02&#151;Edward M. Kaye 03&#151;Wendell Wierenga + Mark here to vote Mark here to WITHHOLD For All EXCEPT&#151;To withhold authority to vote for any FOR all nominees vote from all nominees nominee(s), write the name(s) of such nominee(s)
below. For Against Abstain For Against Abstain 2. Ratification of selection of PricewaterhouseCoopers LLP 3. Approval of an amendment to the Amended and Restated 2004 as the independent registered public accounting firm of Equity Incentive Plan to
increase the number of authorized Cytokinetics, Incorporated for the fiscal year ending shares reserved for issuance thereunder by 3,900,000 shares. December&nbsp;31, 2017. 4. Approval, on an advisory basis, of the compensation of the named
executive officers. The Board of Directors recommends a vote for &#147;EVERY THREE YEARS&#148; for Proposal 5. Every 3 Every 2 Every Abstain Years Years Year 5. Determination, on an advisory basis, of the frequency of the advisory vote on
compensation of the named executive officers. B Authorized Signatures &#151; This section must be completed for your vote to be counted. &#151; Date and Sign Below Please sign as name appears hereon. Joint owners should each sign. When signing as
attorney, executor, administrator, trustee or guardian, please give full title as such. Date (mm/dd/yyyy) &#151; Please print date below. Signature 1 &#151; Please keep signature within the box. Signature 2 &#151; Please keep signature within the
box. C 1234567890 J N T MR A SAMPLE (THIS AREA IS SET UP TO ACCOMMODATE 140 CHARACTERS) MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND 1UPX 3 1 7 9 2 1 1 MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND + 02JLPC
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g307694img002.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Important notice regarding the Internet Availability of Proxy Materials for the Annual Meeting of Stockholders to be held on
May&nbsp;18, 2017. The Proxy Statement, Notice of Annual Meeting, Form of Proxy Card and 2016 Annual Report to Stockholders are available at: cytokinetics.com/proxy IF YOU HAVE NOT VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE PERFORATION,
DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. + Proxy &#151; Cytokinetics, Incorporated Annual Meeting of Stockholders &#151; May&nbsp;18, 2017 THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS OF THE COMPANY The undersigned hereby
appoints Robert I. Blum and Caryn G. McDowell, and each of them, with power to act without the other and with power of substitution, as proxies and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and
hereby authorizes them to represent and vote, as provided on the other side, all the shares of Cytokinetics, Incorporated Common Stock which the undersigned is entitled to vote, and, in their discretion, to vote upon such other business as may
properly come before the Annual Meeting of Stockholders of the Company to be held May&nbsp;18, 2017 or at any adjournment or postponement thereof, with all powers which the undersigned would possess if present at the Annual Meeting of Stockholders.
(Continued and to be marked, dated and signed, on the other side) C <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Items Change of Address &#151; Please print new address below. Comments &#151; Please print your comments below. IF VOTING BY
MAIL, YOU MUST COMPLETE SECTIONS A&#151;C ON BOTH SIDES OF THIS CARD. + </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
